NOVEL AMINO ARYL DERIVATIVE USEFUL AS A DIACYGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF

Abstract

The present invention relates to an amino aryl derivative compound, represented by the chemical formula (1) and exhibiting the activity of a diacylglycerol acyltransferase 2 (DGAT2) inhibitor, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof.

Description

NOVEL AMINO ARYL DERIVATIVE USEFUL AS A DIACYL GLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE OF THE SAME TECHNICAL FIELD The present invention relates to a compound derived from amino aryl represented by Formula (1) that shows inhibitory activity against diacylglycerol acyltransferase 2 (DGAT2), a pharmaceutical composition comprising the same as an active ingredient and use thereof. BACKGROUND TECHNIQUE The improvement of living standards in accordance with economic development, frequent consumption of instant foods, and changes in meat-based dietary habits caused excessive accumulation of caloric energy in the body. These changes in the dietary life of modern people have also led to a reduction in caloric energy consumption due to lack of exercise, leading to a serious prevalence of metabolic diseases such as obesity, hyperlipidemia, diabetes, cardiovascular disease and kidney disease. coronary artery. Specifically, obesity is one of the rapidly increasing diseases and is reported to be the cause of metabolic diseases such as diabetes. The development of therapeutic agents for metabolic diseases by controlling the functions of enzymes involved in the triglyceride biosynthetic pathway—which is the primary cause of obesity—is attracting attention. ccz / nn / zznz / E / Y Neutral fats, such as triglycerides (TG), play a very important role in storage function as a source of energy in the body. However, when neutral fats are excessively accumulated in organs or tissues, they cause obesity, hypertriglyceridemia, fatty liver, etc., thereby causing serious diseases such as diabetes, arteriosclerosis, metabolic abnormalities and organ hypofunction. Diacylglycerol acyltransferase—which is a crucial enzyme in triglyceride biosynthesis—is found in several mammalian tissues, and is an enzyme that synthesizes TG by linking fatty acyl-CoA to the hydroxyl group of diacylglycerol in the final step of the pathway. glycerol phosphate which is the main route for the synthesis of triglycerides. Currently, two isoforms are known—DGAT1 and DGAT2. Although their biochemical functions are similar, there is a difference in that DGAT1 is mainly expressed in the small intestine and adipose tissue, and DGAT2 is mainly expressed in the liver and adipose tissue. Furthermore, with respect to the gene family, DGAT1 belongs to the ACAT family, and DGAT2 belongs to the MGAT family. As such, their function in TG biosynthesis is expected to be different as well. Several studies, including animal studies, have shown that DGAT2 mainly contributes to TG biosynthesis in vivo. Unlike DGAT2 knockout mice—which hardly synthesize TG and die shortly after birth due to an abnormal skin layer—DGAT1 knockout mice showed a slight decrease in TG levels and no problems with mouse survival ( Stone SJ et al., 2000. Nat. Genet. 25:87-90). Furthermore, as a result of reducing the expression level of DGAT1 or DGAT2 by using antisense oligonucleotide (ASO) in an animal model of fatty liver, the symptoms of fatty liver were alleviated and the rate of glucose production in the liver was reduced. significantly only when the amount of DGAT2 was reduced (Choi CS et al., 2007. Hepatology. 45:1366-74). The molecular mechanisms involved have not been completely elucidated, but it has been thought that inhibition of DGAT2 results in the downregulation of the expression of multiple genes encoding proteins involved in lipid production, such as proteins that bind the element. sterol regulator 1c (SREBPlc) and stearoyl CoA-desaturase 1 (SCD1). At the same time, it has been thought that the oxidative pathway was induced by an increase in genes such as carnitine palmitoyltransferase 1 (CPT1). This change in turn led to a decrease in hepatic DAG and TAG lipid levels, and thus improved insulin responsiveness in the liver. Furthermore, DGAT2 inhibition inhibited hepatic VLDL TAG secretion and ccz / nn / zznz / E / v ccz / nn / zznz / E / Y reduced circulating cholesterol levels. Finally, plasma apolipoprotein B (APOB) levels were suppressed, which was thought to be due to the reduced supply of TAG upon lipidation of the newly synthesized APOB protein. That is, when DGAT2 is inhibited, beneficial effects were shown on both the glycemic control profile and plasma cholesterol, which means that the inhibition of DGAT2 can be applied to the treatment of metabolic disorders. DESCRIPTION OF THE INVENTION TECHNICAL PROBLEM An object of the present invention is to provide a novel amino aryl derivative compound represented by Formula (1) that shows inhibitory activity against diacylglycerol acyltransferase 2 (DGAT2). Another object of the present invention is to provide a method for preparing the amino aryl derivative compound. Still another object of the present invention is to provide a pharmaceutical composition for the treatment of metabolic diseases associated with DGAT2 comprising the compound derived from amino aryl as an active ingredient, and a method for preparing the same. Still another object of the present invention is to provide a method for treating metabolic diseases associated with DGAT2 in a subject in which the efficacy in animal models of diseases is improved as well as the efficacy and convenience in take in the subject are improved by using the compound derived from amino aryl as an active ingredient that has improved physical and chemical properties compared to conventional compounds. SOLUTION TO THE PROBLEM In order to achieve the above objective, the present invention provides a compound of the following Formula (1), or a pharmaceutically acceptable salt or isomer: [Formula 1) ] where A and D are each independently CH or N; B and E are each independently CH, C-halogen, C-haloalkyl or N; R1 is alkyl, cycloalkyl or haloalkyl; R2 is hydrogen, halogen or alkyl; R3es -G-J; where G is aryl, arylene, arylene-alkylene, heteroaryl or heteroarylene; J is hydrogen, amino, aminocarbonyl, alkoxyalkyl, cycloalkyl, cycloalkyl-oxy, heterocycloalkyl, aryl, aryl-oxy, aryl-alkoxy, heteroaryl, heteroaryl-amino, carboxyaikyl, carboxyaiqueniium, carboxyaikyl-aryl, carboxyalkoxyaryl, carboxyakyl-heterocycloalkyl, carboxyalkoxy-heterocycloalkyl, carboxyalkoxy-heterocycloalkyl, carboxyalkyl-amino-aryl, carboxyalkyl-aryl-oxy or carboxyalkyl-heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with one or more substituents selected from halo, -COOH, alkyl, alkoxy, haloalkyl, alkylsulfonyl and heteroaryl-alkyl; and heterocycloalkyl, heteroaryl and heteroarylene include one or more heteroatoms selected from N, O and S. The compound of Formula (1) according to the present invention can form a pharmaceutically acceptable salt. A pharmaceutically acceptable salt may include an acid addition salt that is formed from an inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid; an organic acid such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, ccz / nn / zznz / E / Y lactic acid, fumaric acid, maleic acid and salicylic acid; or sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and ptoluenesulfonic acid, which forms the non-toxic acid addition salt including pharmaceutically acceptable anion. Furthermore, a pharmaceutically acceptable carboxylic acid salt includes the salt with alkali metal or alkaline earth metal such as lithium, sodium, potassium, calcium and magnesium; amino acid salts such as lysine, arginine and guanidine; an organic salt such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline and triethylamine. The compound of Formula (1) according to the present invention can be converted to its salts by conventional methods. Meanwhile, since the compound of Formula (1) according to the present invention can have an asymmetric carbon center and asymmetric axis or plane, it can exist as E or Z isomer, R or S isomer, racemic mixtures or mixtures of diastereoisomer and each diastereoisomer, all of which are within the scope of the present invention. Herein, unless otherwise indicated, the term compound of Formula (1) is used to mean all compounds of Formula (1), including pharmaceutically acceptable salts and isomers thereof. . ccz / nn / zznz / E / Y Herein, the following concepts defined as substituents are used to define the compound of Formula (1). The term halogen or halo means fluorine (F), chlorine (Ci), bromine (Br) or iodine (I). The term alkyl or alkylene means straight or branched hydrocarbons, may include a single bond, a double bond or a triple bond, and is preferably Ci-Cio alkyl or Ci-Cio alkylene, or C1-C7 alkylene or C1-C7 alkylene. C1-C7. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, tex-butyl, acetylene, vinyl, trifluoromethyl and the like. The term alkenyl means straight or branched hydrocarbons having at least one carbon-carbon double bond, and is preferably C2-C10 alkenyl or C2-C7 alkenyl. Examples of alkenyl include, but are not limited to, vinyl, allyl, butenyl, isopropenyl, isobutenyl and the like. The term cycloalkyl means partially or fully saturated single or fused ring hydrocarbons, and is preferably C3-C10 cycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. ccz / nn / zznz / E / Y Unless otherwise defined, the term alkoxy means alkyloxy having 1 to 10 carbon atoms. The term aryl or arylene means aromatic hydrocarbons, preferably C5-C12 aryl or C5-C12 arylene, more preferably Ce-Cio aryl or Cs-Cio arylene, and include, but are not limited to, phenyl, naphthyl and the like. The term "heteroaryl" or "heteroarylene" means 3 to 12 membered aromatic hydrocarbons, more preferably 5 to 12 members forming a single or fused ring—which may be fused with benzo or C3-C8 cycloalkyl—including one or more heteroatoms selected from N, O and S as a member in the ring. Examples of heteroaryl include, but are not limited to, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxadiazolyl, isoxadiazolyl, tetrazolyl, triazolyl, indolyl, indazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, furanyl, benzofuranyl, imidazolyl, thiophenyl, benzthiazol, benzimidazole, guinolinyl, indolinyl, 1,2,3,4tetrahydroisoquinolyl, 3,4-dihydroisoquinolinyl, thiazolopyridyl, 2,3-dihydrobenzofuran, 2,3-dihydrothiophene, 2,3dihydroindole, benzo[1,3]dioxin, croman, thiocroman, 1,2,3,4tetrahydroquinoline, 4H-benzo[1,3]dioxin, 2,3-dihydrobenzo[1,4]-dioxin, 6,7-dihydro-5H-cyclopenta[d]pyrimidine and the like. The term "heterocycloalkyl" means partially or fully saturated hydrocarbons that form a single or fused ring that includes one or more heteroatoms selected from N, O and S, and is preferably 3- to 12-membered heterocycloalkyl or 5- to 12-membered heterocycloalkyl. Examples of heterocycloalkyl include, but are not limited to, pyrrolidinyl, piperidinyl, morpholinyl, imidazolinyl, piperazinyl, tetrahydrofuran, tetrahydrothiofuran and the like. Aryl-alkoxy, alkyl-aryl, heteroaryl-alkyl and alkyl-heteroaryl mean groups that are formed by the combination of the aryl or heteroaryl mentioned above with alkyl or alkoxy. Examples include, but are not limited to, benzyl, methoxyphenyl, thiophenemethyl, pyrimidine methyl and the like. According to an embodiment of the present invention, in the above Formula (1) A and D are each independently CH or N; B and E are each independently CH, C-halogen, C-halo-C1-C7 alkyl or N; R1 is C1-C7 alkyl, C3-C7 cycloalkyl or C1-C7 haloalkyl; R2 is hydrogen, halogen or C1-C7 alkyl; R3es -G-J; ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y where G is Ce-Cio aryl, Cg-Cio arylene, Ce-Cio arylene-C1-C7 alkylene, 5 to 12 heteroaryl members or 5- to 12-membered heteroarylene; J is hydrogen, amino, aminocarbonyl, CiC7 alkoxy-C1-C7 alkyl, C3-C10 cycloalkyl, C3Cio-oxy cycloalkyl, 5-12 membered heterocycloalkyl, Ce-Cio aryl, Cg-Cio-oxy aryl, Cs-Cio-C1-C7-alkoxy aryl, 5-12 membered heteroaryl, 5-12 membered heteroaryl-amino, C1-C7 carboxy-alkyl, C2-C7 carboxy-alkenyl, Ci-C7-carboxyalkyl Ce-Cio aryl, Ci-C7 carboxy-alkoxy-Ce-Cio aryl, 5- to 12-membered carboxy-C7-heterocycloalkyl, 5- to 12-membered carboxy-C7-heterocycloalkyl, 5- to 12-membered Ci-C7-heterocycloalkyl carboxy-alkoxy, Ci-C7-amino-aryl carboxy-alkyl of Cg-Cio, Ci-C7-aryl carboxy-alkyl of Ce-Cio-oxy or carboxy-alkyl 5- to 12-membered Ci-Cv-heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with 1 to 4 substituents selected from halo, -COOH, C1-C7 alkyl, C1-C7 alkoxy, halo-C1-C7 alkyl , C1-C7 alkylsulfonyl and 5- to 12-membered heteroaryl-C1-C7 alkyl; and heterocycloalkyl, heteroaryl and heteroarylene include 1 to 5 heteroatoms selected from N, O and S. Representative compounds of Formula (1) of ccz / nn / zznz / E / Y according to the present invention include, but are not limited to, the following compounds: (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)thiazole-5-carboxylic acid; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4,5-dimethylthiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4-phenylthiazol-2-amine; (A)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)benzo[d]thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-6-methoxybenzo[ d]thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-6-(methanesulfonyl)benzo[d]thiazol-2-amine; (R)-N- (6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-3-(1-(2-methoxyethoxy)-2-methylpropan-2-yl)isooxazole-5 -amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4-phenyloxazole-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)benzo[d]oxazol-2-amine; (R)-5-chloro-7V-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)benzo[ d]oxazol-2-amine; acid (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl))> u N C N N C C N a u pyrazin-2-yl)amino)benzo[ d]oxazol-5-yl)acetic acid; (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)-2-methylpropanoic acid; (R)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-ii)amino)benzoL dj oxazol-b-ii)-2,2dimethylpropanoic acid; (R,E)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)acrylic acid; (R)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)propanoic acid; (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-6-yl)-2-methylpropanoic acid; (R)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-6-yl)propanoic acid; (R)-6-(3-(2-ethoxyphenoxy)piperidin-1-yl)-N-(1Hpyrazol-3-yl)pyrazin-2-amine; (R)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-IH-pyrazol-l-yl)acetic acid; (R)-3-(3-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-IH-pyrazol-l-yl)-2,2-dimethylpropanoic acid; acid (.R) - 3- (3- (6 - ( (4 - (3- (2-ethoxyphenoxy) piperidin-1yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)phenyl)- 2,2dimethylpropanoic acid; (R)-6-(3-(2-ethoxyphenoxy)piperidin-1-yl)-N-(1-methyllH-tetrazol-5-yl)pyrazin-2-amine; > you N C N N C C N a u (R)-N-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-Nphenylpyrazin-2-amine; (R)-N-(4-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)methanesulfonamide; (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)-N-(pyridin-4-ylmethyl)acetamide; (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid; (R)-2-(4-((6-(3-(2-ethoxyphenoxy)pyridin-1yl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid; (R)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid; acid (.R)-3-(3'-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-[1,1'-biphenyl]-4-yl) -2,2dimethylpropanoic acid; (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(pyridin-2yl)pyrazin-2-amine; (R)-6-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)nicotinic acid; (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)isonicotinic acid; (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)nicotinic acid; (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)-2-methylpropanoic acid; > yes N C N N C C N 15 a u (R)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-3-yl)acetic acid; (R,E)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-3-yl)acrylic acid; (R)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-3-yl)propanoic acid; (R)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)-2,2-dimethylpropanoic acid; (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(5phenylpyridin-2-yl)pyrazin-2-amine; (A)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(4-phenylpyridin-2-yl)pyrazin-2-amine; (A)-2-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2-methylpropanoic acid; (A)-2-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2-methylpropanoic acid; acid (R)-3-(3-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2,2- dimethylpropanoic acid; acid (R)-3-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2,2- dimethylpropanoic acid; (R)-3-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)propanoic acid; acid (A)-3-(3-(5-((6-(3-(2-ethoxyphenoxy)piperidin-1> u N C N N C C N α u il)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-2,2-dimethylpropanoic acid; acid (R)-3-(3-(5-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2- dimethylpropanoic acid; (A)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-2-methylpropanoic acid; (A)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-2-methylpropanoic acid; (R)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-2,2-dimethiIpropanoic acid; 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)pyrrolidine-3-carboxylic acid; 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-3-methylpyrrolidine-3carboxylic acid; 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3-carboxylic acid; (R)-1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3-carboxylic acid; (A)-1-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-4-carboxylic acid; (R)-2-(1-(6-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-4-yl)acetic acid ; acid (R)-2-(1-(6-( (6- (3- (2-ethoxyphenoxy)piperidin-1ccz / nn / zznz / E / Y il)pyrazin-2-yl)amino)pyridin-2- il)piperidin-4-yl)-2-methylpropanoic acid; 2-(((S)-1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl) acid piperidin-3yl)acetic acid; (R)-2-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2-methylpropanoic acid; (R)-2-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2-methylpropanoic acid; acid (R)-2-(4-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- yl)phenyl)-2methylpropanoic acid; (A)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- yl)phenyl)-2,2dimethylpropanoic acid; (A)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyridin-2-yl)amino)pyridin-2-yl)phenyl)-2,2dimethyllpropanoic acid; acid (R) -3 - (3 - (6-( (2-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)-2, 2-dimethylpropanoic acid; acid (A)-3-(3-(6-( (6-(3- (2-ethoxyphenoxy)piperidin-lyl )pyrimidin-2-yl)amino)pyridin-2-yl)phenyl)-2,2- dimethyl> you N C N N propanoic; acid (R)-3-(3-(6-( (4- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrimidin-2-yl)amino)pyridin-2- yl)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(3-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino) -1 Jí-pyrazol-l-yl)phenyl) -2,2 -dimethylpropanoic acid; (R)-3-(3-(6-( (2 - (3-(2-ethoxyphenoxy)piperidin-1yl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl acid )- 2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (4-(3- (2-ethoxyphenoxy)piperidin-lyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)pyridin-2-yl)phenyl acid )- 2,2-dimethylpropanoic acid; acid (R)-3-(4-(6-( (6- (3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2- dimethylpropanoic acid; (R)-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-(4-(6-( (6- (3 - ((3-ethoxypyridin-2-yl)oxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine ; (A)-(4-(6-((2-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-(4-(6-((4-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine; acid (R) -2- ( (4- (6 - ( (6- (3- (2-ethoxyphenoxy) piperidm-1> yes N C N N C C N 19 a u il)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)amino)-2-methylpropanoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenyl)-2 acid ,2dimethiipropanoic acid; acid (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- il)-4-fluorophenyl)- 2,2-dimethylpropanoic acid; (R)-2-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy)-2-methylpropanoic acid; acid (A)-2-(3-(6-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- il)phenoxy)-2methylpropanoic acid; (R)-2-(4-(6-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy)-2-methylpropanoic acid; acid (R)-2-(4-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- il)phenoxy)-2methylpropanoic acid; (R)-2-(3-(6-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenoxy)-2methylpropanoic acid ; acid (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- il)-4-fluorophenoxy)-2-methylpropanoic acid; acid (R)-3-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1> u N C N N C C N 20 to u il)pyrazin-2-yl)amino)pyridin-2-yl)-1 íí-pyrazol- 1-yl)-2,2dimethylpropanoic acid; (R)-3-((6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid; (R)-3-((6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl acid oxy)benzoic; (R)-4-((6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid; (R)-4-((6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl acid oxy)benzoic; (A)-2-(3-( (6-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl)-2 acid -methylpropanoic acid; (R)-2-(3-((6— ((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)oxy)phenyl)-2methylpropanoic acid; (R)-2-(4-( (6-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl)-2 acid -methylpropanoic acid; (R)-2-(4-( (6 - ( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)oxy)phenyl)-2methylpropanoic acid; (R)-2-(3-((6-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl acid acetic; acid (R)-2-(3-( (6-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)21 piperidin-l-yl)pyrazin-2-yl)amino)pyridin- 2-yl)oxy)phenyl)acetic acid; (R)-2-(4-((6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl)acetic acid; (R)-2-(4-( (6-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)oxy)phenyl)acetic acid; (R)-4-(((6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)methyl)benzoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-5-fluoropyridin-2-i1)phenyl)-2 acid ,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin acid -2-yl)phenyl)2,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-i1)phenyl)-2 acid ,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin acid -2-yl)phenyl)2,2-dimethylpropanoic acid; (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin acid -2yl)phenoxy)-2-methylpropanoic acid; acid (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)oxy)> u N C N N C C N 22 a u piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl)phenoxy)-2-methylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin acid -2-yl)-4fluorophenii)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)-5-fluoropyridin-2-yl)-4-fluorophenyl acid )2,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin acid -2-yl)-4fluorophenyl)-2,2-dimethylpropanoic acid; (R)-2-(4-(6-( (6- (3- (2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)-3-(trifluoromethyl)pyridin-2-yl)phenyl acid )-2 me tilpropanoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-4-(triflucromethyl)pyridin-2-yl)phenyl acid )2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (6- (3- (2-ethoxyphenoxy)piperidin-lyl )pyrazin-2-yl)amino)-3-methylpyridin-2-yl)phenyl)-2 acid ,2-dimethylpropanoic acid; acid (R)-3-(3-(6-( (6- (3- (2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrazin-2-yl)phenyl)-2,2- dimethylpropanoic acid; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)pyrimidin-2-amine; > yes N C N N C C N a u (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidine-5-carboxylic acid; (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)pyrimidin-4-yl)-2-methylpropanoic acid; (R)-2-(2-((4-(3-((3-ethoxypyridin-2-ii)oxy)piperidin-l-yl)pyrimidin-2-yl)pyrimidin-4-yl)-2methylpropanoic acid; (2-((6-((33)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin2-yl)amino)pyrimidin-4-yl)-L-proline; 1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-yl)pyrrolidine-3-carboxylic acid; 1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)-3-methylpyrrolidine-3carboxylic acid; 1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)piperidine-3-carboxylic acid; (R)-1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-yl)piperidine-3-carboxylic acid; 1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-i1)-3-methylpiperidine-3carboxylic acid; (R)-1-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-yl)piperidine-4-carboxylic acid; 5-(2-((6-((23)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-i1)bicyclo[2.2.1]heptan-2> acid you N C N N C C N 24 a u carboxylic; (R)-2-(1-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-i1)piperidin-4-yl)acetic acid ; acid (R)-2 - (1- (2 - ( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-ii)amino)pyrimidin-4-i1)piperidin-4-ii)- 2-methylpropanoic acid; acid (R)-2-(4-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)piperaz in-1-yl) acetic; 2-((5)-1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)piperidin acid -3yl)acetic; (5)-3-((5)-1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4 acid -i1)piperidin-3yl)acrylic; 3-((5)-1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)piperidin acid -3yl)propanoic; acid 2-(((5)-1-(2-((6 — ((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1) piperidin-3yl)oxy)acetic acid; acid 2-(((R)-1-(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1) piperidin-3yl)oxy)acetic acid; acid 2-(((R)—1—(2-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1) piperidin-3> u N C N N C C N 25 to u yl)oxy)-2-methylpropanoic acid; (R)-4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)oxy)cyclohexane-1carboxylic acid; (lR,4r)-4-( (2- ((6-( (R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)oxy acid )-cyclohexan-l-carboxylic acid; acid (IB,4r)-4-((2-((6-((R)-3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin- 4-yl)oxy)cyclohexan-1-carboxylic acid; (lS,4s)-4-((2-((6-((A)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)oxy acid )-cyclohexan-1-carboxylic acid; (1S,4s)-4-((2-((6-((R)-3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin- acid 4-i1)oxy)cielohexan-1-carboxylic; (R)-6-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)picolinic acid; (R)-2-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)phenyl)acetic acid; acid (A)-2-(3-(2-( (6-(3- (2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2- methylpropanoic acid; acid (R)-2-(3-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4- i1)phenyl)-2 methylpropanoic acid; > yes N C N N C C N 26 a u (R)-2-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2-methylpropanoic acid; acid (R)-2-(4-(2-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4- i1)phenyl)-2 methipropanoic acid; (R)-3-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)propanoic acid; acid (R)-3-(3-(2-( (6- (3- (2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2,2- dimethylpropanoic acid; acid (A)-3-(3-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4- i1)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(3-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-lyl )pyridin-2-yl)amino)pyrimidin-4-yl)phenyl)-2,2- dimethylpropanoic acid; (R)-3-(3-(2-( (2 - (3- (2-ethoxyphenoxy)piperidin-l-yl)pyrimidin-4-yl)amino)pyrimidin-4-i1)phenyl)-2 acid, 2-dimethylpropanoic acid; acid (R)-3-(3-(2-((4-(3-(2-ethoxyphenoxy)piperidin-lyl )pyrimidin-2-yl)amino)pyrimidin-4-i1)phenyl)-2,2- dimethylpropanoic acid; (R)-2-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)acetic acid; acid (R)-2-(4-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy))> u N C N N C C N a u piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-i1)phenyl)acetic acid; acid (R)-3-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2,2- dimethylpropanoic acid; acid (R)-3-(4-(2-( (6- (3- ( (3-ethoxypyridin-2-ii)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4- i1)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(4-(2-((2-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrimidin-4-yl)amino)pyrimidin-4-yl)phenyl)-2,2- dimethylpropanoic acid; acid (A)-3-(4-(2-( (4 - (3- (2-ethoxyphenoxy)piperidin-1yl)pyrimidin-2-yl)amino)pyrimidin-4-i1)phenyl)-2,2- dimethylpropanoic acid; acid (R)-3- (4- (2- ( (4- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrimidin-2-yl)amino)pyrimidin-4- i1)phenyl)-2,2dimethylpropanoic acid; acid (R)-2-(3-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenoxy)-2- methylpropanoic acid; acid (R)-2-(3-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4- i1)phenoxy)-2methylpropanoic acid; (R)-2-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenoxy)-2-methylpropanoic acid; acid (R)-2 -( (4 - (2 - ( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-i1)phenyl)amino)-2 -methyl> you N C N N propanoic; (R)-2-(4-((2-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)oxy)phenyl)acetic acid; acid (R)-2-(4-((2-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-ii)pyrazin-2-ii)amino)pyrimidin-4 -ii)phenii)acetic; acid (R)-3-(3-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-5-fluoropyrimidin-4-yl)phenyl)-2 ,2dimethylpropanoic; acid (R)-3-(3-(2-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-5-( trifluoromethyl)pyrimidin4-yl)phenyl)-2,2-dimethylpropanoic acid; acid (R)-3-(3-(2-( (6- (3- ((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-6-( trifluoromethyl)pyrimidin4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (6-(3- (2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-6-(triflucromethyl)pyrimidin-4-yl)phenyl acid )2,2-dimethylpropanoic acid; (R)-2-(3-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2-methylpropanoic acid; (R)-2-(4-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2-methylpropanoic acid; acid (R)-3-(3-(4-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2,2- dimethylpropanoic acid; acid (R) -3- (3- (4- ( (6- (3- ( (3-ethoxypindin-2-yl) oxy) oxy) > u N C N N C C N 29 a u piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(4-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2,2- dimethylpropanoic acid; acid (R)-3-(4-(4-( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2- yl)phenyl)-2,2dimethylpropanoic acid; (R)-2-(3-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenoxy)-2-methylpropanoic acid; acid (1?)-2- (3- (4- ( (6- (3- ( (3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2 -yl)phenoxy)-2me tilpropanoic acid; (R)-2-(3-(2-( (6- (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenoxy)-2-methylpropanoic acid; (R)-2-(4-(6-((6-(3-(2-ethoxy-4-fluorophenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy acid )-2methylpropanoic acid; (R)-2-(4-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenoxy)-2-methylpropanoic acid; and (R)-2-(4-(4-( (6- (3- ((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2 acid -yl)phenoxy)-2methylpropanoic acid. Terms and abbreviations used in this ccz / nn / zznz / E / Y retain their original meanings unless otherwise indicated. The present invention also provides a method for preparing the compound of Formula (1). Hereinafter, the method for preparing the compound of Formula (1) is explained based on the exemplary reactions to illustrate the present invention. However, a person skilled in the art could prepare the compound of Formula (1) by various methods based on the structure of Formula (1), and such methods should be construed as being within the scope of the present invention. . That is, the compound of Formula (1) can be prepared by the methods described herein or by combining various methods described in the art, which could be interpreted as being within the scope of the present invention. Accordingly, a method for preparing the compound of Formula (1) is not limited to the following methods. As depicted in the following Reaction Scheme 1, the compound of formula (1) can be prepared by directly introducing a substituted amine group into the compound (2), or through a cross-coupling reaction using a palladium catalyst. compound (3) which is prepared by introducing a protected amine to compound (2) and removing a protecting group. ccz / nn / zznz / E / Y [Reaction Scheme 1] The compound (2) is hydroxypiperidine-1-carboxylate according to the method can be prepared from tert-butyl-3 as a starting material of the following Scheme. Reaction 2. [Reaction Scheme 2] Furthermore, compound (3) can be prepared according to the method of the following Reaction Scheme 3. [Reaction Scheme 3] 2) HCI, DCM, ta 1) Buchwald coupling Furthermore, aryl amino intermediates were synthesized by introducing an amino group to a compound obtained through a cross-coupling reaction of a dioxaborolane core intermediate and various types of aryl chloro compounds. . For example, methyl 2-(4-(2aminopyrimidin-4-yl)phenyl)-2-methylpropanoate can be prepared according to the method of the following Reaction Scheme 4 by using 2-(4-bromophenyl)-2-methylpropanoate. of methyl as a starting material. [Reaction Scheme 4] -4 -o or PdCI2(dppf)-CH2CI2O KOAc, II A A - ---------->0 O 1,4-dioxane PdCI?(dppf)-CH?CI?, Na2CO3, DME / cr water 1. t-butyl carbamate CS2CO3. Pd2(dba)3, Xantphos, 1,4-dioxane EITHER' HCI 4M, DCM A compound not specifically described in the preparation method of the present specification is a known compound or a compound that can be easily synthesized from a known compound by a known synthesis method or a similar method. The compound of Formula (1) obtained by the above methods can be separated or purified from the reaction products by conventional methods such as recrystallization, ionospheresis, silica gel column chromatography or ion exchange chromatography. As explained above, the compounds according to the present invention, starting materials or intermediates for the preparation thereof can be prepared by a variety of methods, which should be interpreted as being within the scope of the present invention. with respect to the preparation of the compound of Formula (1). The compound of Formula (1) according to the present invention exhibits inhibitory activity against diacylglycerol acyltransferase 2 (DGAT2). Accordingly, the present invention provides a pharmaceutical composition for the treatment of diseases associated with DGAT2 comprising the compound of Formula (1), or a pharmaceutically acceptable salt or isomer thereof, together with a pharmaceutically acceptable carrier. Various classes of prodrugs, which are converted to the compound of Formula (1) in vivo, are also within the scope of the present invention. Exemplary diseases associated with DGAT2 that can be treated by the pharmaceutical composition according to the ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y present invention include, but are not limited to, those selected from the group that It consists of fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes, obesity, hyperlipidemia, atherosclerosis, and hyperchoiesterolemia. In the present invention, a pharmaceutical composition may include other components such as carriers, diluents, excipients, etc., in addition to the active ingredient of the present invention. Accordingly, the pharmaceutical composition may include pharmaceutically acceptable carriers, diluents, excipients or combinations thereof, if necessary. The pharmaceutical composition facilitates the administration of the compounds in the body. Various methods of administering the compounds include, but are not limited to, oral, injection, aerosol, parenteral and local administration. Herein, a carrier means a compound that facilitates the addition of the compounds into the cell or tissue. For example, dimethyl sulfoxide (DMSO) is a conventional carrier that facilitates the delivery of many organic compounds into living cells or tissues. Herein, a diluent means a compound that not only stabilizes a biologically active form but is diluted in the solvent that dissolves the compounds. A salt dissolved in the buffer is used as a diluent in this field. A conventionally used buffer is a phosphate-buffered saline solution that mimics salt in body fluid. Since a buffer can control the pH of the solution at a low concentration, a buffer diluent harshly modifies the biological activity of the compounds. Herein, pharmaceutically acceptable means such property that does not impair the biological activity and physical property of the compounds. Compounds according to the present invention can be formulated as various pharmaceutically administered dosage forms. In the preparation of the pharmaceutical composition of the present invention, an active component—specifically, the compound of Formula (1) or a pharmaceutically acceptable salt or isomer thereof—is mixed with selected pharmaceutically acceptable carriers that consider the dosage form be prepared. For example, the pharmaceutical composition of the present invention can be formulated as injections, oral preparations and the like, as necessary. The compound of the present invention can be formulated by conventional methods using known pharmaceutical carriers and ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y excipients, and inserted into a unit or multi-unit container. The formulations may be solution, suspension or emulsion in oil or aqueous solvent and include conventional dispersing agents, suspending agents or stabilizing agents. Furthermore, the compound may be, for example, the dry powder form that is dissolved in sterilized pyrogen-free water before use. The compound of the present invention can be formulated into suppositories by using a conventional suppository base such as cocoa butter or other glycerides. Solid forms for oral administration include capsules, tablets, pills, powders and granules. Capsules and tablets are preferred. Tablets and pills are preferably enteric coated. Solid forms are manufactured by mixing the compounds of the present invention with at least one carrier selected from inert diluents such as sucrose, lactose or starch, lubricants such as magnesium stearate, disintegrating agents, binders and the like. The compound or a pharmaceutical composition comprising the same according to the present invention may be administered in combination with other drugs—for example, other metabolic disorder therapeutic agents—as required. The dosage of the compound of Formula (1) according to ccz / nn / zznz / E / Y with the present invention is determined by a doctor's prescription considering the patient's body weight, age and disease condition. A typical adult dose is in the range of approximately 0.3 to 50 0 mg per day depending on the frequency and intensity of administration. A typical daily dose for intramuscular or intravenous administration for adults is in the range of approximately 1 to 300 mg per day which may be administered in divided unit dosages. Some patients need a higher daily dose. Herein, the term treatment is used to mean deterring, retarding or slowing the progress of diseases in a subject exhibiting symptoms of the diseases. ADVANTAGEOUS EFFECTS OF THE INVENTION The novel amino aryl derivative compound of Formula (1) according to the present invention exhibits excellent inhibitory activity against diacylglycerol acyltransferase 2 (DGAT2), and thus can be usefully used in the prevention, alleviation or treatment of associated metabolic disorders with DGAT2. Furthermore, the novel amino aryl derivative compound of Formula (1) according to the present invention exhibits increased lipophilicity and hepatic selectivity, thereby improving efficacy through exposure to the liver, as well as expecting convenience benefits. in taking because the half-life is relatively long in animal models of the disease and clinical practice. MODE FOR THE INVENTION Next, the present invention will be described in more detail through preparation examples and examples. However, these examples are only illustrative, and the scope of the present invention is not limited thereto. In the following examples, M refers to the molar concentration, and N refers to the normal concentration. In addition, the descriptions of abbreviations and terms used in the Reaction Scheme, Preparation Examples and Examples are as follows: DCM: dichloromethane DIPEA: diisopropylethylamine DME: dimethoxyethane DMF: N,N-dimethylformamide HC1: hydrochloric acid Pd / C: palladium / charcoal TEA: triethylamine TFA: trifluoroacetic acid THF: tetrahydrofuran Preparation Example 1: (R)-2-chloro-6-(3-(2-ethoxyphenoxy) piperidin-l-yl)pyrazine ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y Step 1: tert-butyl-(Λ)-3-(2-ethoxyphenoxy)piperidine-1carboxylate (S)-tert-butyl-3-hydroxypiperidine-l-carboxylate (30.0 g, 149 mmol), 2-ethoxyphenol (20.6 g , 149 mmol), triphenylphosphine (43.8 g, 167 mmol) were dissolved in 500 ml of toluene and stirred at room temperature. Diethylazodicarboxylate (30.4 ml) was diluted in 50 ml of toluene and slowly added dropwise to the reaction mixture. After stirring at room temperature for 15 hours, it was filtered, washed with 300 ml of diethyl ether, washed with 100 ml of 3N sodium hydroxide solution, the organic solvent was dried over magnesium sulfate, and the organic solvent was stirred under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:6). (47% performance) iR NMR (300 MHz, CHLOROFORM-D): £6.89-6.95 (m, 4H), 4.07 (m, 3H), 3.9 (bs, 1H), 3.66 (bs, 1H), 3.16 ( m, 2H), 2.07 (bs, 1H), 1.76-1.83 (m, 2H), 1.45 (m+s, 3H) Step 2: (.R)-3-(2-ethoxyphenoxy)piperidine hydrochloride Tert-butyl-(R)-3-(2-ethoxyphenoxy)piperidine-1carboxylate (10.0 g, 31.1 mmol) obtained in step 1 was ccz / nn / zznz / E / Y dissolved in 100 ml of dichloromethane and acid solution 4 M hydrochloric acid was added dropwise at room temperature. After stirring at room temperature for 4 h, the reaction was confirmed to be complete by TLC experiment, and the organic solvent was removed under reduced pressure. After diluting with ethyl acetate and washing with aqueous sodium hydrogen carbonate solution, the organic solvent was dried over magnesium sulfate, and the crude compound obtained through distillation under reduced pressure was used in the following reaction without further purification . m / z (M+H)+calculated for C13H19NO2: 221, found 222 Step 3: (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazine (R)-3-(2-ethoxyphenoxy)piperidine hydrochloride obtained in step 2, 2,6-dichloropyrazine (5.10 g, 34.2 mmol) and triethylamine (13 ml, 93 mmol) were mixed with 100 ml of ethanol and stirred at room temperature. After stirring at room temperature for 24 hours, the reaction was confirmed to be complete through a TLC experiment, and the organic solvent was removed under reduced pressure, dissolved in ethyl acetate, and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. ccz / nn / zznz / E / Y (91% Yield) 6.92-6.80 (m, 2H), 4.35-4.24 (m, 1H), 4.07-3.89 (m, 3H), 3.82-3.68 (m, 1H), 3.67-3.46 (m, 2H), 2.09 (q, J = 4.3 Hz, 1H), 2.02-1.9 / (m, 1H), 1.93 (q, J = 4.3 Hz, 1H), 1.68-1.58 (m, 1H), 1.38 (t, J = 7.0 Hz, 3H) Example Preparation 2: (B)-6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-amine Step 1: tert-butyl (R)-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)carbamate After dissolving (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (1.41 g, 4.22 mmol) obtained in Preparation Example 1, tert-butyl carbamate (0.55 g, 4.65 mmol), cesium carbonate (3.44 g, 10.56 mmol), 4,5bis(diphenylphosphino)-9,9-dimethylxanthine (220 mg, 0.38 mmol) and tris(dibenzylideneacetone)dipalladium (0) (232 mg, 0.25 mmol) in 50 ml of 1,4-dioxane, dissolved oxygen was removed through nitrogen bubbling under stirring, and the outside air flow inlet was blocked in a sealed container. The reaction was stirred at 110°C for 5 hours and then cooled to room temperature. After filtering through a Celite pad and removing the organic solvent under reduced ccz / nn / zznz / E / Y pressure, the reaction was dissolved in ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 3:1). (89% performance) ^-NMR (500 MHz, CHLOROFORM-D) δ 8.40 (s, 1H), 7.78 (s, 1H), 6.96 (t, J = 7.0 Hz, 2H), 6.91-6.77 (m, 2H), 6.66 (s, 1H), 4.48-4.15 (m, 1H), 4.14-3.85 (m, 3H), 3.84-3.69 (m, 1H), 3.52-3.41 (1H), 3.40-3.23 (m, 1H), 2.11 (t, J = 6.1 Hz, 1H), 2.01-1.92 (m, 1H), 1.88 (q, J = 4.3 Hz, 1H), 1.57 (dt, J = 13.4, 4.0 Hz, 1H), 1.52 (s, 9H), 1.37 (t, J = 7.0 Hz, 3H) Step 2: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-amine (R)-(6-(3-(2-Ethoxyphenoxy)piperidin-l-yl)pyrazin-2 -yl) tert-butyl carbamate obtained in step 1 was dissolved in 10 ml of dichloromethane, stirred and 2 ml of trifluoroacetic acid was added dropwise thereto. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure, diluted with ethyl acetate, and washed with aqueous sodium hydrogen carbonate solution. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure to obtain a crude product, and the following reaction was carried out without further purification. ccz / nn / zznz / E / Y 1H NMR (300 MHz, CHLOROFORM-D): δ 7.49 (s, 1H), 7.28 (s, 1H), 7.27 (d, 1H), 6.90-7.05 (m, 3H), 3.80-4.25 (m, 7H) , 3.25 (m, 2H) , 2.18 (m, 1H) , 1.75-1.98 (m, 2H) , 1.91 (m, 1H) , 1.43 (t, 3H), 1.27 (m, 1H) Preparation Example 3: (K)-2-chloro-6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazine Stage 1: 2-chloro-3-ethoxypyridine 2-Chloropyridin-3-ol (10.0 g, 77 mmol), iodoethane (14.45 g, 93 mmol) and potassium carbonate (21.34 g, 154 mmol) were added to 77 mL of DMF and stirred at room temperature for 48 hours. . The reaction mixture was filtered and water was added, followed by extraction with ethyl acetate. After washing with water and brine, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The desired product was obtained by purification with column chromatography. (99% performance) NMR (400 MHz, CHLOROFORM-D): δ 7.96 (t, J = 3.0 Hz, 1H), 7.17 (d, J = 3.2 Hz, 2H), 4.10 (q, J = 7.0 Hz, 2H), 1.48 (t , J = 7.1 Hz, 3H) Step 2: tert-butyl (R)-3-((3-ethoxypyridin-2-yl)oxy)piperidine-1carboxylate Sodium hydride (3.38 g, 84 mmol) was added to 96 ccz / nn / zznz / E / Y mL of anhydrous DMF, and tert-butyl (R)-3-hydroxypiperidin1-carboxylate (17.00 g, 84 mmol) was added. mmol). The temperature was raised to 60°C, stirred for 1 hour, and 2chloro-3-ethoxypyridine (12.1 g, 77 mmol) obtained in step 1 was added, followed by stirring for 24 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. After washing with water and brine, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The desired product was obtained by purification with column chromatography (75% yield). NMR (400 MHz, CHLOROFORM-D) : δ 7.68 (td, J = 3.2, 1.7 Hz, 1H), 7.03 (dt, J = 7.8, 1.4 Hz, 1H), 6.82-6.72 (m, 1H), 5.06 ( s, 1H), 4.03 (q, J = 7.0 Hz, 2H), 3.55 (d, J = 100.2 Hz, 4H), 2.16-1.96 (m, 1H), 1.96-1.70 (m, 2H), 1.68-1.50 (m, 1H), 1.50-1.27 (m, 12H) Step 3: (R)-2-chloro-6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazine The title compound was obtained in a similar manner to Step 3 of Preparation Example 1 by using tert-butyl (R)-3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-carboxylate (31.5 g, 98 mmol) obtained in step 2, (R)-3-ethoxy-2-(piperidin-3-yloxy)pyridine hydrochloride (30 g, 116 mmol) obtained by using in a manner similar to Step 2 of Example Preparation 1 and 2,6-dichloropyrazine (19 g, 128 mmol). (80% performance) ccz / nn / zznz / E / Y 1H NMR (400 MHz, CHLOROFORM-D) : δ 7.96 (d, J =11.0 Hz, 1H), 7.74-7.66 (m, 2H), 7.04 (dd, J = 7.8, 1.4 Hz,1H), 6.83 (dd, J = 7.8, 5.0 Hz, 1H), 5.24 (td, J = 7.0, 3.4 Hz,1H), 4.05-3.83 (m, 3H), 3.83-3.70 (m, 2H), 3.67-3.53 (m, 1H), 2.222.09 (m, 1H), 2.07-1.93 (m, 2H), 1.75-1.60 (m , 1H), 1.35-1.27 (t, J = 7.1 Hz, 3H) Preparation Example 4: (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyridine The desired product was obtained in a similar manner to step 3 of Preparation Example 1 by using (R)-3-(2-ethoxyphenoxy)piperidine hydrochloride (10 g, 45.2 mmol) obtained in step 2 of Preparation Example 1 and 2,6-dichloropyridine (11.37 g, 77 mmol). (41% yield) XH-NMR (400 MHz, Chloroform-D): δ 7.44-7.29 (M, 1h), 7.17-7.05 (m, 1h), 6.94-6.86 (m, 3h), 6.73-6.49 (m, 1h), 6.49 —6.32 (m, 1H), 4.30-4.17 (m, 2H), 4.04-3.96 (m, 2H), 3.95-3.78 (m, 1H), 3.35-3.18 (m, 2H), 2.22-2.07 (m, 1H), 1.97-1.75 (m, 2H), 1.64-1.52 (m, 1H), 1.40 (q, J = 6.9 Hz, 3H) Preparation Example 5: (R)-4-chloro-2-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrimidine ccz / nn / zznz / E / Y The title compound was synthesized in a similar manner to Preparation Example 1 (Step 2, Step 3) by using tert-butyl-(.R)-3-(2-ethoxyphenoxy)piperidine-l-carboxylate (15.0 g, 46.7 mmol) obtained in step 1 of Preparation Example 1 and 2,4-dichloropyrimidine (13.9 g, 93 mmol). (19% performance) , 1H) , 4.44(dd, 1H), 4.22 (m, 1H), 4.10 (m, 1H), 4.02 (m, 2H), 3.63 (m,1H), 3.51 (m, 1H), 2.12 (m, 1H), 1.92 (m, 2H), 1.55 (m, 1H), 1.40 (t, 3H) Preparation Example 6: (Λ)-2-chloro-4-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrimidine The title compound was synthesized in a similar manner to Preparation Example 1 (Step 2, Step 3) by using tert-butyl-(R)-3-(2-ethoxyphenoxy)piperidine-lcarboxylate (15.0 g, 46.7 mmol) obtained in step 1 of Preparation Example 1 and 2,4-dichloropyrimidine (13.9 g, 93 mmol). (72% yield) ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D): δ 7.97 (d, 1H), 6.98 (m, 2H), 6.89 (m, 2H), 6.32 (d, 1H), 4.31 (m, 1H), 4.01 (m, 3H), 3.71 (m, 3H), 2.01 (m, 3H), 1.61 (m, 1H), 1.38 (t, 3H) Preparation Example 7: (J?)-2-chloro-4-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrimidine It was used in a similar way to Stage 3 of the Preparation Example 1 to obtain the desired product by using (K)-3-ethoxy-2-(piperidin-3yloxy)pyridine hydrochloride (5.90 g, 22.80 mmol) obtained in step 3 of Preparation Example 3 and 2.4 -dichloropyrimidine (3.74 g, 25.08 mmol). (26% performance)1H-NMR (400 MHz, CHLOROFORM-D): δ 7.91 (d, J= 6.4 Hz, 1H), 7.70 (dd, J = 4.8, 1.6 Hz, 1H), 7.03 (dd, J = 7.8, 1.4 Hz, 1H), 6.82 (q, J = 4.1 Hz, 1H), 6.32 (d, J = 5.9 Hz, 1H), 5.19 (s, 1H), 4.05-3.59 (m, 6H), 2.25 -1.90 (m, 3H), 1.76-1.57 (m, 1H), 1.31 (t, J = 6.9 Hz, 3H) Preparation Example 8: (K) -2-chloro-4-(3-(2-ethoxyphenoxy) piperidin-l-yl)-5-fluoropyrimidine The title compound was synthesized in a ccz / nn / zznz / E / Y manner similar to Step 3 of Preparation Example 1 by using (R)-3-(2-ethoxyphenoxy)piperidine hydrochloride (4 g, 18.08 immol ) synthesized in step 2 of Preparation Example 1 and 2,4-dichloro-5-fluoropyrimidine (7.54 g, 45.2 mmol). (Yield 81%) Hz, 1H), 4.08-3.95 (m, 2H), 3.93 (s, 1H), 3.82 (dd, J = 24.6, 7.5 Hz, 2H), 2.151.95 (m, 3H), 1.63 (d, J = 7.9 Hz, 1H), 1.40 (q, J = 6.9 Hz, 3H) Preparation Example 9: (R) -4-chloro-2-(3-(2-ethoxyphenoxy)piperidin-l-yl)-5-( trifluoromethyl)pyrimidine The title compound was synthesized in a manner similar to Step 3 of Preparation Example 1 by using (R)-3-(2-ethoxyphenoxy)piperidine hydrochloride (1 g, 4.52 mmol) synthesized in step 2 of Preparation Example 1. Preparation 1 and 2,4dichloro-5-(trifluoromethyl)pyrimidine (2.45 g, 11.3 mmol). (38% performance) 1H-NMR (400 MHz, CHLOROFORM-D) : δ 8.37 (d, J = 21.0 Hz, 1H), 6.96 (t, J = 7.5 Hz, 2H), 6.87 (t, J = 5.5 Hz, 2H), 4.28 (td, J = 6.6, 3.4 Hz, 1H), 4.19 (s, 1H), 4.06-3.89 (m, 4H), 3.89-3.72 (1H), 2.16-1.88 (m, 3H) , 1.67 (s, 1H), 1.62-1.48 ccz / nn / zznz / E / Y (m, 1H) , 1.48-1.30 (m, 3H) Preparation Example 10: (R)-2-chloro-4-(3-(2-ethoxyphenoxy)piperidin-l-yl)-5-(trifluoromethyl)pyrimidine The title compound was synthesized in a similar manner to Step 3 of Preparation Example 1 by using (R)-3-(2-ethoxyphenoxy)piperidine hydrochloride (1 g, 4.52 mmol) synthesized in step 2 of Preparation Example 1. Preparation 1 and 2,4dichloro-5-(triflucromethyl)pyrimidine (2.45 g, 11.3 mmol). (28% performance)1H-NMR (400 MHz, CHLOROFORM-D): δ 8.36 (s, 1H), 7.127.01 (m, 1H), 7.01-6.91 (m, 1H), 6.90-6.78 (m, 2H), 4.32 (td, J = 7.5, 3.7 Hz, 1H), 4.16 (dd, J = 13.5, 3.0 Hz, 1H), 4.01 (td, J = 7.3, 6.3 Hz, 2H), 3.76 (dd, J = 13.5, 5.7 Hz, 1H), 3.683.47 (m, 2H), 2.19-1.84 (m, 4H), 1.71-1.57 (m, 1H), 1.39 (t, J = 7.1 Hz, 3H) Preparation Example 11: 4-Phenylpyridin-2-amine H?N Phenylboronic acid (0.14 g, 1.16 mmol), 4-bromopyridine-2-amine (0.2 g, 1.16 mmol), [1,1'-bis(diphenyIphosphino)ferrocene]dichloropalladium dichloromethane adduct (0.09 g, 0.12 mmol) was dissolved in 3 mi of 1.2- ccz / nn / zznz / E / Y dimethoxyethane, and 1 M saturated aqueous sodium hydrogen carbonate solution (3.47 ml, 3.47 mmol) were added dropwise, followed by stirring at 90°C for 5 hours. After cooling to room temperature, filtering through a Celite pad, and washing with dichloromethane, the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (Biotage 40 M column). (97% performance). δ = 7.3 Hz, 1H), 7.04-6.78 (m, 1H), 6.42 (q, J= 2.6 Hz, 1H), 4.57 (s, 1H) Preparation Example 12: Methyl 2-(6-Aminopyridin)acetate H2N Step 1: 2-(6-chloropyridin-3-yl)acetonitrile 2-Chloro-5-(chloromethyl)pyridine (5.0 g, 30.9 mmol) was dissolved in 20 ml of ethanol, and potassium cyanide (2.21 g, 33.9 mmol) was dissolved in 9 ml of water and added dropwise to 0°C. The reaction was stirred at reflux for 2 hours and then stirred at room temperature for 18 hours. After diluting in 500 ml of dichloromethane and washing with brine, the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product is ccz / nn / zznz / E / Y obtained by purification with a silica gel column (dichloromethane:hexane = 7:3). (83% performance) B-NMR (500 MHz, CHLOROFORM-D) δ 8.36 (d, J = 2.4 Hz, 1H), 7.77-7.60 (m, 1H), 7.38 (d, J = 8.6 Hz, 1H), 3.87-3.63 (2H) ) Step 2: Methyl 2-(6-Chloropyridin-3-yl)acetate 2-(6-chloropyridin-3-yl)acetonitrile (3.92 g, 25.7 mmol) obtained in step 1 was dissolved in 5 ml of concentrated hydrochloric acid and stirred at 80°C for 24 hours. The reaction was poured into ice water, extracted with 500 ml of dichloromethane, washed with brine, and then the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:1). (90% performance)XH-NMR (500 MHz, CHLOROFORM-D) J = 8.6 Hz, 1H), 3.71 (s, 3H), 3.61 (s, 2H) Step 3: Methyl 2-(6-Aminopyridin)acetate The desired product was obtained in a similar manner to Preparation Example 2 (Step 1, Step 2) by using methyl 2(6-chloropyridin-3-yl)acetate (2.0 g, 10.8 mmol) obtained in step 2 and carbamate. tert-butyl (3.8 g, 32.3 mmol). (26.8% performance) ccz / nn / zznz / E / Y iH-NMR (500 MHz, CHLOROFORM-D) δ 7.93 (d, J = 2.4 Hz, 1H), 7.39 (dd, J = 7.9, 2.4 Hz, 1H), 6.48 (d, J = 8.6 Hz, 1H), 4.49 (s, 2H), 3.68 (s, 3H), 3.47 (s, 2Η) Preparation Example 13: (E) -3-(6-Aminopyridin-3-yl)methyl acrylate _ H2N To a solution of 2-amino-5-bromopyridine (2.70 g, 15.61 mmol), palladium (II) acetate (0.16 g, 0.70 mmol), tris(o-tolyl)phosphine (0.48 g, 1.56 mmol), TEA ( 2.61 ml, 18.73 mmol) in 30 ml of DMF, methyl acrylate (1.48 g, 17.17 mmol) was added, and the mixture was stirred at 100°C for 6h. The reaction was quenched by the addition of water and everything was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over MgSCh, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / EA / MeOH = 4:1:0 to 2:1:0 to 2:1:0.1) to give the desired product as a yellow solid. (83% yield)1H-NMR (500 MHz, CHLOROFORM-D) δ 8.18 (d, J = 1.8 Hz, 1H), 7.74-7.63 (m, 1H), 7.56 (s, 1H), 6.50 (d, J = 8.6 Hz, 1H), 6.25 (d, J = 15.9 Hz, 1H), 4.73 (s, 2H) ), 3.78 (s, 3H) Preparation Example 14: Methyl 2-(4-Aminophenyl)-2-methylpropanoate ccz / nn / zznz / E / Y xy i η2ν Step 1: Methyl 2-(4-Nitrophenyl)acetate Concentrated sulfuric acid (34 ml, 0.64 mol) was added to water (34 ml), and 4-nitropheniiacetonitrile (11.8 g, 73 mmol) was added to this mixture. The reaction mixture was heated at reflux for 30 min, diluted with 34 ml of water, and cooled to 0°C when the colorless crystalline solid separated. The solid was filtered, washed with ice cold water to remove trace acid, and dried to produce the acid. And then the solid was treated with THF / diazomethane at 0°C. The product was obtained by evaporation and column chromatography. (56% performance) (s, 3H) Step 2: methyl 2-methyl-2-(4-nitrophenyl)propanoate To a suspension of sodium hydride (60 percent in oil, 1.47 g, 37 mmol) in DMF (50 mL) at 0°C, methyl 2(4-nitrophenyl)acetate (3.25 g, 16.7 mmol) obtained in stage 1. The mixture was stirred for 15 minutes at 0°C and iodomethane (4.2 ml, 6.6 mmol) was added. The mixture was stirred for an additional 5 minutes at 0°C and at room temperature for 12 hours, then quenched with 1N aqueous hydrochloric acid (1 mL) and extracted with EtOAc (30 x 2 mL). The organic layer was washed with water (30 χ 2 mL) and ccz / nn / zznz / E / Y brine (20 mL), dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (EtOAc: Hexane = 1:3) to give the desired product. (57% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 8.17 (d, J = 8.7 Hz, 2H), 7.49 (d, J = 8.7 Hz, 2H), 3.66 (s, 3H), 1.61 (s, 6H) Step 3: Methyl 2-(4-Aminophenyl)-2-methylpropanoate A mixture of methyl 2-methyl-2-(4-nitrophenyl)propanoate (2.11 g, 9.45 mmol) and Pd / C (0.2 g) in MeOH (30 ml) was stirred under a balloon of H2 at room temperature for 4 hours. , then filtered through celite to give the product (Yield 95%). !H-NMR (400 MHz, CHLOROFORM-D) δ 7.12 (d, J = 8.2 Hz, 2H), 6.64 (d, J = 8.7 Hz, 2H), 3.62 (s, 3H), 1.52 (d, J = 0.9 Hz, 6H) Preparation Example 15: Methyl 2-(3-Aminophenyl)-2-methylpropanoate H2N The desired product was obtained in a similar manner to Preparation Example 14 by using 2-(3nitrophenyl)acetic acid (4 g, 22.08 mmol). (30% 3-stage performance) ^-NMR (400 MHz, CHLOROFORM-D) δ 7.15-7.03 (m, 1H), 6.78-6.67 (m, 1H), 6.67-6.59 (1H), 6.58-6.51 (m, 1H), 3.65 (q, ccz / nn / zznz / E / Y J = 14.9 Hz, 3H), 1.61-1.45 (m, 6H) Preparation Example 16: Methyl 2-(2-Aminobenzo[d]oxazol-5-yl)acetate The desired product was obtained in a similar manner to Preparation Example 18 (Step 1, Step 2, Step 3, Step 5, Step 6) by using 2-(4-hydroxyphenyl)acetic acid (20 g, 10,131 mmol). (5-stage performance of 48%) Ή NMR (400 MHz, CHLOROFORM-D) δ 7.27 (s, 1H), 7.21 (d, J = 8.2 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 5.46 (s, 2H), 3.69 (s, 3H), 3.67 (s, 2H) Preparation Example 17: Methyl 2-(2-Aminobenzo[ d]oxazol-5-yl)-215 methylpropanoate The desired product was prepared in a similar manner to Preparation Example 18 (Step 1, Step 2, Step 3, Step 4, Step 5, Step 6) by using 2-(4hydroxyphenyl)acetic acid (20 g, 131 mmol). (6-stage performance of 43%)LH-NMR (400 MHz, CHLOROFORM-D) δ 7.34 (d, 7=1.8 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.04 (dd, J = 8.7, 1.8 Hz, 1H), ccz / nn / zznz / E / Y 5.58 (s, 2H), 3.65 (s, 3H), 1.61 (s, 6H) Preparation Example 18: Methyl 2-(2-Aminobenzo[d]oxazol-6-yl)-2methylpropanoate Io— / =\ O H2N^N Stage 1: 2-(3-hydroxy-4-nitrophenyl)acetic acid 2-(3-hydroxyphenyl)acetic acid (2 g, 13.15 mmol) and 4 ml of 70% nitric acid were stirred at room temperature for 30 minutes. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The following reaction was carried out without an additional column. m / z (M+H)+calculated for CsHvNOs: 198, found 198 Step 2: Methyl 2-(3-Hydroxy-4-nitrophenyl)acetate 2-(3-hydroxy-4-nitrophenyl)acetic acid (2.59 g , 13.14 mmol) obtained in step 1 and 0.245 ml of sulfuric acid were dissolved in 50 ml of methanol and stirred at 70°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic ccz / nn / zznz / E / Y solvent was dried over magnesium sulfate, and removed under reduced pressure. . The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (26.8% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 10.57 (s, 1H), 8.05 (d, J= 8.7 Hz, 1H), 7.10-7.03 (m, 1H), 6.90 (dd, J = 8.7, 1.8 Hz, 1H), 3.71 (s, 3H), 3.65 (s, 2H) Step 3: Methyl 2-(3-(Benzyloxy)-4-nitrophenyl)acetate Methyl 2-(3-Hydroxy-4-nitrophenyl)acetate (0.744 g, 3.52 mmol) obtained in step 2, 0.4 61 ml of benzyl bromide and potassium carbonate (1.315 g, 9.52 mmol) were added to 30 ml of DMF and stirred at room temperature for 15 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (30.1% yield)1H-NMR (400 MHz, CHLOROFORM-D) δ 7.90-7.73 (m, 1H), 7.45 (dd, J = 16.5, 9.1 Hz, 2H), 7.42-7.35 (m, 2H), 7.35-7.28 (m, 1H), 7.12-7.04 (m, 1H), 6.93 (dd, J = 8.2, 1.4 Hz, 1H), 5.28-5.18 (m, 2H), 3.71-3.66 (m, 3H), 3.66-3.59 (m, 2H) ccz / nn / zznz / E / Y Step 4: Methyl 2-(3-(Benzyloxy)-4-nitrophenyl)-2-methylpropanoate Sodium hydride (0.076 g, 3.19 mmol) was dissolved in 10.6 ml of DMF in the presence of nitrogen, methyl 2-(3-(benzyloxy)4-nitrophenyl)acetate (0.32 g, 1.062 mmol) obtained in step 3 It was dissolved in DMF and added slowly drop by drop, followed by stirring at 0°C for 15 minutes. Then, 0.166 ml of methyl iodide was added and stirred at room temperature for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 χ 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (85% yield) , 7.35 (t, J = 7.2 Hz, 1H), 7.07 (s, 1H), 7.02 (d, J = 8.5 Hz, 1H), 5.26 (s, 2H), 3.69-3.58 (m, 3H), 1.58- 1.53 (m, 6H) Step 5: Methyl 2-(4-Amino-3-hydroxyphenyl)-2-methylpropanoate The desired product was obtained in a similar manner to step 3 of Preparation Example 94 by using methyl 2-(3(benzyloxy)-4-nitrophenyl)-2-methylpropanoate (0.297 g, ccz / nn / zznz / E / AND 0.902 mmol) obtained in step 4. (89% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 6.78-6.65 (m, 3H), 3.76-3.60 (m, 3H), 1.49 (d, J = 15.1 Hz, 6H) Step 6: Methyl 2-(2-Aminobenzo[d]oxazol-6-yl)-2-methylpropanoate Methyl 2-(4-Amino-3-hydroxyphenyl)-2-methylpropanoate (0.167 g, 0.798 mmol) obtained in step 5 and cyanogen bromide (0.423 g, 3.99 mmol) were dissolved with 5.7 ml of methanol and 5.7 ml of water and stirred at room temperature for 6 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 X 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The following reaction was carried out without further purification. XH-NMR (400 MHz, CHLOROFORM-D) δ 7.29-7.26 (m, 1H), 7.25 (d, J = 2.7 Hz, 1H), 7.16 (dd, J = 8.7, 1.8 Hz, 1H), 5.44 (s, 1H), 3.66-3.61 (m, 3H), 1.64-1.55 (m, 6H) Preparation Example 19: Methyl 2-(6-Aminopyridin-3-yl)-2-methylpropanoate Step 1: Methyl 2-(6-Chloropyridin-3-yl)acetate At 0°C, acetyl chloride was added dropwise to ccz / nn / zznz / E / Y 48.6 ml of methanol, followed by stirring for 15 minutes. After adding 2-(6-chloropyridin-3-yl)acetic acid (2.50 g, 14.6 mmol), the mixture was stirred at 100°C for 5 hours, and the organic solvent was removed under reduced pressure. It was diluted with ethyl acetate, washed with brine, and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure to obtain the desired product. (96% performance) AH-NMR (400 MHz, CHLOROFORM-D) δ 8.29 (d, J = 2.3 Hz, 1H), 7.62 (dd, J = 8.2, 2.7 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 3.72 (s, 3H), 3.62 (s, 2H) Step 2: Methyl 2-(6-Chloropyridin-3-yl)-2-methylpropanoate DMF in which sodium hydride (60%, 0.948 g, 23.7 mmol) was dissolved was lowered to 0°C, and methyl 2-(6chloropyridin-3-yl)acetate synthesized in step 1 was added. After stirring for 15 minutes at 0°C, iodomethane (2.70 ml, 43.1 mmol) was added dropwise thereto. After stirring for an additional 5 minutes at 0°C, the mixture was stirred at room temperature for 15 hours. After washing with ethyl acetate, it was washed with 1N hydrochloric acid solution, and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (59% yield) ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D) δ 8.38 (d, J = 2.7 Hz, 1H), 7.63 (dd, J = 8.2, 2.7 Hz, 1H), 7.29 (d, J = 8.2 Hz, 1H), 3.67 (s, 3H), 1.61 (s, 6H) Step 3: Methyl 2-(6-((tert-Butoxycarbonyl)amino)pyridin-3yl)-2-methylpropanoate After dissolving methyl 2-(6-chloropyridin-3-yl)-2methylpropanoate (0.47 g, 2.2 mmol) synthesized in step 2, tez-butyl carbamate (0.77 g, 6.6 mmol), cesium carbonate (1.08 g , 3.30 mmol), 4,5-bis(diphenylphosphino)-9,9dimethylxanthine (255 mg, 0.440 mmol) and tris(dibenzylideneacetone)dipalladium (0) (201 mg, 0.220 mmol) in 1,4-dioxane 11.0 ml, the Dissolved oxygen was removed through nitrogen bubbling under agitation, and the outside air flow inlet was blocked in a sealed container. The reaction was stirred at 140°C for 15 hours and then cooled to room temperature. After filtering through a Celite pad and removing the organic solvent under reduced pressure, it was dissolved in ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (26% performance) , 7.47-7.36 (1H), 3.65 (s, 3H), 1.66-1.58 (6H), 1.52 (s, 9H) ccz / nn / zznz / E / Y Step 4: Methyl 2-(6-Aminopyridin-3-yl)-2-methylpropanoate After dissolving methyl 2-(6-((tert-butoxycarbonyl)amino)pyridin-3-yl)-2-methylpropanoate (169 mg, 0.574 inmol) synthesized in step 3 in 3.00 ml of DCM, 4 N solution of Hydrogen chloride in dioxane was added dropwise. After stirring at room temperature overnight, the organic solvent was removed under reduced pressure, neutralized, extracted with ethyl acetate, and purified by a silica gel column (DCM: methanol) to obtain the desired product. (71% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.81-7.62 (m, 2H), 7.43 (s, 2H), 7.18 (d, J = 9.1 Hz, 1H), 3.68 (s, 3H), 1.55 (s, 6H) Preparation Example 20: Ethyl 2-(2-aminopyrimidin-4-yl)-2-methylpropanoate Step 1: Diethyl 2-(2-Chloropyrimidin-4-yl)-malonate Sodium hydride (60%, 7.89 g, 197 mmol) was added to 300 ml of THF in which diethyl malonate (15.8 g, 99.0 mmol) at 0°C. After stirring at the same temperature for 30 minutes, 2,4-dichloropyrimidine (9.80 g, 65.8 mmol) was added, followed by stirring at ccz / nn / zznz / E / Y reflux at 90°C for 3 hours. The reaction was terminated by adding saturated aqueous ammonium chloride solution to the reaction solution, followed by extraction with ethyl acetate. The organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (96% performance) -4.17 (m, 4H), 1.29 (q, J = 7.0 Hz, 6H) Step 2: ethyl 2-(2-Chloropyrimidin-4yl)acetate Diethyl 2-(2-Chloropyrimidin-4-yl)-malonate (17.3 g, 63.4 mmol) synthesized in step 1 and sodium ethoxide (20%, 6.48 g, 19.0 mmol) were dissolved in 150 ml of ethanol and stirred at reflux for 3 hours. The pH was adjusted to pH 7 with 1 N aqueous hydrochloric acid, extracted with ethyl acetate, dried over magnesium sulfate, and purified by silica gel column (ethyl acetate:hexane) to obtain the desired product. (68% performance)1H-NMR (400 MHz, CHLOROFORM-D) 8.59 (d, J = 5.0 Hz, 1H), 7.34 (d, J = 5.0 Hz, 1H), 4.31-4.12 (2H), 3.83 ( s, 2H), 1.38-1.19 (m, 3H) Step 3: Ethyl 2-(2-Aminopyrimidin-4-yl)-2-methylpropanoate The desired product was obtained in a similar manner ccz / nn / zznz / E / Y to Preparation Example 19 (Step 2, Step 3, Step 4) by using ethyl 2-(2-chloropyrimidin-4-yl)acetate ( 5.70 g, 28.4 mmol) synthesized in Stage 2. (3-stage yield of 36%) m / z (M+H)+calculated for C10H16N3O2: 210, found 210 Preparation Example 21: Methyl 3-(2-Aminobenzo[d]oxazol-5-yl)-2,2dimethylpropanoate Step 1: Methyl 3-(4-Hydroxyphenyl)-2,2-dimethylpropanoate Indium(III) bromide (0.41 g, 1.16 mmol) and dimethylketene trimethylsilyl methyl acetal (6.08 g, 34.9 mmol) were dissolved in dichloromethane, and then 1(benzyloxy)-4-(bromomethyl)benzene (6.44 g, 23.2 mmol). After stirring at room temperature for 2 hours, the reaction solution was poured into a saturated aqueous sodium bicarbonate solution. After the mixture was extracted with ethyl acetate, the organic solvent was dried over magnesium sulfate, and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:3). (60% yield) ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D) δ 6.96 (d, J = 8.7 Hz, 2H), 6.75-6.68 (2H), 4.86-4.71 ( 1H), 3.65 (s, 3H), 2.78 (s, 2H), 1.20-1.13 (m, 6H) Step 2: Methyl 3-(4-Hydroxy-3-nitrophenyl)-2,2-dimethylpropanoate Methyl 3-(4-Hydroxyphenyl)-2,2-dimethylpropanoate (2.9 g, 13.9 mmol) synthesized in step 1 was dissolved in acetic acid, lowered to 0°C, and nitric acid (70%, 1.02) was slowly added. mi, 16.01 mmol), and the reaction temperature was gradually raised to room temperature over 1 hour, followed by stirring. After completion of the reaction, it was extracted with ethyl acetate, and the organic solvent was dried over magnesium sulfate, and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:3). (56% performance) , 7.06 (d, J = 8.2 Hz, 1H), 3.68 (t, J = 15.1 Hz, 3H), 2.82 (d, J = 15.1 Hz, 2H), 1.20 (s, 6H) Step 3: Methyl 3-(3-Amino-4-hydroxyphenyl)-2,2-dimethylpropanoate methyl 3-(4-Hydroxy-3-nitrophenyl)-2,2-dimethylpropanoate (1.97 g, 7.78 mmol) prepared in Stage 2 was dissolved in methanol, Pd / C (207 mg, 0.19 mmol) was added, and then a ccz / nn / zznz / E / Y hydrogen balloon was connected and stirred at room temperature for 4 hours. After completion of the reaction, the desired compound was synthesized by Celite filter. (98% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 6.84 (s, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.62-6.54 (1H), 5.44 (s, 2H) , 3.62 (s, 3H), 2.65 (s, 2H), 1.12 (d, J = 7.8 Hz, 6H) Step 4: Methyl 3-(2-Aminobenzo[d]oxazol-5-yl)-2,2-dimethylpropanoate Methyl 3-(3-Amino-4-hydroxyphenyl)-2,2-dimethylpropanoate (1.7 g, 7.61 mmol) synthesized in step 3 was dissolved in methanol, lowered to 5°C, and cyanogen bromide (3.1 ml , 9.14 mmol) dissolved in 10 ml of water was added slowly while stirring vigorously. After stirring at room temperature for 2 hours, sodium bicarbonate (640 mg, 7.61 mmol) was added for 1 hour to adjust the pH of the reaction solution from 6.5 to 7.0, followed by stirring at room temperature for an additional 1 hour. The resulting solid was filtered, washed with cold water, and recrystallized to obtain the desired compound. (65% performance) (s, 2H), 3.66 (s, 3H), 2.90 (s, 2H), 1.17 (d, J = 13.3 Hz, 6H) Preparation Example 22: (E)-3-(2-Aminobenzo[d]oxazol-5yl)methyl acrylate ccz / nn / zznz / E / Y Stage 1: (E)-3-(4-Hydroxy-3-nitrophenyl)methyl acrylate Sodium hydride (2.154 g, 90 mmol) was dissolved in 6 ml of DMF in the presence of nitrogen, and methyl-2(diethoxyphosphoryl)acetate (11.32 g, 53.9 mmol) was dissolved in THF, added slowly dropwise, and then stirred for 15 minutes at 0°C. Then, 4-hydroxy-3-nitrobenzaldehyde (3 g, 17.95 mmol) was added and stirred at room temperature for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 χ 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The following reaction was carried out without further purification. Step 2: Methyl (E)-3-(3-Amino-4-hydroxyphenyl)acrylate (E)-methyl 3-(4-Hydroxy-3-nitrophenyl)acrylate (4 g, 17.92 mmol) synthesized in step 1, iron (3.5 g, 62.7 mmol) and 3.08 ml of acetic acid were dissolved in 60 ml of ethanol and stirred at 75°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent ccz / nn / zznz / E / Y was removed under reduced pressure. After extraction with ethyl acetate (2X 30 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (20% performance)1H-NMR (400 MHz, METHANOL-D4) δ 7.59-7.42 (m, 1H), 7.07-6.88 (m, 1H), 6.88-6.74 (m, 1H), 6.73-6.58 (m , 1H), 6.296.10 (m, 1H), 3.82-3.63 (m, 3H), 3.35-3.21 (m, 2H) Step 3: Methyl (E)-3-(2-Aminobenzo[d]oxazol-5-yl)acrylate The desired product was obtained in a similar manner to step 6 of Preparation Example 18 by using methyl (Ej-3-(3amino-4-hydroxyphenyl)acrylate (0.7 g, 3.62 mmol) synthesized in step 2. (Yield of 67%)XH-NMR (400 MHz, METHANOL-D4) δ 7.82-7.58 (m, 1H), 7.55-7.38 (m, 1H), 7.36-7.19 (m, 2H), 6.53-6.35 (m, 1H), 3,863.62 (3H) Preparation Example 23: Methyl 3-(2-Aminobenzo[d]oxazol-5-yl)propanoate EITHER- H2N^N Stage 1 :Methyl 3-(3-Amino-4-hydroxyphenyl)propanoate ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Step 3 of Preparation Example 94 by using methyl (E)-3(4-hydroxy-3-nitrophenyl)acrylate (5.34 g, 23.93 mmol) obtained in Step 1 of Preparation Example 22. The following reaction was carried out without further purification. Step 2: Methyl 3-(2-Aminobenzo[d]oxazol-5-yl)propanoate The desired product was obtained in a similar manner to step 6 of Preparation Example 18 by using methyl 3—(3—amino-4-hydroxyphenyl)propanoate (4.67 g, 23.92 mmol) synthesized in step 1. (Yield of 40%) m / z (M+H)+ calculated for C11H13N2O3: 221, found 221 Preparation Example 24: Methyl 3-(2-Aminobenzo[d]oxazol-6-yl)propanoate h2n n Step 1: methyl 3-(4-Amino-3-hydroxyphenyl)propanoate The desired product was obtained in a similar manner to Preparation Example 22 (Step 1) and Preparation Example 94 (Step 3) by using 3-hydroxy-4nitrobenzaldehyde (1.8 g, 10.77 mmol). (2-stage performance of 36%)XH-NMR (400 MHz, METHANOL-D4) δ 6.74-6.57 (m, 1H), 6.57- 6.50 (m, 1H), 6.50-6.35 (m, 1H), 3.65-3.49 (m, 3H), 2,822.59 (m, 2H), 2.59-2.39 (2H) Step 2: Methyl 3-(2-Aminobenzo[djoxazol-6-yl)propanoate The desired product was obtained in a similar manner to Preparation Example 18 (step 6) by using methyl 3-(4-amino3-hydroxyphenyl)propanoate (0.75 g, 3.87 mmol) synthesized in step 1. (Yield 51.7% ) m / z (M+H)+calculated for C11H13N2O3: 221, found 221 Preparation Example 25: 4-phenyloxazole-2-amine H2N 2-Bromo-l-phenylethan-l-one (0.100 g, 0.502 mmol) was dissolved in acetonitrile (5.02 ml), stirred at room temperature, and urea (0.302 g, 5.02 mmol) was added. After stirring at 80°C for 16 hours, the solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (19.8% yield)XH-NMR (500MHz, CHLOROFORM-D) δ 7.74-7.55 (m, 2H), 7.55- 7.44 (m, 1H), 7.44-7.34 (m, 2H), 7.30 (t, J = 7.5 Hz, 1H), 5.15 (d, J = 42.1 Hz, 2H) ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y Preparation Example 26: Methyl 2-(4-(2-Aminopyridin-4-yl)phenyl)-2-methylpropanoate Stage 1 : Methyl 2-Methyl-2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxophorolein-2-yl)phenyl)propanoate Methyl-(4-Bromophenyl)-2-methylpropanoate (1 g, 3.89 mmol) and bis(pinacolato)diborone (1.481 g, 5.83 mmol) were dissolved in toluene (19.45 ml), dichloromethane complex of [1, 1'-bis(diphenylphosphino)ferrocene]dichloropalladium (0.159 g, 0.194 mmol) and potassium acetate (1.527 g, 15.56 mmol). The mixture was stirred at reflux for 16 hours at 110°C. It was filtered through a Celite pad and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (72% performance) (d, J = 13.7 Hz, 7H), 1.32 (s, 12H) Stage 2 : Methyl 2-(4-(2-Aminopyridin-4-yl)phenyl)-2-methyl propanoate The desired product was obtained in a similar manner to Preparation Example 11 by using 2-methyl-2-(4-(4,4,5,5tetramethyl-1,3,2-dioxophorolein-2-yl)phenyl)propanoate. methyl (0.851 g, 2.80 mmol) obtained in step 1 and 4-bromopyridin2-amine (0.484 g, 2.80 mmol). (100% performance) , 6.86 (dd, J = 5.5, 1.4 Hz, 1H), 6.68 (s, 2H), 4.46 (s, 1H), 3.67 (s, 3H), 1.60 (s, 6H) Preparation Example 27: Methyl 2-(3-(2-Aminopyridin-4-yl)phenyl)-2methylpropanoate H2N The desired product was obtained in a similar manner to Preparation Example 26 by using methyl 2-(3-bromophenyl)-2methylpropanoate (1 g, 3.89 mmol). (90% 2-stage performance) (dd, J = 5.2, 1.5 Hz, 1H), 6.71 (s, 1H), 4.51 (s, 2H), 3.70 (s, 3H), 1.65 (s, 6H) Preparation Example 28: 1-(2- Ethyl aminopyrimidin-4-yl)piperidin4-carboxylate ccz / nn / zznz / E / Y EITHER Step 1: Ethyl 1-(2-Chloropyrimidin-4-yl)piperidine-4carboxylate ccz / nn / zznz / E / Y 2,4-Dichloropyrimidine (0.1 g, 0.671 mmol) was dissolved in ethanol (6.71 ml), and ethyl piperidine-4-carboxylate (0.124 ml, 0.806 mmol) and TEA (0.187 ml, 1.343 mmol) were added. It was stirred at 85°C for 3 hours. After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The desired product was obtained by purification with a silica gel column. (80% yield)XH-NMR (CHLOROFORM-D) δ 8.05 (d, J = 6.4 Hz, 1H), 6.42 (d, J = 6.1 Hz, 1H), 4.27 (s, 2H), 4.22-4.16 (2H), 3.22-3.06 (2H), 2.63 (tt, J = 10.6, 4.1 Hz, 1H), 2,061.96 (m, 2H), 1.86-1.67 (2H), 1.29 (td, J = 7.2, 4.5 Hz, 3H) Step 2: Ethyl 1-(2-((tert-Butoxycarbonyl)amino)pyrimidin-4yl)piperidine-4-carboxylate The desired product was obtained in a similar manner to Step 1 of Preparation Example 2 by using ethyl l—(2—chloropyrimidin-4-yl)piperidine-4-carboxylate (1.43 g, 5.30 mmol) obtained in step 1 and tert-butyl carbamate (0.683 g, 5.83 mmol). (37% performance)1H-NMR (500MHz, CHLOROFORM-D) δ 7.88 (d, J = 6.1 Hz, 1H), 6.04-5.92 (1H), 4.76-4.70 (1H), 4.26 (d, J = 13.1 Hz, 2H), 4.22-4.09 (m, 2H), 3.09-2.93 (m, 2H), 2.66-2.50 (m, 1H), 1.98 (dd, J = 13.6, 3.8 Hz, 2H), 1.82-1.68 ( 2H), 1.64 (s, 9H), 1.311.22 (m, 3H) Step 3: ethyl 1-(2-Aminopyrimidin-4-yl)piperidin-474 ccz / nn / zznz / E / Y carboxylate Ethyl 1-(2-((ter-Butoxycarbonyl)amino)pyrimidin-4-yl)piperidine-4-carboxylate (0.480 g, 1.370 mmol) obtained in step 2 was dissolved in DCM (12.3 ml), and then acid Trifluoroacetic acid (1.37 ml) dissolved in DCM was added and stirred at room temperature for 2 hours. After removing the solvent under reduced pressure, it was dissolved in DCM and washed with water. The desired product was obtained by purification with a silica gel column. (100% performance) Ή NMR (CHLOROFORM-D) δ 10.02-9.49 (1H), 7.56 (d, J = 7.3 Hz, 1H), 6.10 (d, J= 7.6 Hz, 1H), 4.90-4.54 (1H), 4.20 (q, J = 7.1 Hz, 2H), 4.00-3.77 (1H), 3.28 (d, J = 16.5 Hz, 2H), 2.74-2.62 (m, 1H), 2.07 (d, J = 12.5 Hz, 2H), 1.91- 1.69 (2H), 1.30 (t, J = 7.2 Hz, 3H) Preparation Example 29: Ethyl 1-(6-Aminopyridin-2-yl)piperidine-4carboxylate EITHER Step 1: Ethyl 1-(6-Chloropyridin-2-yl)piperidine-4carboxylate 2,6-Dichloropyridine (0.565 g, 3.82 mmol) was dissolved in ethanol (6.71 ml), and ethyl piperidine-4-carboxylate (0.500 g, 3.18 mmol) and DIPEA (1.11 ml, 6.36 mmol) were added. ccz / nn / zznz / E / Y was stirred at 100°C for 16 hours. After the reaction was completed by adding water, it was dissolved in diethyl ether and washed with water. The desired product was obtained by purification with a silica gel column. (53% yield)1H-NMR (CHLOROFORM-D) ¿7.40 (t, J= 7.8 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H) , 4.38-4.04 (m, 4H), 3.13-2.91 (m, 2H), 2.55 (tt, J = 11.0, 3.9 Hz, 1H), 2.01 (dd, J = 13.4, 3.4 Hz, 2H), 1.88-1.68 (m, 2H), 1.29 (t, J = 7.2 Hz, 3H) Step 2: ethyl 1-(6-Aminopyridin-2-yl)piperidine-4carboxylate The desired product was obtained in a similar manner to Preparation Example 28 (step 2, step 3) by using ethyl 1(6-chloropyridin-2-yl)piperidin-4-carboxylate obtained in step 1. (yield of 2 36%)XH-NMR (500 MHz, CHLOROFORM-D) Hz, 2H), 3.94 (d, J = 13.7 Hz, 2H), 3.22 (t, J = 10.8 Hz, 2H), 2.69-2.54 (m, 1H), 2.08 (dd, J = 13.9, 3.5 Hz, 2H) ), 1.98-1.79 (m, 2H), 1.29 (t, J = 7.0 Hz, 3H) Preparation Example 30: Ethyl (R)-1-(2-Aminopyrimidin-4-yl)piperidine-3-carboxylate ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Preparation Example 28 by using ethyl (R)-piperidine-3carboxylate (0.621 ml, 4.03 mmol). (3-stage performance of 6%)1H-NMR (500MHz, CHLOROFORM-D) δ 7.68 (d, J = 6.7 Hz, 1H), 6.49-6.21 (1H), 6.07 (d, J = 6.Ί Hz, 1H), 4.31 (d, J = 13.1 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 4.01 (d, J = 13.1 Hz, 1H), 3.43-3.30 (1H), 3.30-3.16 ( 1H), 2.63-2.47 (m, 1H), 2.192.03 (m, 1H), 1.91-1.76 (m, 2H), 1.65-1.46 (m, 1H), 1.26 (t, J = 7.0 Hz, 3H) Preparation Example 31: Ethyl (R)-1-(6-Aminopyridin-2yl)piperidine-3-carboxylate The desired product was obtained in a similar manner to Preparation Example 29 by using ethyl (R)-piperidine-3carboxylate (0.500 g, 3.18 mmol). (37% 3-stage performance) J = 7.0 Hz, 2H), 3.94 (d, J = 13.7 Hz, 2H), 3.22 (t, J= 10.8 Hz, 2H), 2.69-2.54 (m, 1H), 2.08 (dd, J = 13.9, 3.5 Hz, 2H), 1.98-1.79 (m, 2H), 1.29 (t, J = 7.0 Hz, 3H) Preparation Example 32: 2- (1-(2-Aminopyrimidin-4-yl)piperidin-4-yl) ethyl acetate ccz / nn / zznz / E / Y Step 1:2-(1-(2-Chloropyrimidin-4-yl)piperidin-4yl)ethyl acetate The desired product was obtained in a similar manner to Step 4 of Preparation Example 36 by using ethyl 2(piperidin-4-yl)acetate (0.315 g, 1.84 mmol) obtained in Step 3, 2,6-dichloropyrimidine ( 2.023 mmol) and 0.77 ml of triethylamine. (86% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.90-7.72 (m, 1H), 6.34- 6.17 (m, 1H), 4.65-4.02 (m, 2H), 3.98 (q, J = 7.2 Hz, 2H), 2.94-2.62 (m, 2H), 2.21-2.04 (m, 2H), 2.04- 1.81 (m, 1H), 1.811.55 (m, 2H), 1.23-0.93 (m, 5H) Step 2:2-(1-(2-Aminopyrimidin-4-yl)piperidin-4yl)ethyl acetate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using ethyl 2(1-(2-chloropyrimidin-4-yl)piperidin-4-yl)acetate (0.45 g, 1.586 mmol) synthesized in Stage 1. (2-stage yield of 61%) 4.88-4.57 (2H), 4.32 (d, J = 13.3 Hz, 2H), 4.13 (q, J = 7.2 Hz, 2H), 3.00-2.71 (m, 2H), 2.41-2.11 (m, 2H), 2.06 (qt, J = 11.2, 3.8 Hz, 1H) , 1.87-1.63 (m, 2H) , 1.371.04 (m, 5H) ccz / nn / zznz / E / Y Preparation Example 33: Methyl 2-(1-(2-Aminopyrimidin-4-yl)piperidin-4-yl)-2-methylpropanoate Step 1: Methyl 2-(1-(2-Chloropyrimidin-4-yl)piperidin-4-yl)2-methylpropanoate The desired product was obtained in a similar manner to Step 4 of Preparation Example 36 by using methyl 2-methyl-2(piperidin-4-yl)propanoate (0.26 g, 1.403 mmol) obtained in Step 4 of Example 36. Preparation 34 and 2,4dichloropyrimidine (0.23 g, 1.544 mmol. (Yield 81%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.13-7.81 (m, 1H), 6.44- 6.26 (m, 1H), 4.41 (s, 1H), 3.72-3.52 (m, 3H), 2.82 (d, J = 9.1 Hz, 2H), 2.32-1.74 (m, 2H), 1.63 (d, J = 8.7 Hz, 2H), 1.43-1.16 (m, 2H), 1.16-0.91 (m, 6H) Step 2: Methyl 2-(1-(2-Aminopyrimidin-4-yl)piperidin-4-yl)2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3 and Step 4) by using methyl 2(1-(2-chloropyrimidin-4-yl)piperidin-4-yl)-2-methylpropanoate (0.344 g, 1,155 mmol) obtained in step 1. (59% 2-stage performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.92-7.67 (m, 1H), 5.96- 5.77 (m, 1H), 4.83 (d, J = 43.0 Hz, 2H), 4.50-4.27 (m, ccz / nn / zznz / E / Y 2Η), 3.72-3.58 (m, 3H), 2.81-2.59 (m, 2H), 1.93-1.70 (m, 1H), 1.68-1.42 (m, 2H), 1.31-1.15 (m, 2H), 1.15- 0.96 (m, 6H) Preparation Example 34: Methyl 2-(1-(6-Aminopyridin-2-yl)piperidin4-yl)-2-methylpropanoate Step 1: tert-butyl 4-(2-methoxy-2-oxoethylidine)piperidine-1carboxylate Methyl 2-(Triphenyl-X5-phosphanylidene)acetate (15.6 g, 46.7 mmol) and tert-butyl 4-oxopiperidin-l-carboxylate (5 g, 25.09 mmol) were dissolved in 50 ml of toluene and stirred at temperature environment for 4 hours. After confirming that the starting material disappeared by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 χ 30 ml), the mixture was washed with brine (20 ml), the organic solvent was dried over magnesium sulfate, and then the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica qel column (ethyl acetate:hexane = 1:9). (94% performance) AH-NMR (400 MHz, CHLOROFORM-D) δ 5.70 (s, 1H), 3.743.63 (3H), 3.56-3.38 (m, 4H), 2.92 (t, J = 5.7 Hz, 2H), 2.362.20 (m, 2H), 1.51-1.37 (m, 9H) Step 2: 4-(2-methoxy-2-oxoethyl)piperidin-180 ccz / nn / zznz / E / Y tert-butyl carboxylate The desired product was obtained in a manner similar to Step 3 of Preparation Example 94 by using tert-butyl 4—(2—methoxy-2-oxoethylidin)piperidine-l-carboxylate (1 g, 3.92 mmol) obtained in the Stage 1. (99% Yield) 2.21 (2H), 2.00-1.89 (m, 1H), 1.70 (d, J = 13.1 Hz, 2H), 1.51-1.41 (m, 9H), 1.17 (qd, J = 12.3, 4.2 Hz, 2H) Step 3: tert-butyl 4-(l-methoxy-2-methyl-l-oxopropan-2-yl)piperidine-l-carboxylate 1.67 ml of diisopropylamine was dissolved in 7.5 ml of THF in the presence of nitrogen, and 4.66 ml of n-butyllithium was added slowly dropwise at 0°C, followed by stirring for 30 minutes. Then, tert-butyl 4-(2-methoxy-2-oxoethyl) piperidine-lcarboxylate (1 g, 3.89 mmol) synthesized in step 2 was dissolved in 5 ml of THF in the presence of nitrogen, slowly added dropwise , and stirred for 30 minutes. After that, 1.22 measures of methyl iodide were added and stirred at -78°C for 1 hour. This was repeated once more, and after stirring at room temperature for 4 hours, the reaction was confirmed to be complete by TLC. The reaction was terminated with ammonium chloride, extracted with ethyl acetate (2 χ 20 ml), washed with brine (10 ml), and the organic solvent was dried over ccz / nn / zznz / E / Y magnesium sulfate. and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (68% yield)1H-NMR (CHLOROFORM-D) J4.14 (q, J= 7.1 Hz, 2H), 3.70 (q, J = 4.1 Hz, 3H), 2.66 (d, J = 12.5 Hz, 2H) ), 1.77-1.67 (m, 1H), 1.66-1.59 (m, 2H), 1.47 (s, 9H), 1.31-1.18 (m, 2H), 1.181.08 (m, 6H) Step 4: Methyl 2-Methyl-2-(piperidin-4-yl)propanoate The desired product was obtained in a similar manner to step 3 of Preparation Example 36 by using tert-butyl 4-(1methoxy-2-methyl-l-oxopropan-2-yl)piperidin-l-carboxylate (0.35 g, 1.226 mmol ) synthesized in step 3. (99% yield) m / z (M+H) + calculated for C10H20NO2: 186, found 186 Step 5: Methyl 2-(1-(6-Chloropyridin-2-yl)piperidin-4-yl)-2methylpropanoate The desired product was obtained in a similar manner to step 4 of Preparation Example 36 by using methyl 2-methyl-2(piperidin-4-yl)propanoate (0.227 g, 1.225 mmol) synthesized in step 4. (Yield of 42%) H-NMR (400 MHz, CHLOROFORM-D) δ 7.48-7.29 (m, 1H), 6.60-6.48 (1H), 6.48-6.37 (1H), 4.44-4.23 (m, 2H), 3.73-3.54 ccz / nn / zznz / E / Y (m, 3H) , 2.83-2.62 (m, 2H) , 1.90-1.71 (m, 1H) , 1.71-1.47(m, 2H), 1.47-1.19 (m, 2H), 1.19-1.05 (m, 6H) Step 6: Methyl 2-(1-(6-Aminopyridin-2-yl)piperidin-4-yl)-2methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3 and Step 4) by using methyl 2(1-(6-chloropyridin-2-yl)piperidin-4-yl)-2-methylpropanoate (0.16 g , 0.539 mmol) synthesized in step 5. (2-step yield of 43%)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.30-7.17 (m,1H), 6.07-5.91 (m, 1H), 5.91-5.73 (m, 1H), 4.29 (d, J = 12.8 Hz, 2H), 4.12 (d, J = 18.8 Hz, 2H), 3.66 (dd, J = 15.8, 14.9 Hz, 3H), 2.75-2.50 (2H), 1.85-1.70 (m, 1H), 1.61-1.43 (m , 2H), 1.43-1.26 (m, 2H), 1.18-1.04 (m, 6H) Preparation Example 35: Ethyl 2-(4-(2-Aminopyrimidin-4-yl)piperazin-l-yl)acetate Step 1: tert-butyl 4-(2-chloropyrimidin-4-yl)piperazin-1carboxylate 2,4-dichloropyrimidine (0.200 g, 1.343 mmol) was dissolved in DCM (6.71 ml) and then tert-butyl piperazine-1carboxylate (0.300 g, 1.611 mmol) and DIPEA (0.586 ml, 3.36 mmol) were added. The mixture was stirred at room temperature ccz / nn / zznz / E / Y for 16 hours. After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The desired product was obtained by purification with a silica gel column. (83% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 8.06 (d, 7=5.9 Hz, 1H), 6.38 (d, 7 = 5.9 Hz, 1H), 3.71-3.59 (3H), 3.57-3.45 (m, 4H), 1.52-1.43 (9H) Stage 2: 2-Chloro-4-(piperazin-l-yl)pyrimidine hydrochloride The desired product was obtained in a similar manner to step 3 of Preparation Example 28 by using tert-butyl 4—(2—chloropyrimidin-4-yl)piperazin-l-carboxylate (0.332 g, 1.11 mmol) obtained in the stage 1. (100% performance) 1H-NMR (400 MHz, METHANOL-D4) δ 8.25 (d, 7 = 6.9 Hz, 1H), 7.13 (dd, 7= 7.1, 1.1 Hz, 1H), 4.15 (t, 7= 4.8 Hz, 4H), 3.40 (t, 7 = 5.3 Hz, 4H) Step 3:2 - (4 - (2-Chloropyrimidin-4-yl)piperazin-lil) ethyl acetate -Chloro-4-(piperazin-l-yl)pyrimidine hydrochloride (0.095 g, 0.404 mmol) obtained in step 2 was dissolved in acetonitrile (4 ml), followed by ethyl 2-bromoacetate (0.067 ml, 0.606 mmol) and potassium carbonate (0.168 g, 1.212 mmol) was added. It was stirred at 60°C for 16 hours. After removing the solvent under reduced pressure, ethyl acetate was dissolved in ccz / nn / zznz / E / Y and washed with water. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (33% performance) 2H), 3.72 (s, 4H), 3.27 (s, 2H), 2.67 (t, J = 5.0 Hz, 4H), 1.28 (t, J = 7.0 Hz, 3H) Step 4:2-(4-(2-aminopyrimidin-4-yl)piperazin-1yl)ethyl acetate The desired product was obtained in a similar manner to Preparation Example 2 by using ethyl 2-(4-(2-chloropyrimidin4-yl)piperazin-l-yl)acetate (0.038 g, 133 mmol) obtained in step 3. (33% 2-stage performance) ), 4.18 (q, J = 7.2 Hz, 2H), 3.62 (t, J = 4.8 Hz, 4H), 3.24 (d, J = 7.8 Hz, 2H), 2.60 (t, J = 5.0 Hz, 4H), 1.31-1.23 (m, 3H) Preparation Example 36: 2-(1-(6-aminopyridin-2-yl)piperidin ethyl 4-yl)acetate Step 1: tert-butyl 4-(2-ethoxy-2-oxoethylidin)piperidin-1ccz / nn / zznz / E / Y carboxylate Ethyl 2-(Diethoxyphosphoryl)acetate (6.75 g, 30.1 mmol) was dissolved in 40 ml of THF in the presence of nitrogen, sodium hydride (1.204 g, 50.2 mmol) was added at 0°C, and dissolved 4- tert-butyl oxopiperidin-l-carboxyate (5 g, 25.09 mmol) in 10 ml of THF and added slowly drop by drop. After stirring at room temperature for 15 hours, the starting material was confirmed to disappear by TLC. The reaction was terminated with ammonium chloride, extracted with ethyl acetate (2 χ 30 ml) and washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (25% performance) ), 3.08-2.91 (2H), 2.07 (d, J = 38.4 Hz, 2H), 1.55-1.36 (9H), 1.31-1.18 (m, 3H) Step 2: tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-l-carboxylate The desired product was obtained in a manner similar to Step 3 of Preparation Example 94 by using tert-butyl 4—(2—ethoxy-2-oxoethylidin)piperidine-l-carboxylate (0.6 g, 2.228 mmol) obtained in the Stage 1. (99% Yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 4.26-3.90 (m, 4H), ccz / nn / zznz / E / Y 2.84-2.58 (m, 2H), 2.21 (d, J= 7.3 Hz, 2H), 2.01-1.78 (m, 1H), 1.73-1.59 (2H), 1.48-1.39 (m, 9H), 1.32-1.19 ( m, 3H), 1.19-1.02 (m, 2H) Step 3: Ethyl 2-(Piperidin-4-yl)acetate Tert-butyl 4-(2-Ethoxy-2-oxoethyl)piperidin-l-carboxylate (0.6 g, 2.248 mmol) obtained in step 2 was dissolved in 10 ml of dichloromethane, 2.76 ml of 4.0 Μ hydrochloric acid solution (1, 4-dioxane) was added dropwise and stirred at room temperature for 15 hours. The reaction was terminated with a 1 N aqueous sodium hydroxide solution, extracted with ethyl acetate (2 x 15 ml), and washed with brine (10 ml), the organic solvent was dried over magnesium sulfate, and the Organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (99% yield) m / z (M+H)+calculated for C9H18NO2: 172, found 172 Step 4:2-(1-(6-Chloropyridin-2-yl)piperidin-4yl)ethyl acetate Ethyl 2-(Piperidin-4-yl)acetate (0.385 g, 2.247 mmol) obtained in step 3, 2,6-dichloropyridine (0.399 g, 2.7 mmol) and 0.982 ml of DIPEA were dissolved in 8 ml of DMF and They were stirred at 100°C for 15 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After ccz / nn / zznz / E / Y extraction with ethyl acetate (2 * 15 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure . The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (35% yield) ), 4.38-4.23 (2H), 4.17 (q, J = 7.1 Hz, 2H), 2.88 (td, J = 12.7, 2.3 Hz, 2H), 2.36-2.19 (m, 2H), 2.17-1.98 (m, 1H), 1.88-1.75 (2H), 1.37-1.19 (m, 5H) Step 5: Ethyl 2-(1-(6-Aminopyridin-2-yl)piperidin-4-yl)acetate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using ethyl 2(1-(6-chloropyridin-2-yl)piperidin-4-yl)acetate (0.22 g, 0.778 mmol) obtained in Step 4. (2-step yield of 69%) = 7.9 Hz, 1H), 4.33-4.22 (2H), 4.17 (q, J = 7.2 Hz, 2H), 2.80 (t, J = 12.2 Hz, 2H), 2.28 (t, J = 7.6 Hz, 2H), 2.02 (tt, J = 11.3, 3.8 Hz, 1H), 1.80 (d, J = 12.8 Hz, 2H), 1.41-1.21 (m, 5H) Preparation Example 37: (2-Aminopyrimidin-4-yl)-L -methyl prolinate ccz / nn / zznz / E / Y ι The desired product was obtained in a similar manner to Preparation Example 28 by using methyl Lprolinate hydrochloride (0.267 g, 1.611 mmol). (40% 3-stage performance) (1H), 3.88-3.70 (3H), 3.70-3.55 (1H), 3.55-3.30 (1H), 2.52-2.22 (1H), 2.22-2.00 (m, 3H) Preparation Example 38: Methyl 1-(6-Aminopyridin-2-yl)pyrrolidine-3carboxylate The desired product was obtained in a similar manner to Preparation Example 29 by using methyl pyrrolidine-3-carboxylate hydrochloride (0.500 g, 3.02 mmol). (10% 3-stage performance) ), 4.26-4.07 (m, 2H), 3.85-3.70 (m, 4H), 3.70-3.53 (m, 2H), 3.53-3.37 (m, 1H), 3.18 (t, J = 7.6 Hz, 1H), 2.37-2.20 (m, 2H) Preparation Example 39: 1-(2-Aminopyrimidin-4-yl)pyrrolidin89 ccz / nn / zznz / E / Y methyl 3-carboxylate The desired product was obtained in a similar manner to Preparation Example 28 by using methyl pyrrolidine-3-carboxylate hydrochloride (0.667 g, 4.03 mmol). (14% 3-stage performance) , 3.79-3.65 (m, 4H), 3.65-3.46 (m, 2H), 3.40 (s, 1H), 3.13 (t, J= 7.0 Hz, 1H), 2.21 (d, J = 7.0 Hz, 2H) Preparation Example 40: Ethyl 1-(2-Aminopyrimidin-4-yl)-3methylpiperidine-3-carboxylate Step 1: l-(tert-butyl)3-ethyl piperidine-1,3-dicarboxylate Ethyl piperidine-3-carboxylate (1.0 g, 6.36 mmol) was dissolved in DCM (50 ml), and then di-tert-butyl dicarbonate (1.754 ml, 7.63 mmol) and TEA (1.733 ml, 12.72 mmol) were added. . It was stirred at room temperature for 4 hours. After the reaction was terminated by adding water, it was dissolved in DCM and washed with water. The organic solvent was dried over ccz / nn / zznz / E / Y magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (70% performance) 2.75 (m, 1H), 2.45 (t, J = 10.5 Hz, 1H), 2.06 (dd, J = 13.1, 4.0 Hz, 1H), 1.72 (dt, J = 13.1, 3.7 Hz, 1H), 1.68-1.59 (m, 1H), 1.511.45 (m, 10H), 1.32-1.17 (m, 3H) Step 2: 1(tert-butyl)3-ethyl 3-methylpiperidin-l,3-dicarboxylate Diisopropylamine (1.277 ml, 8.96 mmol) was dissolved in THF (22.4 ml), and then n-butyllithium (3.58 ml, 8.96 mmol) was added at -78°C. The mixture was stirred at -78°C for 10 minutes, and stirred at room temperature for 10 minutes, and then the temperature was decreased to -78°C. To the reaction mixture, 1-(tert-butyl)3-ethyl piperidine-1,3-dicarboxylate (1.153 g, 4.48 mmol) obtained in step 1 was dissolved in THF (22.40 ml) and added. After stirring at -78°C for 1 hour, iodomethane (0.336 ml, 5.37 mmol) was added and stirred at room temperature for 1 hour. After the reaction was terminated with aqueous ammonium chloride solution, it was dissolved in ethyl acetate and washed with water. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. ccz / nn / zznz / E / Y (21% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 4.21-4.03 (m, 2H), 3.82 (d, J = 13.3 Hz, 1H), 3.48-3.36 (m, 1H), 3.32-3.18 (m, 1H), 3.17-3.07 (1H), 2.07-1.95 (m, 1H), 1.58 (d, J = 7.3Hz, 1H), 1.56 (s, 1H), 1.52 (dd, J = 9.6, 4.1 Hz, OH), 1.48-1.38 (m, 11H), 1.29-1.20 (m, 3H), 1.14 (s, 3H) Stage 3: Ethyl 3-me ti Ipipe r i din- 3carboxylate hydrochloride The desired product was obtained in a similar manner to Step 2 of Preparation Example 1 by using 1-(tert-butyl)3-ethyl 3-methylpiperidine-1,3-dicarboxylate (0.250 g, 0.921 mmol) obtained in step 2 and the next step was used immediately without further purification. m / z (M+H)+ calculated for C9H18NO2: 172, found 172 Step 4: Ethyl 1-(2-Aminopyrimidin-4-yl)-3-methylpiperidin3-carboxylate The desired product was obtained in a similar manner to Preparation Example 28 by using ethyl 3methylpiperidine-3-carboxylate hydrochloride (0.191 g, 0.921 mmol) obtained in step 3. (3-step yield of 45%)XH-NMR (500MHz, CHLOROFORM-D) δ 7.83 (q, J = 6.2 Hz, 1H) , 6.01 (d, J= 6.4 Hz, 1H) , 4.84 (d, J = 17.1 Hz, 2H) , 4.314.02 (m, 3H), 3.98 (d, J = 12.2 Hz, 1H), 3.24-2.93 (m, 2H), 2.18 (dt, J = 13.2, 5.0 Hz, 1H), 1.69-1.53 ​​(m, 2H), 1.53-1.41 (m, 1H), 1.20-0.94 (m, 6H) ccz / nn / zznz / E / Y Preparation Example 41: (S)-2-(1-(2-Aminopyrimidin-4-yl)piperidin-3-yl)benzyl acetate Stage 1:(R)-1-(2-chloropyrimidin-4-yl)piperidine-3-carboxylic acid The intermediary obtained in the Example of Preparation 30, ethyl (R)-1-(2-chloropyrimidin-4-yl)piperidine-3-carboxylate (0.950 g, 3.52 mmol) was added to THE (17.6 ml) and ethanol (17.6 ml), and then 6 N aqueous sodium hydroxide solution (2.94 ml, 17.61 mmol) was added and stirred at room temperature for 4 hours. After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The desired product was obtained by purification with a silica gel column. (66% performance) -4.11 (2H), 4.02 (s, 1H), 3.39 (dd, J = 13.5, 9.4 Hz, 1H), 3.25 (t, J = 10.5 Hz, 1H), 2.61-2.44 (m, 1H), 2.16- 2.04 (m, 1H), 1.93-1.70 (m, 2H), 1.63-1.54 (m, 1H), 1.25 (td, J = 7.1, 2.7 Hz, 3H) Step 2: (S)-2-(1-(2-Chloropyrimidin-4-yl)piperidin-3yl)benzyl acetate (R)—1—(2-chloropyrimidin-4-yl)piperidine-3carboxylic acid (0.300 g, 1.241 mmol) obtained in step 1 was ccz / nn / zznz / E / Y dissolved in DCM (12.4 ml), and then oxalyl chloride (0.543 ml, 6.21 mmol) and DMF (0.481 μΐ, 6.21 pmol) were added sequentially drop by drop. After stirring at room temperature for 1 hour, the solvent was removed under reduced pressure. The reaction was dissolved in acetonitriium (10.3 ml) and THF (10.3 ml), and then trimethylsilyldiazomethane (1.86 ml, 3.72 mmol) dissolved in 2 M in diethyl ester was added at 0°C. After stirring at room temperature for 16 hours, the solvent was removed under reduced pressure. The reaction was dissolved in 2,4,6-trimethylpyridine (8.26 ml), benzyl alcohol (0.271 ml, 2.61 mmol) was added, followed by stirring at 180°C for 7 minutes. After the reaction was terminated by adding water, it was dissolved in diethyl ether, washed with water, and dried over magnesium sulfate. The desired product was obtained by purification with a silica gel column. (52% performance) (t, J= 6.1 Hz, 1H), 3.45 (dd, J = 13.3, 9.3 Hz, 1H), 3.40-3.26 (m, 1H), 2.73-2.59 (m, 1H), 2.17 (dd, J = 17.7 , 4.6 Hz, 1H), 2.01-1.79 (m, 2H), 1.73-1.54 (m, 1H) Step 3: (S)-2-(1-(2-Aminopyrimidin-4-yl)piperidin-3yl)benzyl acetate The desired product was obtained in a similar manner to Preparation Example 2 by using (5)-2-(1-(294-chloropyrimidin-4-yl)piperidin-3-yl)benzyl acetate (0.224 g, 0.648 mmol) obtained in stage 2. (2-stage performance of 40%)XH-NMR (500MHz, CHLOROFORM-D) δ 7.82 (d, J = 6.4 Hz, 1H), 7.43-7.35 (m, 5H), 5.89 (d, J = 6.1 Hz, 1H), 5.17 (t, J = 12.8 Hz, 2H), 4.66 (s, 2H), 4.18 (d, J = 11.6 Hz, 2H), 3.032.92 (m, 1H), 2.77 (dd, J = 13.1, 10.1 Hz, 1H), 2.44-2.25 (m, 2H), 2.07 (dd, J = 10.7, 7.3 Hz, 1H), 1.96-1.86 (m, 1H), 1.72 (dt, J = 13.4, 4.0 Hz, 1H), 1.60-1.47 (m, 1H), 1.39 -1.22 (m, 1 HOUR) Preparation Example 42: Ethyl (S,E)-3-(1-(2-Aminopyrimidin-4yl)piperidin-3-yl)acrylate ccz / nn / zznz / E / Y Step 1: tert-butyl (R)-3-Formylpiperidin-l-carboxylate 1-(tert-butyl)3-ethyl piperidine-1,3-dicarboxylate (1.73 g, 6.72 mmol) obtained in step 1 of Preparation Example 40 was dissolved in toluene (67.2 ml) and then 1 M diisobutylaluminum hydride (16.81 ml, 16.81 mmol) was added dropwise at -78°C and stirred for 3 hours and 30 minutes. The reaction was terminated by slowly adding ethyl acetate (10 ml) and methanol (5 ml) at -78°C. After 15 minutes, a 1 M aqueous solution of sodium ccz / nn / zznz / E / Y potassium tartrate was added and stirred for 1 hour, and then diluted with ethyl acetate and filtered to remove the precipitate. The organic solvent was removed under reduced pressure and then purified by a silica gel column to obtain the desired product. (20% performance) (dd, J = 13.5, 8.5 Hz, 1H), 3.14-2.99 (m, 1H), 2.41 (s, 1H), 1.93 (d, J = 3.7 Hz, 1H), 1.76-1.59 (m, 2H), 1.52-1.46 (m, 1H), 1.46-1.36 (9H) Step 2: (S, E) - 3- (3-ethoxy-3-oxopro-1 - phen-l-yl) tert-butyl piperidin-l-carboxylate (R)-3-Formylpiperidin-l-carboxylate tert. -butyl (0.283 g, 1.327 mmol) obtained in step 1 was dissolved in DCM (6.63 ml), and ethyl 2-(triphenyl-15-phosphanylidene)acetate (0.601 g, 1.725 mmol) was added, and stirred at room temperature for 16 hours. The organic solvent was removed under reduced pressure and then purified by a silica gel column to obtain the desired product. (96% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 6.83 (dd, J = 15.8, 6.6 Hz, 1H), 5.85 (dd, J = 16.0, 1.4 Hz, 1H), 4.18 (q, J= 7.0 Hz, 2H), 3.89 (td, J= 8.6, 4.3 Hz, 2H), 2.81 (t, J = 11.2 Hz, 2H), 2.43-2.22 (m, 1H), 1.87 (dd, J = 13.0 , 3.9 Hz, 1H), 1.67 (dt, J = 13.0, 3.9 Hz, 1H), 1.48 (s, 1H), 1.43 (d, J = 14.6 Hz, 9H), 1.41-1.31 (m, 1H), 1.27 (dd, J= 13.5, 6.2 Hz, 3H) ccz / nn / zznz / E / Y Step 3: Ethyl (S,E)-3-(1-(2-Chloropyrimidin-4-yl)piperidin3-yl)acrylate Ethyl (S,E)-3-(piperidin-3-yl)acrylate hydrochloride was obtained in a manner similar to Step 2 of Preparation Example 1 using (S,E)-3-(3-ethoxy- Ten-butyl 3-oxopro-l-phen-1yl)piperidin-l-carboxylate obtained in step 2, and then the desired product was obtained in a similar manner to Step 1 of Preparation Example 28 without further purification. (91% performance) 5.9 Hz, 1H), 5.89 (dd, J = 16.0, 1.4 Hz, 1H), 4.51-4.15 (m, 3H), 3.06-2.92 (m, 1H), 2.86 (dd, J = 13.0, 10.7 Hz, 1H) ), 2.51-2.31 (m, 1H), 2.01-1.92 (1H), 1.90-1.78 (1H), 1.65-1.55 (m, 1H), 1.54 (s, 3H), 1.52-1.41 (m, 1H), 1.29 (t, J= 7.1 Hz, 3H) Step 4: Ethyl (5,E)-3-(1-(2-Aminopyrimidin-4-yl)piperidin3-yl)acrylate The desired product was prepared in a similar manner to Preparation Example 2 by using ethyl (S,E)-3-(1-(2chloropyrimidin-4-yl)piperidin-3-yl)acrylate obtained in step 3. ( 2-stage performance of 49%)1H-NMR (500MHz, CHLOROFORM-D) δ 7.94-7.81 (m, 1H), 6.91 (dd, J = 15.9, 7.0 Hz, 1H), 5.97 (t, J = 6.0 Hz, 1H), 5.95-5.84 (1H), 4.73 (d, J = 18.0 Hz, 2H), 4.41 (s, 1H) ), 4.23 (q, J = 7.1 Hz, 2H), 4.20-4.06 (m, 1H), 3.00-2.85 (m, 1H), 2.78 ccz / nn / zznz / E / Y (dd, J= 13.1, 10.4 Hz, 1H), 2.48-2.31 (1H), 1.98 (d, J = 12.5 Hz, 1H), 1.87-1.77 (m, 1H), 1.62-1.53 ​​(m, 1H), 1.53-1.42 (m, 1H), 1.32 (t, J = 7.2 Hz, 3H) Preparation Example 43: Ethyl 1-(2-Aminopyrimidin-4-yl)piperidin3-carboxylate The desired product was obtained in a similar manner to Preparation Example 28 by using ethyl piperidine-3carboxylate (0.626 ml, 4.03 mmol), (3-step yield of 14%) XH-NMR (500MHz, CHLOROFORM-D) £7.86 (d, J = 6.1 Hz, 1H), 6.01 (d, J = 6.4 Hz, 1H), 4.93 (s, 2H), 4.58-4.29 (1H), 4.294.14 (2H), 4.14-4.01 (1H) , 3.33-3.12 (1H), 3.12-2.98 (1H), 2.67-2.43 (m, 1H), 2.23-1.96 (1H), 1.82 (d, J = 4.0 Hz, 1H), 1.74-1.61 (1H), 1.56 (s, 1H), 1.39-1.23 (3H) Preparation Example 44: (S)-2-((1-(2-aminopyrimidin-4yl)piperidin-3-yl)oxy)tert-butyl acetate Step 1: Benzyl (S)-3-Hydroxypiperidine-l-carboxylate (S)-piperidin-3-ol hydrochloride (1.0 g, 7.27 mmol) was dissolved in DCM (14.5 ml), TEA (2.026 ml, 14.53 mmol), and benzyl carbonhydrochloride (1.025 ml, 7.27 mmol) were added. drop by drop at 0°C for 2 hours and 30 minutes. The mixture was further stirred at 0°C for 30 minutes, diluted with DCM, and washed with 1 N HCi aqueous solution. The organic solvent was dried over magnesium sulfate and then the organic solvent was removed under reduced pressure. It was used in the next reaction immediately without further purification. 1H-NMR (500 MHz, CHLOROFORM-D) δ 7.57-7.31 (m,5H), 5.27-5.09 (2H), 3.90-3.70 (m, 2H), 3.61 (s, 1H), 3.38-3.15 (m, 2H), 2.00-1.87 (m, 1H), 1.87-1.73 (1H), 1.73- 1.46 (m, 3H) Step 2: Benzyl (S)-3-(2-(tert-Butoxy)-2-oxoethoxy)piperidine1-carboxylate After dissolving the benzyl (S)-3-hydroxypiperidine-lcarboxylate (7.27 mmol) obtained in step 1 in toluene (14.5 ml), tert-butyl 2-bromoacetate (1.611 ml, 10.91 mmol) and hydrogen sulfate were added. of tetra-nbutylammonium (0.074 g, 0.218 mmol) dissolved in 5 ml of water. Sodium hydroxide (7.27 g, 182 mmol) dissolved in 7.27 ml of water was added dropwise to the reaction. After stirring at room temperature for 16 hours, it was dissolved in ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (59% yield) ccz / nn / zznz / E / Y ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D) δ 7.46 -7.26 (5H), 5.11 (s, 2H), 3.96 (s, 2H), 3.88 (d, J= 11.4 Hz, 1H), 3.66 (d, J = 12.8 Hz, 1H), 3.41 (s, 1H) , 3.21-3.07 (2H), 1.96 (s, 1H), 1.77 (d, J = 3.7 Hz, 1H), 1.59 (d, J= 9.6 Hz, 1H), 1.45 (s, 9H) Step 3: Benzyl (S)-2-(piperidin-3-iioxy)tert-butyl acetate (S)-3-(2-(ter-Butoxy)-2-oxoethoxy)piperidine-lcarboxylate obtained in step 2 was dissolved in ethanol (21.2 ml), and then Pd / C (0.1485 g, 1.395 mmol) was added and a deprotection reaction was carried out using a hydrogen balloon. After filtration through the Celite pad, the solvent was removed under reduced pressure, and purified by silica gel column to obtain the desired product. (100% performance) , 1H), 2.90-2.78 (m, 1H), 2.78-2.62 (2H), 2.04-1.91 (m, 1H), 1.79-1.70 (1H), 1.61 (tt, J= 12.8, 4.4 Hz, 1H), 1.56-1.39 (m, 11H) Step 4: (S)-2-((1-(2-Aminopyrimidin-4-yl)piperidin3-yl)oxy)tert-butyl acetate The desired product was obtained in a similar manner to Preparation Example 28 by using tert-butyl (S)-2-(piperidin-3yloxy)acetate (0.517 g, 1.577 mmol) obtained in 100 ccz / nn / zznz / E / Y stage 3. (3-stage performance 50%)XH-NMR (400 MHz, CHLOROFORM-D) £7.83 (t, J = 3.2 Hz, 1H) , J= 6.4 Hz, 1H) , 4.64 (s, 2H) , 4.15 (d, J= 11.9 Hz, 1H) , 4.06-4.00 (2H) , 3.87 (s, 1H) , 3.41 (t, J = 4.1 Hz , 1H) , 3.21-3.04 (m, 2H) , 2.05 (s, 1H) , 1.83 (s, 1H) , 1.53-1.38 (m, 11H) Preparation Example 45: (S)-2-((1-(6-aminopyridin-2-yl)piperidin-3-yl)oxy)tert-butyl acetate The desired product was obtained in a similar manner to Step 1 of Preparation Example 29 and Preparation Example 2 by using tert-butyl (S)-2-(piperidin-3-yloxy)acetate (0.503 g, 2.336 ml) prepared in Step 3 of Preparation Example 44. (3-step yield of 6%) 1H-NMR (400 MHz, CHLOROFORM-D) £7.22 (d, J = 7.8 Hz, 1H), 6.01 (d, J = 8.2 Hz, 1H), 5.82 (d, J = 7.8 Hz, 1H), 4.25 (dd, J = 12.3, 4.1 Hz, 1H), 4.22-4.09 (m, 2H), 4.05 (s, 2H), 3.94-3.85 (m, 1H), 3.45 (td, J = 9.1, 4.4 Hz, 1H), 2.92-2.80 (m, 2H), 2.09 (d, J= 3.7 Hz, 1H), 1.89-1.74 (m, 1H), 1.55-1.49 (m, 2H), 1.47 (s, 9H) Preparation Example 46: (J?)-2-((1-(2-aminopyrimidin-4yl)piperidin-3-yl)oxy)tert-butyl acetate 101 ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Preparation Example 44 by using (R)5-piperidin-3-ol hydrochloride (1.0 g, 7.27 mmol). (5-stage performance of 23%) ), 4.21-4.08 (1H), 4.08-3.96 (2H), 3.84 (d, J = 12.8 Hz, 1H), 3.55-3.37 (m, 1H), 3.27-3.08 (2H), 2.29-1.89 (m, 1H), 1.90-1.75 (m, 1H), 1.69-1.57 (m, 1H), 1.57-1.48 (m, 1H), 1.47 (s, 9H) Preparation Example 47: tert-butyl (R)-2-((1-(2-aminopyrimidin-4-yl)piperidin-3-yl)oxy)-2-methylpropanoate Step 1: (R)-l-benzylpiperidin-3-ol (R)-Piperidin-3-ol hydrochloride (1.0 g, 7.27 mmol) was dissolved in DMF (14.5 ml) and potassium carbonate (2.210 g, 15.99 mmol) and benzyl bromide (0.951 ml, 7.99 mmol). The reaction was stirred at 60°C for 3 days. After filtering potassium carbonate, the DMF solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (57% yield) k-NMR (500 MHz, CHLOROFORM-D) δ 7.33 (td, J = 8.0, 6.1 Hz, 4H), 7.28-7.23 (m, 1H), 3.84 (t, J = 3.8 Hz, 1H), 3.53 ccz / nn / zznz / E / Y 102 (s, 2H), 2.50 (d, J = 14.0 Hz, 3H), 2.27 (s, 1H), 1.95-1.74 (1H), 1.75-1.46 (m, 3H) Step 2: (R)-2-((l-benzylpiperidin-3-yl)oxy)tez-butyl acetate The desired product was obtained in a similar manner to Step 2 of Preparation Example 44 by using (R)-1benzylpiperidin-3-ol (0.785 g, 4.10 mmol) prepared in Step 1. (40% yield) 1H- NMR (400 MHz, CHLOROFORM-D) δ 7.39-7.26 (m, 4H), 7.24- 7.20 (m, 1H), 3.96 (s, 2H), 3.52 (s, 2H), 3.49-3.39 (m, 1H), 3.06-2.91 (m, 1H), 2.65 (d, J = 11.0 Hz, 1H), 2.ΟΤΙ . 90 (3H), 1.71 (dt, J = 13.7, 3.7 Hz, 1H), 1.55-1.46 (1H), 1.46-1.40 (m, 9H), 1.28 (ddd, J = 22.1, 12.2, 4.5 Hz, 1H) Step 3: tert-butyl (R)-2-((1-benzylpiperidin-3-yl)oxy)-2-methylpropanoate After dissolving tert-butyl (R)-2-((l-benzylpiperidin-3yl)oxy)acetate (0.507 g, 1660 mmol) prepared in step 2 in THF (10 ml), bis(trimethylsilyl)amide was added. of lithium (1.938 mi, 2.52 mmol) at -78°C. After stirring at room temperature for 1 hour, the mixture was cooled to -78°C, and then iodomethane (0.068 ml, 1.109 mmol) was dissolved in THF (0.7 ml). It was stirred again at room temperature for 1 hour. Tert-butyl 2-(((R)-l-Benzylpiperidin-3-yl)oxy)propanoate to which a methyl group was added was obtained 103 ccz / nn / zznz / E / Y by silica gel column purification. The same method was repeated to obtain the desired product. (38% yield) 1R-NMR (400 MHz, CHLOROFORM-D) δ 7.28 (d, J = 4.6 Hz, 4H), 7.24-7.15 (m, 1H), 3.48 (d, J = 3.7 Hz, 2H), 3.46-3.37 (m , 1H) , 3.01 (dt, J = 10.5, 2.1 Hz, 1H) , 2.76-2.64 (m, 1H) , 2.041.81 (m, 4H) , 1.64 (tt, J = 10.2, 3.4 Hz, 1H) , 1.58-1.45 (m, 1H), 1.37 (d, J = 6.9 Hz, 9H), 1.34 (s, 3H), 1.33-1.29 (m, 3H), 1.29-1.14 (m, 1H) Step 4: tert-butyl (R)-2-((1-(2-aminopyrimidin-4-yl)piperidin3-yl)oxy)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 44 (Step 3, Step 4) by using tert-butyl (R)-2-((l-benzylpiperidin-3-yl)oxy)-2-methylpropanoate prepared in the Stage 3. (4-stage performance of 43%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.14 (d, J = 95.6 Hz, 1H), 6.29 (s, 1H), 4.45 (s, 2H), 3.54 (s, 1H), 3.13 (s, 2H), 2.33-2.01 (m, 3H), 1.46 (s, 9H), 1.38 (d, J = 14.2 Hz, 6H) Preparation Example 48: Methyl 1-(2-Aminopyrimidin-4-yl)-3methylpyrrolidine-3-carboxylate 104 ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Preparation Example 40 by using methyl pyrrolidine-3-carboxylate hydrochloride (1.0 g, 6.04 mmol). (30% 6-stage performance) ), 3.99-3.76 (1H), 3.71 (s, 3H), 3.52 (s, 1H), 2.54-2.36 (1H), 1.95-1.81 (m, 1H), 1.63 (m, 2H), 1.38 (s, 3H) Preparation Example 49: Methyl 1-(6-Aminopyridin-2-yl)-3-methylpyrrolidine-3-carboxylate The desired product was obtained in a similar manner to Preparation Example 29 by using the intermediate, methyl 3-methylpyrrolidine-3-carboxylate hydrochloride (0.390 g, 2.171 mmol) prepared in Preparation Example 48. (3-step yield of 10%) ), 4.13 (s, 2H), 3.83 (d, J = 10.5 Hz, 1H), 3.69 (s, 3H), 3.57-3.41 (m, 2H), 3.32 (d, J = 10.5 Hz, 1H), 2.51 -2.36 (m, 1H), 1.92-1.80 (m, 1H), 1.37 (s, 3H) Preparation Example 50: Methyl (Ir,4r)-4-((2-Aminopyrimidin-4yl)oxy)cyclohexan-1-carboxylate 105 Or ccz / nn / zznz / E / Y Stage 1: Methyl (Ir, 4r)-4-Hydroxycyclohexan-l-carboxylate (Ir, 4r)-4-hydroxycyclohexan-l-carboxylic acid (0.300 g, 2.081 mmol) was dissolved in methanol (10 ml) and sulfuric acid (0.017 ml, 0.312 mmol) was added. After stirring at 60°C for 16 hours, the organic solvent was removed under reduced pressure and purified by silica gel column to obtain the desired product. (100% performance) m, 3H), 2.35 (tt, J = 11.4, 3.7 Hz, 1H), 2.18 (dt, J = 12.8, 3.5 Hz, 2H), 2.07 (dd, J = 14.2, 3.7 Hz, 2H), 1.74-1.56 (m, 2H), 1.49 (ddd, J = 23.0, 12.7, 3.5 Hz, 2H) Step 2:(Ir, 4r)-4-((2-Aminopyrimidin-4-yl)oxy)methyl cyclohexan-1-carboxylate The desired product was obtained in a similar manner to Preparation Example 117 by using methyl (lr,4r)-4hydroxycyclohexan-l-carboxylate (0.333 g, 2.105 mmol). (28% 2-stage performance) , 1H), 4.82 (s, 2H), 106 ccz / nn / zznz / E / Y 3.68 (dd, V = 7.3, 2.7 Hz, 5H), 2.44-2.26 (m, 1H), 2.20-1.99 (m, 4H), 1.71-1.57 (m, 2H), 1.52 (s, 1H), 1.41 ( dd, J = 12.6, 3.4 Hz, 1H) Preparation Example 51: Methyl (ls,4s)-4-((2-Aminopyrimidin-4yl)oxy)cyclohexan-l-carboxylate The desired product was obtained in a similar manner to Preparation Example 50 by using (ls,4s)-4hydroxycyclohexan-l-carboxylic acid (1,000 g, 6.94 mmol). (3-stage performance of 20%) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.93 (t, J = 5.7 Hz, 1H), 6.00 (t, J = 5.7 Hz, 1H), 5.20-4.97 (m, 3H), 3.64 (s, 3H) ), 2.45-2.31 (m, 1H), 2.04-1.81 (m, 4H), 1.79-1.52 (m, 4H) Preparation Example 52: Methyl 2-(3-(6-Aminopyridin-2-yl)phenyl)-2methylpropanoate h2n n Step 1:Methyl 2-Methyl-2-(3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate After dissolving methyl 2-(3-bromophenyl)-2-methylpropanoate (250 mg, 0.972 mmol), 4,4,4,4,5,5,5,5octamethyl-2,2-bi (1,3, 2-dioxaborolane) (296 mg, 1.17 mmol), potassium acetate (286 mg, 2.92 mmol) and ccz / nn / zznz / E / Y complex 107 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane (39.7 mg, 0.0490 mmol) in 9.72 ml of 1,4dioxane, the dissolved oxygen was removed through nitrogen bubbling under stirring, and The outside airflow inlet was blocked in a sealed container. The reaction was stirred at 110°C for 15 hours and then cooled to room temperature. After filtering through a Celite pad and removing the organic solvent under reduced pressure, the desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (94% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 7.11 (s, 1H), 7.69 (d, J = 7.3 Hz, 1H), 7.46-7.37 (1H), 7.33 (t, J= 7.5 Hz, 1H), 3.65 (s, 3H), 1.60 (s, 6H), 1.34 (s, 12H) Step 2: Methyl 2-(3-(6-((tert-Butoxycarbonyl)amino)pyridin2-yl)phenyl)2-methylpropanoate Methyl 2-Methi1-2-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan2-yl)phenyl)propanoate (279 mg, 0.917 mmol) synthesized in step 1 and (6 tert-butyl-bromopyridin-2-yl)carbamate (251 mg, 0.917 mmol) obtained in Preparation Example 73, 2 M aqueous sodium carbonate solution (1.38 ml, 2.75 mmol) and bis(triphenylphosphine)dichloropalladium were dissolved (64 mg, 0.092 mmol) in 7.64 ml of dimethoxyethane, and the dissolved oxygen was removed through nitrogen bubbling under stirring, and the outside air flow inlet was blocked in a sealed container. The reaction is ccz / nn / zznz / E / Y 108 stirred at 100°C for 15 hours and then cooled to room temperature. After filtering through a Celite pad and removing the organic solvent under reduced pressure, it was dissolved in ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (72% performance)1H-NMR (400 MHz, CHLOROFORM-D) δ 7.95 (d, J = 1.8 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.80 (dt, J = 7.3, 1.6 Hz, 1H), 7.76-7.66 (1H), 7.42-7.33 (m, 3H), 7.31 (s, 1H), 3.66 (s, 3H), 1.64 (s, 6H), 1.55 (s, 9H) Step 3: Methyl 2-(3-(6-Aminopyridin-2-yl)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Step 4 of Preparation Example 19 by using methyl 2-(3-(6((tert-butoxycarbonyl)amino)pyridin-2-yl)phenyl)2-methylpropanoate (244 mg, 0.659 mmol) synthesized in step 2. (81% yield) 7.50 (t, J= 8.0 Hz, 1H) , 7.39 (t, J = 7.5 Hz, 1H) , 7.34 (dt, J = 7.9, 1.6 Hz, 1H) , 7.07 (d, J = 7.3 Hz, 1H) , 6.54-6.39 (1H), 4.49 (s, 2H), 3.66 (s, 3H), 1.64 (s, 6H) Preparation Example 53: 2-(3-(2-Aminopyrimidin-4-yl)phenyl)109 ccz / nn / zznz / E / Y methyl 2-methylpropanoate Step 1: Methyl 2-Methyl-2-(3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate methyl 2-(3-Bromophenyl)-2-methylpropanoate methyl (0.5 g, 1,944 mmol) and 4,4,4,4,5,5,5,5-oxamethyl-2,2-bis(1,3,2-dioxaborolane) (0.494 g, 1,944 mmol), potassium acetate (0.478 g , 4.862 mmol), 1,1'bis(diphenylphosphino)ferrocenedichloro-palladium(II) dichloromethane complex (0.08 g, 0.098 mmol) was dissolved in 8 ml of 1,4-dioxane and stirred at 110°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 15 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (85% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.76 (d, J = 0.9 Hz, 1H), 7.72-7.65 (m, 1H), 7.43-7.37 (m, 1H), 7.31 (t, J= 7.5 Hz, 1H), 3.71-3.53 (m, 3H), 1.59 (s, 6H), 1.33 (s, 12H) Step 2: Methyl 2-(3-(2-Chloropyrimidin-4-yl)phenyl)-2-methylpropanoate ccz / nn / zznz / E / Y 110 Methyl 2-Methi1-2-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan2-yl)phenyl)propanoate obtained in step 1 (0.25 g, 0.822 mmol), 2, 4-dichloropyrimidine (0.147 g, 0.986 mmol), 1 ml of sodium carbonate and bis(triphenylphosphine)palladium(II) dichloride (0.058 g, 0.082 mmol) were dissolved in 4 ml of DME and stirred at 100°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 χ 15 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (80% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.66-8.55 (m, 1H), 8.05 (dd, J = 15.1, 1.8 Hz, 1H), 7.98-7.85 (m, 1H), 7.66-7.56 (m, 1H), 7.56-7.38 (m, 2H), 3.70-3.59 (3H), 1.67- 1.58 (m, 6H) Step 3: Methyl 2-(3-(2-Aminopyrimidin-4-yl)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using methyl 2(3-(2-chloropyrimidin-4-yl)phenyl)-2-methylpropanoate (0.19 g, 0.653 mmol ) obtained in Stage 2. (2-stage performance of 64%) ), 7.84 (dt, J = 7.3, 1.6 Hz, 1H), 111 ccz / nn / zznz / E / Y 7.50- 7.38 (2Η), 7.06 (t, J = 5.3 Hz, 1H), 5.43 (s, 2H), 3.65 (t, J = 15.3 Hz, 3H), 1.63 (s, 6H) Preparation Example 54: Methyl 2-(4-(6-Aminopyridin-2-yl)phenyl)-2methylpropanoate h2n ° Step 1: Methyl 2-Methyl-2-(4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate The desired product was obtained in a similar manner to Step 1 of Preparation Example 53 by using methyl 2-(4bromophenyl)-2-methylpropanoate (1 g, 3.89 mmol). (95% yield)XH-NMR (CHLOROFORM-D) δ 7.80 (d, J = 8.2 Hz, 2H), 7.39- 7.31 (m, 2H), 3.74-3.59 (m, 3H), 1.60 (s, 6H), 1.37-1.32 (m, 12H) Step 2: Methyl 2-(4-(6-((tert-Butoxycarbonyl)amino)pyridin2-yl)phenyl)-2-methylpropanoate The desired product was obtained in a manner similar to Step 2 of Preparation Example 53 by using 2-methyl-2(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl methyl)phenyl)propanoate (0.62 g, 2.038 mmol) obtained in Step 1 and tert-butyl (6chloropyridin-2-yl)carbamate (0.559 g, 2.446 mmol). (62% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.88 (dt, J = 8.5, ccz / nn / zznz / E / Y 112 2.1 Hz, 2H), 7.84 (d, J = 8.2 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.44-7.38 (m, 2H), 7.36 (d, J = 7.3 Hz, 1H), 7.31 (d, J = 11.4 Hz, 1H), 3.65 (s, 3H), 1.60 (s, 6H), 1.52 (s, 9H) Step 3: Methyl 2-(4-(6-Aminopyridin-2-yl)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Step 4 of Preparation Example 19 by using methyl 2-(4-(6((tert-butoxycarbonyl)amino)pyridin-2-i1)phenyl)-2-methylpropanoate ( 0.467 g, 1.263 mmol) obtained in step 2. (78% yield) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.99-7.75 (m, 2H), 7.57-7.44 (m, 1H) , 7.44-7.33 (m, 2H) , 7.16-6.94 (m, 1H) , 6.516.35 (m, 1H) , 4.61 (s, 2H) , 3.72-3.51 (m, 3H) ), 1.73-1.51 (m, 6H) Preparation Example 55: Methyl 2-(4-(2-Aminopyrimidin-4-yl)phenyl)2-methylpropanoate Step 1: Methyl 2-(4-(2-Chloropyrimidin-4-yl)phenyl)-2-methylpropanoate The desired product was obtained in a manner similar to Step 2 of Preparation Example 53 by using 2-methyl-2(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl Methyl )phenyl)propanoate (0.7 g, 2.301 mmol) obtained in step 1 of the ccz / nn / zznz / E / Y 113 Preparation Example 54 and 2,4-dichloropyrimidine (0.411 g, 2.76 mmol). (99% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.65-8.56 (m, 1H), 8.09-8.01 (m, 2H), 7.61 (d, J = 5.5 Hz, 1H), 7.53-7.43 (m, 2H), 3.66 (d, J= 5.5 Hz, 3H), 1.62 (d, J = 9.6 Hz , 6H) Step 2: Methyl 2-(4-(2-Aminopyrimidin-4-yl)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using methyl 2(4-(2-chloropyrimidin-4-yl)phenyl)-2-methylpropanoate (0.59 g, 2.029 mmol ) obtained in Stage 1. (2-stage yield of 44%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.43-8.20 (m, 1H), 8.05-7.83 (m, 2H), 7.54-7.34 (2H), 7.06-6.89 (m, 1H), 5.36 (s, 2H), 3.70-3.55 (m, 3H), 1.69-1.51 (m, 6H) Preparation Example 56: Methyl 3-(3-(2-Aminopyridin-4-yl)-phenyl)propanoate The desired product was obtained in a similar manner to Preparation Example 26 by using methyl 3-(3-bromophenyl)propanoate (1 g, 4.11 mmol). (2-stage performance of 69%)XH-NMR (500MHz, CHLOROFORM-D) δ 8.13 (d, J = 5.2 Hz, 114 ccz / nn / zznz / E / Y 1Η), 7.45 (d, J = 7.9 Hz, 2H), 7.40 (t, J = 7.6 Hz, 1H), 7.27 (s, 1H), 6.89 (d, J = 5.5 Hz, 1H), 6.72 (s, 1H), 4.64-4.42 (2H), 3.70 (s, 3H), 3.04 (t, J = 7.8 Hz, 2H), 2.70 (t, J = 7.8 Hz, 2H) Preparation Example 57: Methyl 3-(3-(2-Aminopyrimidin-4-yl)phenyl)propanoate The desired product was obtained in a similar manner to Step 1 of Preparation Example 28 and Preparation Example 2 by using the intermediate, 3-(3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan- Methyl 2-yl)phenyl)propanoate (0.200 g, 0.689 mmol) prepared in Preparation Example 56. (3-step yield of 43%)XH-NMR (500MHz, CHLOROFORM-D) δ 8.33 (d, J = 5.2 Hz, 1H), 7.86 (s, 1H), 7.84-7.74 (m, 1H), 7.47-7.37 (1H), 7.32 (d, J= 7.3 Hz, 1H), 7.01 (d, J= 5.2 Hz, 1H), 5.57-5.31 (2H), 3.70 (d, J = 22.6 Hz, 3H), 3.03 (t, J = 7.8 Hz, 2H), 2.69 (t, J = 7.8 Hz, 2H) Preparation Example 58: 3-(3-(2-Aminopyridin-4-yl)phenyl)- methyl 2,2-dimethylpropanoate ccz / nn / zznz / E / Y 115 Step 1: Methyl 3-(3-Bromophenyl)-2,2-dimethylpropanoate Diisopropylamine (20.5 ml, 144 mmol) was added to 400 ml of anhydrous tetrahydrofuran, and 2.5 M n-butyllithium (57.6 ml, 144 mmol) was added slowly dropwise at -78°C. The reaction solution was stirred at the same temperature for 20 minutes. The temperature was raised to room temperature and stirred for 10 minutes, then decreased to -78°C and stirred for 10 minutes. The reaction solution was added dropwise to methyl isobutyrate (16.5 ml, 144 mmol) dissolved in 100 ml of anhydrous tetrahydrofuran. The reaction solution was stirred at -78°C for 1 hour, and l-bromo-3-(bromomethyl)benzene (30.0 g, 120 mmol) dissolved in 100 ml of anhydrous tetrahydrofuran was added slowly dropwise. The reaction solution was raised to room temperature and stirred for 20 minutes. The reaction was terminated by adding 1 N aqueous hydrochloric acid solution to the reaction solution, followed by extraction with diethyl ether. The organic layer was concentrated under reduced pressure and then purified by a silica gel column (ethyl acetate:hexane) to obtain the desired product. (72% yield). XH-NMR (CHLOROFORM-D) δ 7.35 (d, J = 7.9 Hz, 1H), 7.26- 7.20 (1H), 7.13 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 7.6 Hz, 1H), 3.67 (s, 3H), 2.81 (s, 2H), 1.18 (s, 6H ) Stage 2: 2,2-Dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2ccz / nn / zznz / E / Y 116 Methyl dioxaborolan-2-yl)phenyl)propanoate The desired product was obtained in a similar manner to Step 1 of Preparation Example 52 by using methyl 3—(3—bromophenyl)-2,2-dimethylpropanoate obtained in Step 1. (73% yield)XH-NMR (CHLOROFORM-D) £7.65 (d, J= 7.3 Hz, 1H), 7.54 (s, 1H), 7.29-7.23 (m, 1H), 7.19 (d, J = 7.6 Hz, 1H), 3.66 (s, 3H), 2.86 (s, 2H), 1.33 (s, 12H), 1.18 (s, 6H) Step 3: Methyl 3-(3-(2-Aminopyridin-4-yl)phenyl)2,2-dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 by using 4bromopyridin-2-amine (109 mg, 0.628 mmol) and 2,2-dimethyl-3-(3(4,4,5, Methyl 5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl-propanoate (200 mg, 0.628 mmol) obtained in step 2, and the following reaction was carried out without purification. XH-NMR (Chloroform-D) £ 8.11 (D, J = 5.5 Hz, 1h), 7.43 (D, J = 7.6 Hz, 1h), 7.37-7.29 (m, 2h), 7.15 (D, J = 7.6 Hz , 1H), 6.85 (d, J = 4.0 Hz, 1H), 6.67 (s, 1H), 4.56-4.43 (2H), 3.66 (s, 3H), 2.92 (s, 2H), 1.21 (s, 6H) Preparation Example 59: Methyl 3-(3-(2-Aminopyrimidin-4-yl)phenyl)2,2-dimethylpropanoate ccz / nn / zznz / E / Y 117 Step 1:Methyl 3-(3-(2-Chloropyrimidin-4-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 by using 2,4dichloropyrimidine (1.40 g, 9.43 mmol) and 2,2-dimethyl-3-(3(4,4,5,5- Methyl tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl-propanoate (3.00 g, 9.43 mmol) obtained in step 2 of Preparation Example 58. (76% yield) 1H-NMR (CHLOROFORM-D ) δ 8.62 (d, J= 5.2 Hz, 1H) , 7.91 (d, J = 7.9 Hz, 1H) , 7.87 (s, 1H) , 7.62 (d, J = 5.5 Hz, 1H) , 7.41 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 3.70 (s, 3H), 2.96 (s, 2H), 1.22 (s, 6H) Step 2: Methyl 3-(3-(2-Aminopyrimidin-4-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 3, 4 of Preparation Example 19 by using methyl 3—(3—(2-chloropyrimidin-4-yl)phenyl)-2,2-dimethylpropanoate (2.18 g, 7.15 mmol) obtained in Stage 1. (2-stage yield of 44%) 1H-NMR (400 MHz, CHLOROFORM-D) 8.32 (d, J = 5.5 Hz, 1H), 7.85 (d, J= 7.8 Hz, 1H), 7.80-7.69 (1H), 7.38 (t, J= 7.8 Hz, 1H), 7.23 (d, J= 7.8 Hz, 1H), 7.12-6.97 (1H), 5.31 (d, J = 22.0 Hz, 2H), 3.67 (s, 3H), 2.94 (s, 2H), 1.21 (s, 6H) Preparation Example 60: Methyl 2-(2-Aminopyridin-4-yl)-2-methylpropanoate 118 ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Preparation Example 19 by using 2-(2chloropyridin-4-ii)acetic acid (5.00 g, 29.1 mmol). (4-stage performance of 5%) 2H), 3.67 (s, 3H), 1.52 (s, 6H) Preparation Example 61: Ethyl 2-(6-Aminopyridin-2-.yl)-2methylpropanoate Diisopropylamine (1.77 ml, 12.4 mmol) was added to 1 ml of anhydrous tetrahydrofuran, and 2.5 M n-butyllithium (4.97 ml, 12.4 mmol) was added slowly dropwise at -78°C. The reaction solution was stirred at the same temperature for 20 minutes. The temperature was raised to room temperature and stirred for 10 minutes, then decreased to -78°C and stirred for 10 minutes. 2-Chloro-6-methylpyridine (0.57 ml, 5.2 mmol) dissolved in 100 ml of anhydrous tetrahydrofuran was added dropwise to the reaction solution. The reaction solution was stirred at -78°C for 1 hour, and diethyl carbonate (0.75 ml, 6.2 mmol) dissolved in 100 ml of anhydrous tetrahydrofuran was ccz / nn / zznz / E / Y 119 added slowly drop by drop. The reaction solution was raised to 0°C and stirred for 4 hours. The reaction was terminated by adding saturated aqueous ammonium chloride solution to the reaction solution, followed by extraction with ethyl acetate. The organic layer was concentrated under reduced pressure and then purified by a silica gel column (ethyl acetate:hexane) to obtain the desired product. (88% performance) iH-NMR (CHLOROFORM-D) £7.61 (t, J= 7.8 Hz, 1H), 7.22 (d, J = Ί .6 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 3.80 (s, 2H), 1.29-1.20 (m, 3H) Step 2: Ethyl 2-(6-Aminopyridin-2-yl)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 2, Step 3, Step 4) by using ethyl 2-(6-chloropyridin-2-yl)acetate (903 mg, 4.52 mmol) obtained in the Stage 1. (3-stage performance of 5%)1H-NMR (CHLOROFORM-D) £7.38 (t, J= 7.9 Hz, 1H), 6.62 (d, J = 7.3 Hz, 1H), 6.34 (d, J = 7.9 Hz, 1H), 4.34 (s, 2H), 4.19-4.12 (m, 2H), 1.53 (s, 6H), 1.19 (t, J = 7.0 Hz, 3H) Preparation Example 62: 3-(6 tert-butyl -aminopyridin-2-yl)-2,2dimethylpropanoate ccz / nn / zznz / E / Y 120 Step 1: 2-(Bromomethyl)-6-chloropyridine 2-Chloro-6-methylpyridine (3.00 g, 23.5 mmol), Nbromosuccinimide (4.19 g, 23.5 mmol), and 2,2'-azobis(2methylpropionitrile) (0.077 g, 0.47 mmol) were dissolved in 50 ml of 1,2- dichloroethane, heated to 80°C for 3 hours and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (25% performance) , 4.50 (s, 2H) Step 2: tert-butyl 3-(6-chloropyridin-2-yl)-2,2,-dimethylpropanoate The desired product was obtained in a similar manner to step 1 of Preparation Example 58 by using 2(bromomethyl)-6-chloropyridine (1.23 g, 5.96 mmol) obtained in step 1 and tert-butyl isobutyrate (1.03 g, 5.96 mmol). 7.15 mmol). (84% performance) 7.8 Hz, 1H), 3.00 (s, 2H), 1.44 (s, 9H), 1.18 (s, 6H) Step 3: tert-butyl 3-(6-aminopyridin-2-yl)-2,2-dimethylpropanoate The desired product was obtained in a similar manner ccz / nn / zznz / E / Y to Preparation Example 19 (Step 3, Step 4) by using tert 3(6-chloropyridin-2-yl)-2,2-dimethylpropanoate. -butyl (1.35 g, 5.00 mmol) obtained in Stage 2. (2-stage yield of 9%)1H-NMR (CHLOROFORM-D) J 7.31 (t, J= 7.8 Hz 1H), 6.48 (d, J = 7.3 Hz, 1H), 6.34-6.29 (1H), 4.27 (s, 2H), 2.84 (s, 2H), 1.44 (s, 9H), 1.20-1.13 (6H) Preparation Example 63: tert-butyl 3-(2-aminopyridin-4-yl)-2,2dimethylpropanoate H2N O1 The desired product was obtained in a similar manner to Preparation Example 62 by using 2-chloro-4methylpyridine (3.00 g, 23.5 mmol). (4-stage performance of 3%)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.94 (d J = 5.5Hz 1H), 6.47 (d, J = 5.5 Hz, 1H), 6.30 (s, 1H), 4.30 (s, 2H), 2.70 (s, 2H), 1.44 (s, 9H), 1.14 (s, 6H) Preparation Example 64: tert-butyl 3-amino-lH-pyrazole-l-carboxylate After dissolving lH-pyrazole-3-amine (0.500 g, 6.02 mmol), TEA (1.677 ml, 12.03 mmol) and 4-dimethylaminopyridine (0.049 g, 0.403 mmol) in 1,4-dioxane (20.06 ml), dicarbonate ccz / nn / zznz / E / Y 122 di-tert-butyl (1.590 ml, 6.92 mmol) was added dropwise at room temperature. After stirring at room temperature for 4 hours, the organic solvent was removed under reduced pressure. The mixture was diluted with ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and used in the next reaction without further purification. (84% performance) (s, 9H) Preparation Example 65: Ethyl 1-(6-Aminopyridin-2-yl)piperidine-3carboxylate The desired product was obtained in a similar manner to Preparation Example 29 by using ethyl piperidine-3carboxylate (0.500 g, 3.18 mmol). (24% 3-stage performance)XH-NMR (500MHz, CHLOROFORM-D) J = 7.1 Hz, 2H), 4.05-3.93 (m, 1H), 3.86 (d, J = 13.1 Hz, 1H), 3.38 (dd, J = 13.1, 9.8 Hz, 1H), 3.19 (dd, J = 13.0, 9.9 Hz, 1H), 2.84-2.59 (m, 1H), 2.16 (d, J = 9.5 Hz, 1H), 1.89 (s, 1H), 1.83-1.65 (m, 2H), 1.28 (t, J= 7.2 Hz, 3H) Preparation Example 66: 3-(3-Amino-lH-pyrazol-l-yl)-2.2123 ccz / nn / zznz / E / Y methyl dimethylpropanoate _ 4 / h2n N By using methyl 3-hydroxy-2,2-dimethylpropanoate (0.70 g, 5.31 mmol) and 3-nitro-1H-pyrazole (0.50 g, 4.42 mmol), a method similar to Step 1 of Preparation Example 1 and Step 3 of Preparation Example 94 was used sequentially to obtain a desired product. (63% performance) 3.69 (s, 3H), 1.19 (s, 6H) Preparation Example 67: Methyl 3-(3-(3-Amino-lH-pyrazol-l-yl)phenyl)-2,2-dimethylpropanoate lH-pyrazole-3-amine (0.20 g, 2.41 mmol), copper (I) iodide (0.046 g, 0.24 mmol), cesium carbonate (1.186 g, 3.61 mmol) and tert-butyl 3-(3-bromophenyl)-2,2-dimethylpropanoate (0.75 g, 2.41 mmol) obtained in step 1 of Preparation Example 79 were added to DMF (2.4 mL) and stirred at 120° C for 12 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. 124 ccz / nn / zznz / E / Y magnesium. The solvent was removed under reduced pressure and purified by column chromatography to obtain the title compound. (59% yield) 1R-NMR (400 MHz, CHLOROFORM-D): £7.66 (d, J = 2.3 Hz, 1H), 7.48-7.33 (m, 2H), 7.30-7.25 (m, 1H), 6.99 (d, J= 7.8 Hz, 1H), 5.83 (d, J= 2.3 Hz, 1H), 3.31 (s, 2H), 2.86 (s, 2H), 1.43 (s, 9H), 1.15 (s, 6H) Preparation Example 68: Ethyl 2-(3-(2-Aminopyrimidin-4-yl)phenoxy)2-methylpropanoate Step 1: ethyl 2-(3-Bromophenoxy)-2-methylpropanoate 3-bromophenol (1 g, 5.78 mmol), ethyl 2-bromo-2methylpropanoate (1.24 g, 6.36 mmol) and potassium carbonate (1.598 g, 11.56 mmol) were dissolved in 10 ml of DMF and stirred at room temperature for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (42% performance)XH-NMR (400 MHz, CHLOROFORM-D) £7.13-6.92 (m, 3H), 6.79-6.67 (m, 1H) , 4.24-4.13 (m, 2H) , 1.71-1.43 (m, 6H) , 1.25125 ccz / nn / zznz / E / Y 1.15 (m, 3H) Step 2: Ethyl 2-(3-(2-Aminopyrimidin-4-yl)phenoxy)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 53 (Step 1, Step 2) and Preparation Example 19 (Step 3, Step 4) by using ethyl 2-(3bromophenoxy)-2-methylpropanoate (0.7 g, 2.56 mmol) obtained in stage 1. (4-stage yield of 34%) m, 1H), 7.40-7.26 (m, 1H), 7.03-6.87 (2H), 5.01 (d, J = 31.6 Hz, 2H), 4.34-4.16 (m, 2H), 1.62 (s, 6H), 1.28-1.19 (m, 3H) Preparation Example 69: Ethyl 2-(4-(2-Aminopyrimidin-4-yl)phenoxy)2-methylpropanoate EITHER The desired product was obtained in a similar manner to Step 1 of Preparation Example 68, Preparation 53 (Step 1, Step 2), and Preparation Example 19 (Step 3, Step 4) by using 4-bromophenol (1 g, 5.78 mmol). (21% 5-stage performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.32-8.19 (m, 1H), 7.96-7.81 (m, 2H), 6.98-6.89 (m, 1H), 6.89-6.77 (m, 2H), 5.34 (s, 2H), 4.29-4.14 (m, 2H), 1.63-1.54 (m, 6H) ), 1.25-1.14 (m, 126 ccz / nn / zznz / E / Y 3Η) Preparation Example 70: methyl 2-(3-(2-Aminopyrimidin-4-yl)phenyl) acetate Step 1: Methyl 2-(3-Bromophenyl)acetate 2-(3-bromophenyl)acetic acid (2 g, 9.30 mmol) and 2.79 ml of sulfuric acid were dissolved in 18.6 ml of methanol and stirred at 80°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 χ 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (96% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.46-7.38 (m, 1H), 7.38-7.26 (m, 1H), 7.26-7.02 (m, 2H), 3.71-3.59 (m, 3H), 3,593.48 (m, 2H) Step 2: 2-(3-(2-Aminopyrimidin-4-yl)phenyl)methyl 2-(3-(2-Aminopyrimidin-4-yl)phenyl)acetate The desired product was obtained in a similar manner to Preparation Example 53 (Step 1, Step 2) and Preparation Example 19 (Step 3, Step 4) by using methyl 2-(3bromophenyl)acetate (2.042 g, 8.94 mmol ) obtained in ccz / nn / zznz / E / Y 127 Stage 1. (4-stage performance of 21%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.37-8.30 (m, 1H), 7.94 (d, J = 14.6 Hz, 1H), 7.90-7.81 (m, 1H), 7.44-7.36 (m, 2H), 7.00 (t, J= 5.7 Hz, 1H), 5.26 (t, J= 43.7 Hz , 2H) , 3.69 (s, 5H) Preparation Example 71: tert-butyl 3-(4-(2-aminopyridin-4-yl)phenyl)2,2-dimethylpropanoate Step 1: tert-butyl 2,2-dimethyl-3-(4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate The desired product was obtained in a similar manner to Preparation Example 58 (Step 1, Step 2) by using 1-bromo-4-(bromomethyl)benzene (2.00 g, 8.00 mmol) and tert-butyl isobutyrate (1.39 g, 9.60 mmol ). (2-stage performance of 64%) 1.43 (s, 9H), 1.34 (s, 12H), 1.11 (s, 6H) Step 2: tert-butyl 3-(4-(2-aminopyridin-4-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 by using 4bromopyridine-2-amine (106 mg, 0.611 mmol) and 2,2-dimethyl-3-(4ccz / nn / zznz / E / AND 128 tert-butyl (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)propanoate (220 mg, 0.611 mmol) obtained in Step 1. (86% yield) 1R-NMR (CHLOROFORM-D) 58.11 (d, J= 5.2 Hz, 1H), 7.49 (d, J = 7.6 Hz, 2H), 7.24 (d, J = 7.6 Hz, 2H), 6.88 (d, J = 5.2 Hz, 1H), 6.70 (s, 1H), 4.46 (s, 2H), 2.87 (s, 2H), 1.52-1.36 (m, 9H), 1.21-1.07 (m, 6H) Preparation Example 72: Ethyl 6-(2-Aminopyrimidin-4-yl)picolinate Step 1: Ethyl 6-(Tributylstanyl)picolinate Ethyl 6-Bromopicolinate (300 mg, 1.304 mmol) was dissolved in toluene, and bis(tributyltin) (791 μΐ, 1.57 mmol) and potassium acetate (384 mg, 3.91 mmol). After removing the dissolved oxygen from the reaction mixture, it was refilled with nitrogen and the outside air flow inlet was blocked. 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (53.2 mg, 0.065 mmol) was added and reacted at 90°C for 18 hours. After completion of the reaction, it was filtered through Celite and concentrated under reduced pressure and the mixture was immediately used for the next reaction. T-NMR (400 MHz, CHLOROFORM-D) δ 7.90 (dd, J = 7.8, 1.4 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.51 (dd, J = 7.3, 1.4 129 ccz / nn / zznz / E / Y Hz, 1H), 4.42 (q, J = 7.2 Hz, 2H), 1.68-1.45 (m, 9H), 1.41 (t, J = 7.1 Hz, 3H), 1.33 (td, J= 14.8, 7.5 Hz, 6H) ), 1.25-1.02 (m, 6H), 0.88 (q, J= 7.3 Hz, 10H) Step 2: Ethyl 6-(2-Chloropyrimidin-4-yl)picolinate Ethyl 6-(Tributylstanyl)picolinate synthesized in step 1 was dissolved in toluene, and 2,4dichloropyrimidine (18.6 mg, 0.125 mmol) and sodium carbonate (39.7 mg, 0.375 mmol) were added. After removing the dissolved oxygen from the reaction mixture, it was filled with nitrogen and the outside air flow inlet was blocked. (Triphenylphosphine)palladium (0) (14.4 mg, 0.012 mmol) was added, a reflux cooling device was connected to 130°C and heated for 12 hours. After completion of the reaction, it was filtered through Celite and concentrated under reduced pressure and the mixture was purified by column chromatography (hexane:ethyl acetate) to synthesize the desired compound. (49% performance) 5.0 Hz, 1H), 8.23 ​​(dd, J = 7.5, 1.1 Hz, 1H), 8.02 (t, J = 7.8 Hz, 1H), 4,584.40 (2H), 1.46 (t, J = 7.1 Hz, 3H) Step 3: Ethyl 6-(2-Aminopyrimidin-4-yl)picolinate The desired product was synthesized in a similar manner to Preparation Example 19 (Step 3, Step 4) by using ethyl 6-(2-chloropyrimidin-4-yl)picolinate (76 mg, 130 ccz / nn / zznz / E / Y 0.288 mmol) synthesized in Stage 2. (2-stage yield of 24%) 5.0 Hz, 1H), 8.17 (dd, J = 7.8, 0.9 Hz, 1H), 7.96 (t, J = 7.8 Hz, 1H), 7.81 (d, J = 5.0 Hz, 1H), 5.19 (s, 2H) , 4.48 (q, J = 7.2 Hz, 2H) , 1.46 (t, J = 7.1 Hz, 3H) Preparation Example 73: tert-butyl (6-bromopyridin-2-yl)carbamate and j n N Br H 6-Bromopyridin-2-amine (15.0 g, 87.0 mmol) and 1.3 M lithium hexamethyldisilazide (147 ml, 191 mmol) were dissolved in 93 ml THF, and di-tert-butyl dicarbonate (21.9 ml, 95.0 mmol) which It was diluted in 100 ml of THF at -78°C under nitrogen purge and added dropwise to it. After stirring at room temperature overnight, the organic solvent was removed under reduced pressure, diluted with ethyl acetate, washed with 1 N aqueous hydrochloric acid solution, dried over magnesium sulfate, and purified by column of silica gel (ethyl acetate:hexane) to obtain the desired product. (98% yield) J = 7.6 Hz, 1H), 1.52-1.50 (9H) ccz / nn / zznz / E / Y 131 Preparation Example 74: Methyl 2-(4-(2-Aminopyrimidin-4-yl)phenyl)acetate Step 1: Methyl 2-(4-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan2-yl)phenyl)acetate The desired product was obtained in a manner similar to Step 1 of Preparation Example 53 by using methyl 2-(4-bromophenyl)acetate (2.07 g, 9.04 mmol). (96% performance) t, J = 7.5 Hz, 2H), 1.43-1.29 (m, 12H) Step 2: Methyl 2-(4-(2-Chloropyrimidin-4-yl)phenyl)acetate The desired product was obtained in a manner similar to Step 2 of Preparation Example 53 by using 2—(4—(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl) methyl acetate (2.4 g, 8.69 mmol) obtained in step 1. (14% yield) m, 2H), 7.62 (d, J = 5.0 Hz, 1H), 7.43 (d, J = 8.2 Hz, 2H), 3.71 (dd, J = 15.8, 14.4 Hz, 5H) Step 3: 2-(4-(2-Aminopyrimidin-4-yl)phenyl)acetate 132 methyl The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using methyl 2(4-(2-chloropyrimidin-4-yl)phenyl)acetate (0.32 g, 1.218 mmol) obtained in Stage 2. (2-stage yield of 28%) AH-NMR (400 MHz, CHLOROFORM-D) δ 8.63 (q, J = 2.6 Hz, 1H), 8.04-7.96 (m, 2H), 7.79 (d, J = 13.3 Hz, 1H), 7.39 (d, J = 8.2 Hz, 2H), 7.36-7.29 (m, 2H), 3.69 (s, 3H), 3.68 (s, 2H) Preparation Example 75: 2-(4-(6-Amino-3-(trifluoromethyl)pyridine Methyl -2-yl)phenyl)-2-methylpropanoate ccz / nn / zznz / E / Y Step 1: Methyl 2-(4-(6-Chloro-3-(trifluoromethyl)pyridin-2yl)phenyl)-2-methylpropanoate The desired product was obtained in a manner similar to Step 2 of Preparation Example 53 by using 2-methyl-2(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl methyl)phenyl)propanoate (0.5 g, 1.644 mmol) obtained in step 1 of Preparation Example 54 and 2,6-dichloro-3-(trifluoromethyl)pyridine (0.426 g, 1.972 mmol). (78% yield) AH-NMR (400 MHz, CHLOROFORM-D) δ 8.08-8.01 (m, 1H), 7.99 (dt, J= 8.7, 2.1 Hz, 2H), 7.72 (d, J = 8.2 Hz, 1H), 7.48133 ccz / nn / zznz / E / Y 7.41 (m, 2H), 3.66 (s, 3H), 1.66-1.61 (m, 6H) Step 2: Methyl 2-(4-(6-Amino-3-(trifluoromethyl)pyridin-2yl)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (step 3, step 4) by using methyl 2(4-(6-chloro-5-(trifluorometii)pyridin-2-ii)phenyl)-2-methylpropanoate. (0.46 g, 1.286 mmol) obtained in stage 1. (2-stage yield of 41%) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.90 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 8.2 Hz, 1H), 7.41 (dd, J = 21.5, 12.8 Hz, 2H), 7.17-7.03 (m, 1H), 5.05 (d, J = 43.0 Hz, 2H), 3.72-3.56 (m, 3H) ), 1.62 (d, J = 15.1 Hz, 6H) Preparation Example 76: Methyl 3-(4-(2-Aminopyrimidin-4-yl)phenyl)2,2-dimethylpropanoate EITHER Step 1: tert-butyl 3-(4-(2-((tert-butoxycarbonyl)amino)pyrimidin-4-yl)phenyl)-2,2-dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 and Step 3 of Preparation Example 19 by using 2,4-dichloropyrimidine (4.30 g, 28.9 mmol) and 2,2-dimethyl-3- tert-butyl (4-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)phenyl)propanoate (10.4 g, 28.9 mmol) obtained in step 1 of Preparation Example ccz / nn / zznz / E / Y 134 71. (9% 2-stage yield) m / z (M+H)+calculated for C24H34N3O4: 428, found 428 Step 2: Methyl 3-(4-(2-Aminopyrimidin-4-yl)phenyl)-2,2dimethylpropanoate Tert-butyl 3-(4-(2-((tert-Butoxycarbonyl)amino)pyrimidin-4yl)phenyl)-2,2-dimethylpropanoate (1.63 g, 3.81 mmol) obtained in step 1 was dissolved in 63.5 ml of methanol, and sulfuric acid (1.02 ml, 19.1 mmol) was added slowly drop by drop. It was stirred under reflux at 100°C for 2 hours, cooled, and washed with sodium hydrogen carbonate solution. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (73% yield)XH-NMR (40 0 MHz, CHLOROFORM-D) <^8.3 3 (d, J 1H), 7.98-7.82 (m, 2H), 7.21 (d, J = 8.2 Hz, 2H), 7.02 (d, J = 5.5 Hz, 1H), 5.03 (s, 2H), 3.67 (s, 3H), 2.92 (s, 2H), 1.20 (s, 6H) Preparation Example 77: tert-butyl 3-(4-(6-aminopyridin-2yl)phenyl)-2,2-dimethylpropanoate h2n n The desired product was obtained in a manner similar to ccz / nn / zznz / E / Y 135 Step 2 of Preparation Example 52 by using 6chloropyridin-2-amine (143 mg, 1.11 mmol) and 2,2-dimethyl-3-(4 (4,4,5,5-tetramethyl-l,3,2 tert-butyl-dioxaborolan-2-yl)phenyl)propanoate (500 mg, 1.39 mmol) obtained in step 1 of the Preparation Example 71. (40% Yield) , J = 6.4 Hz, 2H), 7.156.99 (1H), 6.44 (d, J = 7.8 Hz, 1H), 4.46 (s, 2H), 2.87 (s, 2H), 1.45 (s, 9H), 1.13 (s, 6H) Preparation Example 78: Methyl 3-(3-(6-Aminopyridin-2-yl)phenyl)2,2-dimethylpropanoate Step 1: Methyl 3-(3-(6-((tert-Butoxycarbonyl)amino)pyridin2-yl)-phenyl)-2,2-dimethylpropanoate The desired product was obtained in a similar manner to step 2 of Preparation Example 52 by using tert-butyl (6bromopyridin-2-yl)carbamate (17.3 g, 63.5 mmol) obtained in Preparation Example 73 and 2.2 Methyl-dimethyl-3-(3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)propanoate (20.2 g, 63.5 mmol) obtained from Step 2 of Example Preparation 58. (Yield of 66%) . δ = 7.8 Hz, 2H), 7.14 (d, J = 7.3 Hz, 1H), 3.66 (s, 3H), 2.93 (s, 136 ccz / nn / zznz / E / Y 2Η), 1.54 (s, 9H), 1.22 (s, 6H) Step 2:Methyl 3-(3-(6-Aminopyridin-2-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a manner similar to Step 4 of Preparation Example 19 using 3-(3-(6((tert-butoxycarbonyl)amino)pyridin-2-yl)-phenyl)-2,2-dimethylpropanoate. of methyl (16.2 g, 42.1 mmol) obtained in step 1. (86% yield) 1H-NMR (400 MHz, CHLOROFORM-D) £7.78 (d, J = 7.8 Hz, 1H), 7.67 (s, 1H ), 7.57-7.40 (m, 1H), 7.32 (t, J= 7.8 Hz, 1H), 7.11 (d, J = 7.3 Hz, 1H), 7.08-6.99 (m, 1H), 6.53-6.37 (m, 1H), 4.45 (s, 2H), 3.67 (s, 3H), 3.00-2.85 (2H), 1.21 (s, 6H) Preparation Example 79: tert-butyl 3-(3-(2-chloro-5-fluoropyrimidin-4yl)phenyl)-2,2-dimethylpropanoate Step 1: tert-butyl 3-(3-bromophenyl)-2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 1 of Preparation Example 58 using l-bromo-3-(bromomethyl)benzene (5 g, 20.01 mmol) and tert-butyl isobutyrate (4.00 ml, 24.01 mmol ). (70% performance)XH-NMR (400 MHz, CHLOROFORM-D) £7.40-7.27 (m, 2H), 7.11 (t, J = 7.3 Hz, 1H), 7.08-6.99 (m, 1H), 2.84-2.70 (2H), ccz / nn / zznz / E / Y 137 1.43 (s, 9H), 1.12 (s, 6H) Step 2: tert-butyl 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 58 by using tert-butyl 3-(3-bromophenyl)-2,2-dimethylpropanoate (4.38 g, 13.98 mmol) synthesized in Step 1 (72% yield) = 1.4 Hz, 2H), 1.43 (s, 9H), 1.31 (s, 12H), 1.12 (s, 6H) Step 3: tert-butyl 3-(3-(2-chloro-5-fluoropyrimidin-4-yl)phenyl)2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan Tert-butyl -2-yl)phenyl)propanoate (500 mg, 1.39 mmol) synthesized in step 2. (46% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.49 (d, J = 3.2 Hz, 1H), 8.00-7.88 (m, 2H), 7.49-7.31 (m, 2H), 2.92 (s, 2H), 1.43 (s, 9H), 1.15 (s, 6H) Preparation Example 80: tert-butyl 3-(3-(2-aminopyrimidin-4-yl)phenyl)2,2-dimethylpropanoate 138 ccz / nn / zznz / E / Y The desired product was obtained in a manner similar to step 2 of Preparation Example 52 and Example Preparation 19 (Step 3, Step 4) using 2,4dichloropyrimidine (0.620 g, 4.16 mmol) and 2,2-dimethyl-3-(3(4,4,5,5-tetramethyl-l,3,2-dioxaborolan tert-butyl -2-ii)phenyl)propanoate (1.50 g, 4.16 mmol) obtained in step 2 of Preparation Example 79. (3-step yield of 49%) Ή-NMR (CHLOROFORM-D) £8.34 (s, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.36 (s, 1H), 7.28 (s, 1H), 7.03 (s, 1H), 5.02 (s, 2H), 2.91 (s, 2H), 1.43 (s, 9H), 1.16 (s, 6H) Preparation Example 81: tert-butyl 3-(4-(2-aminopyrimidin-4-yl)phenyl)2,2-dimethylpropanoate The desired product was obtained in a manner similar to Step 2 of Preparation Example 52 and Example Preparation 19 (Step 3, Step 4) using 2,4dichloropyrimidine (182 mg, 1.22 mmol) and 2,2-dimethyl-3-(4(4,4,5,5-tetramethyl-l,3,2-dioxaborolan tert-butyl -2-yl)phenyl)propanoate (440 mg, 1.22 mmol) obtained from step 1 of Preparation Example 71. (3-step yield of 19%)XH-NMR (400 MHz, CHLOROFORM-D) £ 8.33 (d, J = 5.5 Hz, 1H), 7.98-7.82 (m, 2H), 7.28 (s, 2H), 7.03 (d, J = 5.5 Hz, 1H), 5.04 (s, 2H), 2.88 ( d, J= 9.1 Hz, 2H), 1.44 (s, 9H), 1.14 (s, 139 ccz / nn / zznz / E / Y 6Η) Preparation Example 82: 3-(3-(6-aminopyrazin-2-yl)phenyl)- tert-butyl 2,2-dimethylpropanoate Step 1: tert-butyl 3-(3-(6-chloropyrazin-2-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 by using 2,6dichloropyrazine (124 mg, 0.833 mmol) and 2,2-dimethyl-3-(3(4,4,5,5- tert-butyl tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate (300 mg, 0.833 mmol) obtained in step 2 of Preparation Example 79. (52% yield) H-NMR (400 MHz, CHLOROFORM-D) δ 8.90 (s, 1H), 8.50 (s, 1H), 7.93-7.78 (m, 2H), 7.49-7.34 (m, 1H), 7.30 (d, J= 7.3 Hz, 1H), 2.93 (s, 2H), 1.45 (s, 9H), 1.24-1.10 (6H) Step 2: tert-butyl tert-butyl 3-(3-(6-aminopyrazin-2-yl)phenyl)2,2-dimethylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using tert-butyl 3(3-(6-chloropyrazin-2-yl)phenyl)-2,2-dimethylpropanoate (151 mg, 0.435 mmol) synthesized in stage 1. (2-stage yield of 69%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.35 (s, 1H), 7.92 140 ccz / nn / zznz / E / Y (s, 1H) , 7.77 (t, J = 7.3 Hz, 2H) , 7.36 (t, J = 7.8 Hz, 1H) , 7.23 (d, J = 7.8 Hz, 1H ), 4.57 (s, 2H), 2.91 (s, 2H), 1.43 (s, 9H), 1.16 (s, 6H) Preparation Example 83: Methyl 3-(3-(5-Aminopyridin-3-yl)phenyl)2,2-dimethylpropanoate Step 1: tert-butyl 3-(3-(5-bromopyridin-3-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 by using 3,5bromopyridine (197 mg, 0.833 mmol) and 2,2-dimethyl-3-(3-(4,4,5,5tetramethyl tert-butyl -1,3,2-dioxaborolan-2-yl)phenyl)propanoate (300 mg, 0.833 mmol) obtained in step 2 of Preparation Example 79. (54% yield)XH-NMR (400 MHz, CHLOROFORM -D) £8.73 (d, J = 1.8 Hz, 1H) , 8.64 (d, J= 2.3 Hz, 1H) , 7.99 (t, J= 2.1 Hz, 1H) , 7.447.32 (m, 3H) , 7.23 (d, J = 6.9 Hz, 1H), 2.91 (s, 2H), 1.43 (s, 9H), 1.16 (s, 6H) Step 2: Methyl 3-(3-(5-Aminopyridin-3-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 3 of Preparation Example 19 and Step 2 of Preparation Example 76 by using 3-(3-(5-bromopyridin-3ccz / nn / zznz / E / Y 141 tert-butyl yl)phenyl)-2,2-dimethylpropanoate (176 mg, 0.451 mmol) synthesized in step 1. (2-step yield of 13%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.23 (d, J = 1.8 Hz, 1H), 8.14-8.00 (1H), 7.40 (dd, J = 7.8, 1.4 Hz, 1H), 7.34 (t, J = 7.5 Hz, 1H), 7.28 (s, 1H) , 7.12 (q, J= 2.3 Hz, 2H), 3.78 (s, 2H), 3.66 (s, 3H), 2.92 (s, 2H), 1.22 (s, 6H) Preparation Example 84: 3-(3- tert-butyl (6-amino-4-(trifluoromethyl)pyridin-2-yl)phenyl)-2,2-dimethylpropanoate Step 1: tert-butyl 3-(3-(6-chloro-4-(trifluoromethyl)pyridin-2yl)phenyl)-2,2-dimethylpropanoate The desired product was obtained in a manner similar to Step 2 of Preparation Example 52 by using 2,6dichloro-4-(trifluoromethyl)pyridine (0.115 ml, 0.799 mmol) and 2,2-dimethyl-3-(3-( Tert-butyl 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl)propanoate (288 mg, 0.799 mmol) obtained in Step 2 of Preparation Example 79. (66% yield ). δ 7.28 (d, J = 7.8 Hz, 1H), 2.94 (s, 2H), 1.45 (s, 9H), 1.17 (s, 6H) ccz / nn / zznz / E / Y 142 Step 2: tert-butyl 3-(3-(6-amino-4-(trifluoromethyl)pyridin-2yl)phenyl)-2,2-dimethylpropanoate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using 3(3-(6-chloro-4-(trifluoromethyl)pyridin-2-yl)phenyl)-2,2dimethylpropanoate. tert-butyl (218 mg, 0.527 mmol) synthesized in stage 1. (2-stage yield of 63%) , 7.75 (s, 1H) , 7.35 (t, J= 7.5 Hz, 1H) , 7.22 (d, J = 8.2 Hz, 2H) , 6.62 (s, 1H) , 4.74 (s, 2H) , 2.91 (s, 2H), 1.44 (s, 9H), 1.16 (s, 6H) Preparation Example 85: tert-butyl 3-(3-(6-amino-5-fluoropyridin-2yl)phenyl)-2,2-dimethylpropanoate Stage 1: 3-(3- (6-chloro-5-fluoropyridin-2-yl)phenyl)- tert-butyl 2,2-dimethylpropanoate The title compound was synthesized in the same manner as in Step 2 of Preparation Example 52 by using 2,2-dimethi1-3-(3-(4,4,5,5-tetramethyl-1,3,2- tert-butyl dioxaborolan-2-yl)phenyl)propanoate (500 mg, 1.39 mmol) obtained in Step 2 of Preparation Example 7 9 and 2,6dichloro-3-fluoropyridine (230 mg, 1.39 mmol). (Performance 10%) 143 ccz / nn / zznz / E / Y iH-NMR (CHLOROFORM-D) £7.79 (d, J= 8.5 Hz, 2H), 7.66 (dd, J = 8.4, 3.2 Hz, 1H), 7.60-7.46 (1H ), 7.38 (t, J = 7.5 Hz, 1H), 7.27-7.18 (1H), 2.94 (s, 2H), 1.45 (d, J = 9.8 Hz, 9H), 1.19 (s, 6H) Step 2: 3-(3-(6-amino-5-fluoropyridin-2-yl)phenyl)- tert-butyl 2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Preparation Example 19 (Step 3, Step 4) by using 3-(3-(6-chloro-5-fluoropyridin-2-yl)phenyl)-2,2-dimethylpropanoate of tert-butyl (500 mg, 1.39 mmol) obtained in stage 1. (2-stage yield of 49%) , 1H) , 7.34 (t, J = 7.8 Hz, 1H) , 7.32-7.25 (m, 1H) , 7.19 (d, J= 7.6 Hz, 1H) , 7.04 (dd, J= 7.9, 3.1 Hz, 1H) , 4.83 (s, 2H), 2.92 (d, J = 6.7 Hz, 2H), 1.49-1.41 (m, 9H), 1.18 (s, 6H) Preparation Example 86: 3-(3-(2-amino- tert-butyl 5-(trifluoromethyl)pyrimidin-4-yl)phenyl)-2,2-dimethylpropanoate Step 1: tert-butyl 3-(3-(2-chloro-5-(trifluoromethyl)pyrimidin-4yl)phenyl)-2,2-dimethylpropanoate The title compound was synthesized in the same manner as in Step 2 of Preparation Example 52 by using 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2144 dioxaborolan tert-butyl -2-yl)phenylpropanoate (500 mg, 1.39 mmol) obtained in step 2 of Preparation Example 79 and 2,6-dichloro-5-(trifluoromethyl)pyrimidine (301 mg, 1.39 mmol) (Yield) of 13%) J= 7.5 Hz, 1H), 7.27-7.18 (1H), 2.94 (s, 2H), 1.45 (d, J = 9.8 Hz, 9H), 1.19 (s, 6H) Step 2: tert-butyl 3-(3-(2-amino-5-(trifluoromethyl)pyrimidin-4yl)phenyl)-2,2-dimethylpropanoate The title compound was synthesized in the same manner as in Preparation Example 19 (Step 3, Step 4) by using 3-(3-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)phenyl)- Tert-butyl 2,2-dimethylpropanoate (232 mg, 0.64 mmol) obtained in step 1. (2-step yield of 43%) m / z (M+H)+calculated for C20H25F3N3O2: 396, found 396 Preparation Example 87: tert-butyl 3-(3-(6-amino-3-fluoropyridin-2yl)phenyl)-2,2-dimethylpropanoate ccz / nn / zznz / E / Y Step 1: 3-(3-(6-chloro-3-fluoropyridin-2-yl)phenyl)- tert-butyl 2,2-dimethylpropanoate ccz / nn / zznz / E / Y 145 The title compound was synthesized in the same manner as in Step 2 of Preparation Example 52 by using 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-1,3,2- tert-butyl dioxaborolan-2-yl)phenyl)propanoate (500 mg, 1.39 mmol) obtained in step 2 of Preparation Example 7 9 and 2,6dichloro-3-fluoropyridine (230 mg, 1.39 mmol). (68% performance) 10.1, 8.2 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 2.7 Hz, 1H), 7.22 (d, J = 3.2 Hz, OH), 2.91 (s, 2H) , 1.46-1.33 (m, 9H), 1.16 (d, J = 8.2 Hz, 6H) Step 2: 3-(3-(6-amino-3-fluoropyridin-2-yl)phenyl)- tert-butyl 2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Preparation Example 19 (Step 3, Step 4) by using tert 3-(3-(6-eloro-3-fluoropyridin-2-yl)phenyl)-2,2dimethylpropanoate. -butyl (192 mg, 0.53 mmol) synthesized in stage 1. (2-stage yield of 12%) ), 7.57 (d, J = 8.5 Hz, 1H), 7.46 (t, J = 9.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 7.26 (s, 1H), 2.96 (s, 2H) ), 1.50-1.43 (m, 11H), 1.22 (d, J = 8.5 Hz, 6H) Preparation Example 88: Ethyl 2-(3-(6-Aminopyridin-2-yl)phenoxy)-2methylpropanoate 146 ccz / nn / zznz / E / Y Step 1: Ethyl 2-(3-Bromophenoxy)-2-methylpropanoate 3-Bromophenol (2.00 g, 11.6 mmol), Ethyl 2-bromo-2methylpropanoate (2.48 g, 12.7 mmol) and potassium carbonate (3.20 g, 23.1 mmol) were dissolved in 23.1 ml of DMF and stirred at room temperature overnight. After extraction with ethyl acetate, the organic solvent was dried over magnesium sulfate, and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (42% performance) 1H), 4.24 (q, J= 7.0 Hz, 2H), 1.59 (s, 6H), 1.25 (t, J = 7.1 Hz, 3H) Step 2: ethyl 2-methyl-2-(3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenoxy)propanoate The desired product was obtained in a similar manner to step 1 of Preparation Example 52 by using ethyl 2-(3bromophenoxy)-2-methylpropanoate (1.39 g, 4.84 mmol) synthesized in step 1. (Yield 80%) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.43 (d, J = 7.3 Hz, 1H), 7.30 (d, J = 2.7 Hz, 1H), 7.23 (d, J = 7.8 Hz, 1H), 6.94 ( dq, J = 8.2, 1.2 Hz, 1H), 4.25 (q, J = 7.2 Hz, 2H), 1.58 (s, 6H), 1.32 (s, 12H), 1.27-1.25 (3H) ccz / nn / zznz / HEY 147 Step 3: Ethyl 2-(3-(6-Aminopyridin-2-yl)phenoxy)-2-methyl1propanoate The desired product was obtained in a similar manner to Preparation Example 78 (step 1, step 2) by using tert-butyl (6bromopyridin-2-yl)carbamate (1.06 g, 3.89 mmol) obtained in Preparation Example 73 and Ethyl 2-methyl-2-(3(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (1.30 g, 3.89 mmol) synthesized in step 2. ( 2-stage performance of 53%) , 7.04 (d, J= 7.3 Hz, 1H) , 6.92-6.77 (m, 1H) , 6.45 (d, J = 8.2 Hz, 1H) , 4.45 (s, 2H) , 4.25 (q, J = 7.2 Hz, 2H), 1.62 (s, 6H), 1.25 (t, J = 7.1 Hz, 3H) Preparation Example 89: tert-butyl 3-(3-(6-aminopyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoate Step 1:3-(3-bromo-4-f luorophenyl)-tert-butyl 2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 1 of Preparation Example 58 using 2-bromo-4-(bromomethyl)-1-fluorobenzene (5 g, 18.66 mmol) and tert-butyl isobutyrate (3.73 ml , 22.39 mmol). (Performance ccz / nn / zznz / E / Y 148 of 79%) 2.75 (s, 2H), 1.47-1.34 (9H), 1.11 (s, 6H) Step 2:3-(4-fluoro-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)-2,2-dimethylpropanoate tert-butyl The title compound was synthesized in a manner similar to Step 2 of Preparation Example 58 by using tert-butyl 3-(3-bromo-4-fluorophenyl)-2,2-dimethylpropanoate (4.86 g, 14.67 mmol) synthesized in Stage 1. (58% Yield) 8.7 Hz, 1H), 2.78 (s, 2H), 1.42 (d, J= 6.4 Hz, 10H), 1.31 (d, J= 15.1 Hz, 13H), 1.11 (d, J = 4.1 Hz, 6H) Step 3: tert-butyl 3-(3-(6-aminopyridin-2-yl)-4-fluorophenyl)2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 3-(4-fluoro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2 tert-butyl -yl)phenyl)-2,2-dimethylpropanoate (500 mg, 1.32 mmol) synthesized in Step 2 and 6-chloropyridin-2-amine (170 mg, 1.32 mmol). (76% performance) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.78 (d, J = 7.3 Hz, 1H), 7.74-7.60 (m, 1H), 7.07 (dd, J = 11.2, 8.5 Hz, 2H), 6.71 149 ccz / nn / zznz / E / Y (d, J = 8.7 Hz, 1H), 2.98-2.89 (2H), 1.42 (s, 11H), 1.15 (s, 6H) Preparation Example 90: Methyl 3-(3-(4-Aminopyrimidin-2-yl)phenyl)2,2-dimethylpropanoate Step 1: terbutyl (2-chloropyrimidin-4-yl)carbamate 2-Chloropyrimidin-4-amine (15.0 g, 116 mmol) and di-tert-butyl dicarbonate (31.9 ml, 139 mmol) were dissolved in 257 ml of anhydrous DCM, and then 4-dimethylaminopyridine (2.83 g, 23.2 mmol) was added. and stirred at room temperature overnight. After removing the organic solvent, it was purified by silica gel column (DCM) to obtain the desired product. (5% yield) 9H) Step 2: Methyl 3-(3-(4-Aminopyrimidin-2-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 and Step 4 of Preparation Example 19 by using tert-butyl (2-chloropyrimidin-4yl)carbamate (361 mg, 1.57 mmol) synthesized in step 1 and methyl 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2150 dioxaborolan-2-yl)phenyl)propanoate (500 mg, 1.57 mmol) obtained in step 2 of Preparation Example 58. (2-step yield of 14%) Hz, 1H), 8.16 (s, 1H), 7.44-7.35 (m, 1H), 7.20 (s, 1H), 6.46 (s, 1H), 5.30 (s, 2H), 3.68 (s, 3H), 2.96 (s, 2H), 1.22 (s, 6H) Preparation Example 91: tert-butyl 3-(3-(6-amino-3-methylpyridin-2yl)phenyl)-2,2-dimethylpropanoate ccz / nn / zznz / E / Y Step 1: tert-butyl 3-(3-(6-chloro-3-methylpyridin-2-yl)phenyl)2,2-dimethylpropanoate The title compound was synthesized in the same manner as in Step 2 of Preparation Example 52 by using 2,2-dimethi1-3-(3-(4,4,5,5-tetramethyl-l,3,2- tert-butyl dioxaborolan-2-yl)phenyl)propanoate (289 mg, 0.80 mmol) obtained in step 2 of Preparation Example 7 9 and 2,6dichloro-3-methylpyridine (260 mg, 1.61 mmol). (16% performance) 2H), 2.87 (s, 2H), 2.30 (s, 3H), 1.40 (s, 9H), 1.12 (d, J = 5.5 Hz, 6H) Step 2: tert-butyl 3-(3-(6-amino-3-methylpyridin-2-yl)phenyl)2,2-dimethylpropanoate ccz / nn / zznz / E / Y 151 The title compound was synthesized in a similar manner to Preparation Example 19 (Step 3, Step 4) by using 3-(3-(6-chloro-3-methylpyridin-2-yl)phenyl)-2,2-dimethylpropanoate tert-butyl (47 mg, 0.13 mmol) obtained in stage 1. (2-stage yield of 54%)XH-NMR (CHLOROFORM-D) δ 7.39 (dd, J = 8.2, 2.7 Hz, 1H), 7.36-7.29 (m, 2H), 7.19 (d, J = 6.1 Hz, 1H), 6.56-6.40 (m, 1H), 4.70 (s, 2H), 2.90 (s, 2H), 2.20 (s , 3H), 1.46 (d, J = 13.4 Hz, 9H), 1.24-1.08 (m, 6H) Preparation Example 92: Ethyl 2-(3-(6-Aminopyridin-2-yl)-4fluorophenoxy)-2-methylpropanoate Step 1: Ethyl 2-(3-Bromo-4-fluorophenoxy)-2-methylpropanoate 3-Bromo-4-fluorophenol (2 g, 10.47 mmol) was dissolved in DMF, ethyl 2-bromo-2-methylpropanoate (2.25 g, 11.52 mmol) and cesium carbonate (6.82 g, 20.94 mmol) was added, and It was stirred at room temperature for 12 hours. After completion of the reaction, water was added, extracted with ethyl acetate, and washed with brine to remove excess DMF. After removing water with magnesium sulfate and distilling under reduced pressure, the mixture was purified by column chromatography (hexane:ethyl acetate) to obtain ccz / nn / zznz / E / Y 152 the desired compound. (58% performance) , 4.23 (q, J = 7.0 Hz, 2H), 1.55 (s, 6H), 1.26 (t, J = 7.1 Hz, 3H) Step 2:2 - Ethyl (4-Fluoro-3-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenoxy)-2-methylpropanoate The title compound was synthesized in a similar manner to Step 1 of Preparation Example 52 by using ethyl 2-(3-bromo-4-fluorophenoxy)-2-methylpropanoate (1.86 g, 6.10 mmol) synthesized in Step 1 .(91% yield)1H-NMR (400 MHz, CHLOROFORM-D) £7.22 (dd, J = 4.6, 3.2 Hz, 1H), 7.01-6.80 (2H), 4.23 (q, J = 7.2 Hz, 2H), 1.54 (s, 6H), 1.32 (s, 12H), 1.24 (d, J = 7.8 Hz, 7H) Step 3: Ethyl 2-(3-(6-Aminopyridin-2-yl)-4-fluorophenoxy)2-methylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 2-(4-fluoro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2 Ethyl -yl)phenoxy)-2-methylpropanoate (400 mg, 1,136 mmol) synthesized in step 2. (59% yield) !H-NMR (400 MHz, CHLOROFORM-D) £ 7.57-7.39 (m, 2H ), 7.10 (dd, J = 7.5, 2.1 Hz, 1H), 6.98 (dd, J = 10.5, 8.7 Hz, 1H), 6.90-6.75 (1H), 6.49 (d, J = 8.2 Hz, 1H), 4.73 (s , 2H), 4.24 (q, J = 7.2 Hz, 2H), 1.65-1.43 (6H), 1.26 (t, J = 7.1 153 ccz / nn / zznz / E / Y Hz, 3H) Preparation Example 93: Methyl 3-(3-(2-Amino-6-(trifluoromethyl)pyrimidin-4-yl)phenyl)-2,2-dimethylpropanoate FN|] O H2N Step 1: Methyl 3-(3-(2-Chloro-6-(trifluoromethyl)pyrimidin-4yl)phenyl)-2,2-dimethylpropanoate The title compound was synthesized in the same manner as in Step 2 of Preparation Example 52 by using 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2- methyl dioxaborolan-2-yl)phenyl)propanoate (1 g, 3.14 mmol) obtained in step 2 of Preparation Example 58 and 2,4dichloro-6-(trifluoromethyl)pyrimidine (682 mg, 3.14 mmol). (63% performance) , 7.34 (d, J = 7.8 Hz, 1H), 3.77-3.58 (m, 3H), 2.96 (s, 2H), 1.21 (d, J = 5.9 Hz, 6H) Step 2: Methyl 3-(3-(2-Amino-6-(trifluoromethyl)pyrimidin-4yl)phenyl)-2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Preparation Example 19 (Step 3, Step 4) by using 3-(3-(2-chloro-6-(trifluoromethyl)pyrimidin-4-yl)phenyl)154 ccz / nn / zznz / E / Y Methyl 2,2-dimethylpropanoate (735 mg, 1.97 mmol) obtained in step 1. (2-step yield of 29%) 1H), 7.78 (d, J = 6.9 Hz, 1H), 7.47-7.33 (m, 1H), 7.28 (s, 1H), 7.27 (s, 1H), 5.49 (s, 2H), 3.65 (d, J = 6.4 Hz, 3H), 2.94 (s, 2H), 1.23 (q, J = 7.8 Hz, 6H) Preparation Example 94: 3-(3'-amino-[1,1'-biphenyl]-4-yl tert-butyl 2,2-dimethylpropanoate O1 Step 1: tert-butyl 2,2-dimethyl-3-(4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate The desired product was obtained in a similar manner to Step 1 of Preparation Example 71 by using l-bromo-4(bromomethyl)benzene (2 g, 8 mmol). (77% 2-stage performance) (s, 9H), 1.34 (s, 12H), 1.11 (s, 6H) Step 2: tert-butyl 2,2-dimethyl-3-(3'-nitro-[1,1'-biphenyl]-4yl)-propanoate Tert-butyl 2,2-Dimethyl-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)propanoate (0.15 g, 0.416 mmol) obtained in stage 1, l-bromo-3-nitrobenzene (0.084 g, ccz / nn / zznz / E / Y 155 0.416 mmol), 1,1'-bis(diphenylphosphino)ferrocene dichloromethane complex (II) (0.007 g, 8.33 pmol) and 0.555 ml of 2N sodium carbonate were dissolved in 1.4 ml of ethylene glycol dimethyl ether and stirred at 90°C for 15 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (60 ml), washed with brine (20 ml) and dried over magnesium sulfate, the organic solvent was concentrated under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane =1:9). (88% performance) 7.64-7.55 (m, 1H), 7.55-7.48 (m, 2H), 7.32-7.26 (m, 2H), 2.90 (d, J = 15.1 Hz, 2H), 1.45 (s, 9H), 1.16 (s, 6H) Step 3: tert-butyl 3-(3'-amino-[1,1'-biphenyl]-4-yl)-2,2dimethylpropanoate Tert-butyl 2,2-Dimethyl-3-(3'-nitro-[1,1'-biphenyl]-4-yl)propanoate (0.255 g, 0.717 mmol) obtained in step 2 was dissolved in 2 ml of methanol, Pd / C (3.82 mg, 0.036 mmol) was added, and then a reduction reaction was carried out using a hydrogen balloon. After confirming that the reaction was complete, it was filtered with a Celite filter, and the organic solvent was removed under reduced pressure to obtain ccz / nn / zznz / E / Y 156 the desired product. (73% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.53-7.44 (m, 2H), 7.28-7.17 (m, 3H), 7.05-6.96 (1H), 6.94-6.87 (m, 1H), 6.72-6.62 (m, 1H), 3.73 (s, 2H), 2.96-2.74 (m, 2H), 1.54-1.38 (9H), 1.261.12 (m, 6H) Preparation Example 95: Ethyl 2-(3-(4-Aminopyrimidin-2-yl)phenoxy)2-dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 and Step 4 of Preparation Example 19 by using tert-butyl (2-chloropyrimidin-4yl)carbamate (344 mg, 1.50 mmol) obtained from Step 1 of Preparation Example 90 and ethyl 2-methyl-2-(3-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)propanoate (500 mg, 1.50 mmol ) obtained from Step 2 of Preparation Example 88. (2-step yield of 22%) , 1H), 7.92 (d, J= 1.8 Hz, 1H), 7.33 (t, J= Ί.9 Hz, 1H), 6.96 (dd, J = 8.1, 2.6 Hz, 1H) , 6.34 (d, J = 5.8 Hz, 1H), 4.90 (s, 2H), 4.27 (q, J= 7.1 Hz, 2H), 1.64 (s, 6H), 1.27 (t, J = 7.0 Hz, 3H) Preparation Example 96: Methyl 3-(4-(4-Aminopyrimidin-2-yl)phenyl)2,2-dimethylpropanoate 157 ccz / nn / zznz / E / Y EITHER Step 1: Methyl 2,2-Dimethyl-3-(4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)propanoate The desired product was obtained in a similar manner to Preparation Example 58 (Step 1, Step 2) by using 1-bromo-4-(bromomethyl)benzene (30.0 g, 120 mmol). (75% 2-stage performance) ), 2.86 (s, 2H), 1.34 (s, 12H), 1.17 (s, 6H) Step 2: Methyl 3-(4-(4-Aminopyrimidin-2-yl)phenyl)-2,2dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52 and Step 4 of Preparation Example 19 by using tert-butyl (2-chloropyrimidin-4yl)carbamate (578 mg, 2.51 mmol) obtained from Step 1 of Preparation Example 90 and methyl 2,2-dimethyl-3-(4(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)propanoate (800 mg , 2.51 mmol) synthesized in Stage 1. (2-stage yield of 68%) Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 6.37 (d, J= 5.9 Hz, 1H), 5.12 (s, 2H), 3.66 (s, 3H), 2.91 (s, 2H), 158 ccz / nn / zznz / E / Y 1.20 (s, 6H) Preparation Example 97: Ethyl 2-(4-(6-Aminopyridin-2-yl)phenoxy)-2methylpropanoate The desired product was obtained in a similar manner to Preparation Example 88 by using 4-bromophenol (2.00 g, 11.6 mmol). (24% 4-stage performance) 1H), 6.89 (dt, J = 9.5, 2.5 Hz, 2H), 6.49-6.33 (m, 1H), 4.44 (s, 2H), 4.24 (q, J = 7.0 Hz, 2H), 1.62 (s, 6H) ), 1.25 (t, J = 7.3 Hz, 3H) Preparation Example 98: Ethyl 2-((4-(6-Aminopyridin-2-yl)phenyl)amino)-2-methylpropanoate Step 1: Ethyl 2-((4-Bromophenyl)amino)-2-methylpropanoate 4-Bromoaniline (3.00 g, 17.44 mmol) was dissolved in DMF, ethyl 2-bromo-2-methylpropanoate (3.40 g, 17.44 mmol) and potassium carbonate (3.62 g, 26.2 mmol) were added and stirred at 100°C for 6 hours. After completion of the reaction, it was cooled to room temperature, and ccz / nn / zznz / E / Y was added. 159 water, extracted with ethyl acetate, washed with brine, and excess DMF was removed. After removing the water with magnesium sulfate and distilling under reduced pressure, the mixture was purified by column chromatography (hexane:ethyl acetate) to obtain the desired compound. (22% yield) , 1.59 (d, J = 22.3 Hz, 7H), 1.22 (t, J = 7.2 Hz, 3H) Step 2: Ethyl 2-Methi 1-2-((4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)phenyl)amino)propanoate The title compound was synthesized in a manner similar to Step 1 of Preparation Example 52 by using ethyl 2-((4-bromophenyl)amino)-2-methylpropanoate (1.82 g, 6.36 mmol) synthesized in Step 1. (65% yield) 12H), 1.19-1.07 (3H) Step 3: Ethyl 2-((4-(6-Aminopyridin-2-yl)phenyl)amino)-2methylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 2-methyl-2-((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- Ethyl 2-yl)phenyl)amino)propanoate (500 mg, 1.50 mmol) synthesized in step 2 and 6-chloropyridin-2-amine (183 mg, 1.422 mmol). 160 (34% Yield) ), 6.65 (d, J = 8.5 Hz, 2H), 6.45 (d, J = 8.2 Hz, 1H), 4.63-4.33 (1H), 4.20 (q, J = 7.0 Hz, 2H), 1.61 (s, 6H ), 1.22 (t, J = 7.2 Hz, 3H) Preparation Example 99: Ethyl 2-((4-(2-Aminopyrimidin-4-yl)phenyl)amino)-2-methylpropanoate ccz / nn / zznz / E / Y Step 1: Ethyl 2-((4-(2-Chloropyrimidin-4-yl)phenyl)amino)-2methylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 2-methyl-2-((4-(4,4,5,5-tetramethi1-1,3,2-dioxaborolan- Ethyl 2-yl)phenyl)amino)propanoate (400 mg, 1.20 mmol) obtained in step 2 of Preparation Example 98 and 2,4dichloropyrimidine (179 mg, 1.20 mmol). (59% yield) 2H), 1.58-1.48 (6H), 1.22-1.07 (3H) Step 2: Ethyl 2-((4-(2-Aminopyrimidin-4-yl)phenyl)amino)-2methylpropanoate The title compound was synthesized in a manner similar to Preparation Example 19 (Step 3, Step 4) at ccz / nn / zznz / E / Y 161 use ethyl 2-((4-(2-chloropyrimidin-4-yl)phenyl)amino)-2-methylpropanoate (83 mg, 0.21 mmol) synthesized in Step 1. (2-step yield of 27%) m / z (M+H)+calculated for C16H21N4O2: 301, found 301 Preparation Example 100: Ethyl (4-(6-Aminopyridin-2-yl)phenyl)glycinate Stage 1: Ethyl (4-Bromophenyl)glycinate The title compound was synthesized in a manner similar to Step 1 of Preparation Example 98 using 4-bromoaniline (3.00 g, 17.44 mmol). (44% yield) (s, 2H) , 1,391.23 (m, 3H) Step 2: Ethyl (4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)phenyl)glycinate The title compound was synthesized in a similar manner to Step 1 of Preparation Example 52 by using ethyl (4-bromophenyl)glycinate (1.99 g, 7.71 mmol) synthesized in Step 1. (44% yield) NMR (400 MHz, CHLOROFORM-D) δ 7.73-7.58 (m, 2H), 6.63 (d, J = 8.2 Hz, 2H), 4.24 (t, J = 7.1 Hz, 2H), 4.22-4.04 162 ccz / nn / zznz / E / Y (m, 1H) , 3.93 (d, J = 1.4 Hz, 2H) , 1.31 (s, 12H) , 1.28 (t, J = 7.1 Hz, 3H) Step 3: Ethyl (4-(6-Aminopyridin-2-yl)phenyl)glycinate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using (4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)glycinate ethyl (700 mg, 2.30 mmol) synthesized in step 2 and 6chloropyridin-2-amine (295 mg, 2.30 mmol). (32% performance) J = 6.9 Hz, 1H), 6.63 (dt, J = 9.3, 2.3 Hz, 2H), 6.47-6.32 (1H), 4.18 (q, J = 7.2 Hz, 2H), 3.93 (s, 2H), 1.24 ( t, J = 7.1 Hz, 3H) Preparation Example 101: Methyl 5-(2-Aminopyrimidin-4-yl)bicyclo[2.2.1]heptan-2-carboxylate EITHER Stage 1: Methyl bicyclo[2.2.1]hept-5-ene-2-carboxylate The desired product was obtained in a similar manner to Step 1 of Preparation Example 50 by using bicyclo[2.2.1]hept-5-ene-2-carboxylic acid (1 g, 7.24 mmol). (100% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 6.18 (q, J = 3.0 Hz, 163 ccz / nn / zznz / E / Y 1Η), 5.91 (q, J = 2.9 Hz, 1H), 3.61 (s, 3H), 3.18 (d, J = 1.4 Hz, 1H), 2.98-2.76 (m, 2H), 1.97-1.81 (m, 1H) ), 1.57 (t, J = 1.6 Hz, 1H), 1.45-1.37 (2H) Step 2: Methyl 5-(2-Chloropyrimidin-4-yl)bicyclo[2.2.1]heptane-2-carboxylate 2,4-Dichloropyrimidine (0.775 g, 5.20 mmol) was dissolved in THF (23.6 ml) and methyl bicyclo[2.2.1]hept-5ene-2-carboxylate (0.720 g, 4.73 mmol) prepared in step 1 was added. Palladium (II) acetate (0.212 g, 0.946 mmol), triphenylphosphine (0.496 g, 1.892 mmol) and formic acid (0.907 ml, 23.65 mmol) were added to the reaction solution, and TEA (4.29 ml, 30.8 mmol) drop by drop to it. After stirring at 60°C for 16 hours, the reaction was terminated with water, diluted with ethyl acetate, washed with brine, and the organic solvent was dried over magnesium sulfate. The desired product was obtained by purification with a silica gel column. (24% performance) , 3.01-2.80 (m, 2H) , 2.80-2.66 (m, 1H) , 2.52-2.39 (m, 1H) , 2.10-1.85 (m, 1H) , 1.85-1.67 (m, 4H), 1.41-1.31 ( m, 1H) Step 3: Methyl 5-(2-Aminopyrimidin-4-yl)bicyclo[2.2.1]heptane-2-carboxylate The desired product was obtained in a similar manner to Preparation Example 2 by using methyl 5-(2-chloropyrimidin-4164 ccz / nn / zznz / E / Y il)bicyclo[2.2.1]heptane-2-carboxylate (0.428 g, 1.605 mmol) prepared in step 2. (2-step yield of 13%) , 6.81 (td, J = 14.5, 5.2 Hz, 1H) , 4.51 (s, 1H) , 3.73 (d, J = 11.3 Hz, 3H) , 2.93-2.80 (m, 2H) , 2.80-2.61 (m, 1H) ), 2.53-2.35 (m, 1H), 2.11-1.97 (m, 1H), 1.85-1.77 (m, 2H), 1.77-1.67 (m, 2H), 1.40-1.20 (m, 1H) Preparation Example 102: Methyl 3-(3-(5-Aminopyridin-2-yl)phenyl)2,2-dimethylpropanoate The desired product was obtained in a similar manner to Step 2 of Preparation Example 52, Step 3 of Preparation Example 19 and Step 2 of Preparation Example 76 by using 2,5-dibromopyridine (189 mg, 0.799 mmol) and 2 tert-butyl 2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)propanoate (288 mg, 0.799 mmol) obtained in step 2 from Preparation Example 79. (3-stage yield of 20%). 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.17 (d, J = 2.7 Hz, 1H), 7.74 (dt, J = 7.8, 1.4 Hz, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.14-6.97 (m, 2H), 3.72 (s, 2H), 3.66 (s, 3H), 2.99-2.85 (2H), 1.21 165 ccz / nn / zznz / E / Y (s, 6H) Preparation Example 103: Methyl 2-(4-((2-Aminopyrimidin-4-yl)oxy)phenyl)acetate The desired product was obtained in a similar manner to Step 1 of Preparation Example 104 and Preparation Example 19 (Step 3, Step 4) by using methyl 2-(4hydroxyphenyl)acetate (1 g, 6.02 mmol). (3-stage performance of 57%)1H-NMR (400 MHz, CHLOROFORM-D) £ 8.11 (d, J = 5.5 Hz, 1H), 7.30 (dd, J = 8.9, 2.5 Hz, 2H), 7.08 (dt , J= 9.1, 2.4 Hz, 2H), 6.18-6.02 (1H), 5.01 (s, 2H), 3.77-3.67 (3H), 3.62 (d, J = 16.0 Hz, 2H) Preparation Example 104: Methyl 4-((6-Aminopyridin-2-yl)oxy)benzoate EITHER Step 1: Methyl 4-((6-Chloropyridin-2-yl)oxy)benzoate , 7.89 mmol) were dissolved in 27.4 ml of DMF and stirred at 120°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under ccz / nn / zznz / E / Y 166 reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (75% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.14-7.94 (m, 2H), 7.74-7.52 (m, 1H), 7.20-7.10 (m, 2H), 7.10-6.96 (m, 1H), 6.896.76 (m, 1H), 3.95-3.80 (m, 3H) Step 2: methyl 4-((6-Aminopyridin-2-yl)oxy)benzoate The desired product was obtained in a similar manner to Preparation Example 19 (step 3, step 4) by using methyl 4((6-chloropyridin-2-yl)oxy)benzoate (1.3 g, 4.93 mmol) synthesized in step 1. (2-stage performance of 76%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.15-7.89 (m, 2H), 7.52-7.37 (m, 1H), 7.12 (dt, J = 9.3, 2.3 Hz, 2H), 6.33-6.10 (2H), 4.58-4.26 (m, 2H), 3.97-3.72 (m, 3H) Preparation Example 105: Methyl 2-(4-((6-Aminopyridin-2-yl)oxy)phenyl)acetate Step 1: Methyl 2-(4-((6-Chloropyridin-2-yl)oxy)phenyl)acetate ccz / nn / zznz / E / Y 167 2, 6-Dichloropyridine (2.67 g, 18.1 mmol), methyl 2-(4-hydroxyphenyl)acetate (3.00 g, 18.1 mmol) and cesium carbonate (7.06 g, 21.7 mmol) were dissolved in 75.0 ml of DMF and stirred at 120°C overnight. It was extracted with DCM and the organic solvent was dried over magnesium sulfate, and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane). (50% performance)1H-NMR (400 MHz, CHLOROFORM-D) £7.61 (t, J = 7.8 Hz, 1H), 7.39-7.28 (2H), 7.10 (td, J = 5.7, 3.2 Hz, 2H) , 7.03 (d, J = 7.8 Hz, 1H) , 6.75 (d, J = 8.2 Hz, 1H) , 3.72 (s, 3H) , 3.64 (s, 2H) Step 2: Methyl 2-(4-((6-Aminopyridin-2-yl)oxy)phenyl)acetate The desired product was obtained in a similar manner to Preparation Example 19 (Step 3, Step 4) by using methyl 2(4-((6-chloropyridin-2-yl)oxy)phenyl)acetate (1.25 g, 4.50 mmol ) synthesized in Stage 1. (2-stage performance of 5%) ), 7.09 (dd, J = 6.6, 2.1 Hz, 2H), 6.28-6.22 (1H), 6.02 (d, J = 8.2 Hz, 1H), 3.72 (s, 3H), 3.663.60 (2H) Preparation Example 106: Methyl 2-(4-((6-Aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate 168 ccz / nn / zznz / E / Y Η2Ν Ν Ο The desired product was obtained in a similar manner to Preparation Example 19 (Step 2, Step 3, Step 4) by using methyl 2-(4-((6-chloropyridin-2-yl)oxy)phenyl)acetate (1.25 g, 4.50 mmol) obtained from Step 1 of Preparation 105. (3-step yield of 41%)XH-NMR (CHLOROFORM-D) δ 7.40 (t, J = 7.6 Hz, 1H), 7.37- 7.29 (m, 2H), 7.09-7.00 (m, 2H), 6.23-6.14 (m, 1H), 6.06 (dd, J = 7.9, 5.2 Hz, 1H), 3.67 (s, 3H), 1.59 ( s, 6H) Preparation Example 107: Methyl 3-((6-Aminopyridin-2-yl)oxy)benzoate EITHER Step 1: Methyl 3-((6-Chloropyridin-2-yl)oxy)benzoate The desired product was obtained in a similar manner to Step 1 of Preparation Example 104 by using methyl 3hydroxybenzoate (0.2 g, 1.315 mmol). (75% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.99-7.82 (m, 1H), 7.82- 7.72 (m, 1H), 7.72-7.54 (m, 1H), 7.54-7.39 (m, 1H), 7.397.28 (1H), 7.08-6.95 (1H), 6.87-6.65 (1H), 3.96- 3.81 (3H) Step 2: Methyl 3-((6-Aminopyridin-2-yl)oxy)benzoate 169 The desired product was obtained in a similar manner to Preparation Example 19 (step 3, step 4) by using methyl 3((6-chloropyridin-2-yl)oxy)benzoate (0.26 g, 0.986 mmol) synthesized in step 1. (54% 2-stage performance) (td, J = 7.9, 3.4 Hz, 2H), 7.30 (dq, J = 8.0, 1.2 Hz, 1H), 6.21 (d, J = 8.2 Hz, 1H), 6.10 (d, J= 7.8 Hz, 1H) , 3.89 (d, J = 3.2 Hz, 3H) Preparation Example 108: Methyl 2-(3-((6-Aminopyridin-2-yl)oxy)phenyl)acetate XX XX 2 H?N Step 1: Methyl 2-(3-Hydroxyphenyl)acetate The desired product was obtained in a manner similar to Step 2 of Preparation Example 76 by using 2(3-hydroxyphenyl)acetic acid (3.00 g, 19.7 mmol). (99% performance) , 5.10-4.91 (m, 1H), 3.70 (s, 3H), 3.58 (s, 2H) Step 2: Methyl 2-(3-((6-Aminopyridin-2-yl)oxy)phenyl)acetate The desired product was obtained in a similar manner ccz / nn / zznz / E / Y to Preparation Example 105 by using 2,6-dichloropyridine 170 ccz / nn / zznz / E / Y (2.90 g, 19.6 mmol) and methyl 2-(3-hydroxyphenyl)acetate (3.26 g, 19.6 mmol) synthesized in step 1. (3-step yield of 12%) 1R-NMR (400 MHz, CHLOROFORM-D) ¿7.44 (t, J = 8.0 Hz, 1H), 7.33 (t, J= 7.8 Hz, 1H), 7.11 (d, J = 7.8 Hz, 1H), 7.096. 96 (m, 2H), 6.23 (d, J = 8.2 Hz, 1H), 6.05 (d, J = 7.8 Hz, 1H), 3.70 (s, 3H), 3.65-3.62 (2H) Preparation Example 109: Methyl 2-(3-((6-Aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate The desired product was obtained in a similar manner to Preparation Example 106 by using methyl 2-(3hydroxyphenyl)acetate (1.45 g, 5.22 mmol) obtained from Step 1 of Preparation Example 108. (3-step yield of 35% )XH-NMR (400 MHz, CHLOROFORM-D) δ 7.49-7.35 (m, 1H), 7.35-7.27 (m, 1H), 7.17-7.07 (m, 2H), 7.04-6.90 (m, 1H), 6.256.15 (m, 1H), 6.06 (d, J = 7.8 Hz, 1H), 4.44 ( s, 2H), 3.65 (s, 3H), 1.44-1.40 (6H) Preparation Example 110: Methyl 4-(((6-Aminopyridin-2-yl)oxy)methyl)benzoate either 171 ccz / nn / zznz / E / Y Step 1: Methyl 4-(((6-Chloropyridin-2-yl)oxy)methyl)benzoate Methyl 4-(Hydroxymethyl)benzoate (0.5 g, 3.01 mmol) and 2,6-dichloropyridine (0.445 g, 3.01 mmol), cesium carbonate (1.176 g, 3.61 mmol), 4,5-bis(diphenyliosfino)-9 ,9-Dimethixanthin (0.244 g, 0.421 mmol) and palladium(II) acetate (0.054 g, 0.241 mmol) were dissolved in 12 ml of toluene and stirred at 120°C for 4 hours. After confirming that the reaction was complete by TLC, the organic solvent was removed under reduced pressure. After extraction with ethyl acetate (2 x 20 ml), it was washed with brine (20 ml), and the organic solvent was dried over magnesium sulfate and removed under reduced pressure. The desired product was obtained by purification with a silica gel column (ethyl acetate:hexane = 1:9). (24% performance) 6.66 (m, 1H), 5.52-5.34 (m, 2H), 3.89 (d, J = 16.0 Hz, 3H) Step 2: Methyl 4-(((6-Aminopyridin-2-yl)oxy)methyl)benzoate The method was obtained in a similar manner to Preparation Example 19 (step 3, step 4) by using methyl 4-(((6chloropyridin-2-yl)oxy)methyl)benzoate (0.2 g, 0.72 mmol) synthesized in the stage 1. (performance of 2 stages of 19%) 5.99 (m, 1H), 5.46-5.28 (m Preparation Example 111: ccz / nn / zznz / E / Y methyl 2-methylpropanoate 172 iH-NMR (400 MHz, CHLOROFORM-D) δ 8.12-7.91 (m, 2H), 7.60-7.42 (m, 2H), 7.42-7.30 (m, 1H), 6.26-6.11 (m, 1H), 6.112H), 3.96-3.81 (m, 3H) 2-(3-(4-Aminopyrimidin-2-yl)phenyl) h2n N Mi ° The desired product was obtained in a similar manner to Preparation Example 53 (Step 1, Step 2) and Preparation Example 19 (Step 3, Step 4) by using methyl 2-(3-bromophenyl)2-methylpropanoate (0.25 g, 0.972 mmol). (4-stage performance of 36%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.40-8.27 (m, 2H), 8.27- 8.16 (m, 1H), 7.45-7.35 (m, 2H), 6.32 (d, J = 5.9 Hz, 1H), 5.14 (s, 2H), 3.70-3.49 (m, 3H), 1.72-1.56 ( m, 6H) Preparation Example 112: methyl 2-(4-(4-Aminopyrimidin-2-yl)phenyl) 2-methylpropanoate c< The desired product was obtained in a similar manner to Preparation Example 53 (Step 1, Step 2) and Preparation Example 19 (Step 3, Step 4) by using methyl 2-(4-bromophenyl)2-methylpropanoate (5 g, 19.45 mmol). (Performance 173 ccz / nn / zznz / E / Y steps of 36%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.37-8.28 (m, 1H), 8.26 (d, J = 8.2 Hz, 2H), 7.46-7.34 (m, 2H), 6.35-6.23 (m, 1H), 4.99 (s, 2H), 3.77-3.46 (m, 3H), 1.67-1.52 ( m, 6H) Preparation Example 113: tert-butyl 3-(3-(6-aminopyridin-2-yl)phenyl)2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 2,2-dimethyl-3-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan tert-butyl -2yl)phenyl)propanoate (500 mg, 1.39 mmol) obtained in step 2 of Preparation Example 79 and 6-chloropyridin-2amine (178 mg, 1.39 mmol). (66% performance) -7.30 (m, 1H), 7.02 (d, J = 7.8 Hz, 1H), 6.64 (d, J = 7.3 Hz, 2H), 6.36 (d, J = 8.2 Hz, 1H), 4.52 (s, 2H) , 2.91 (s, 2H), 1.40 (d, J = 6.9 Hz, 9H), 1.14 (t, J = 4.6 Hz, 6H) Preparation Example 114: tert-butyl 3-(3-(6-amino-3-fluoropyridin-2yl)-4-fluorophenyl)-2,2-dimethylpropanoate ccz / nn / zznz / E / Y 174 Step 1: tert-butyl 3-(3-(6-chloro-3-fluoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 3-(4-fluoro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2 tert-butyl -yl)phenyl)-2,2-dimethylpropanoate (1.52 g, 4.01 mmol) obtained in Step 2 of Preparation Example 8 9 and 2,6dichloro-3-fluoropyridine (799 mg, 4.81 mmol). (21% yield) m / z (M+H)+ calculated for C20H23CIF2NO2: 382, ​​found 382 Step 2: tert-butyl 3-(3-(6-amino-3-fluoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoate The title compound was synthesized in a similar manner to Preparation Example 19 (Step 3, Step 4) by using 3-(3-(6-chloro-3-fluoropyridin-2-yl)-4-fluorophenyl)-2, Tert-butyl 2-dimethylpropanoate (327 mg, 0.86 mmol) obtained in step 1. (2-step yield of 17%) Hz, 1H), 7.34-7.15 (m, 1H), 7.15-7.04 (m, 2H), 7.04-6.90 (1H), 4.89-4.60 (2H), 2.84 (s, 2H), 1.40 (d, J = 6.9 Hz, 9H), 1.17-1.03 (m, 6H) Preparation Example 115: tert-butyl 3-(3-(6-amino-5-fluoropyridin-2yl)-4-fluorophenyl)-2,2-dimethylpropanoate 175 ccz / nn / zznz / E / Y F Step 1: tert-butyl 3-(3-(6-chloro-5-fluoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoate The title compound was synthesized in a manner similar to Step 2 of Preparation Example 52 by using 3-(4-fluoro-3-(4,4,5,5-tetramethi1-1,3,2-dioxaborolan-2 tert-butyl -yl)phenyl)-2,2-dimethylpropanoate (1.52 g, 4.01 mmol) obtained in Preparation Example Step 89 and 2,6dichloro-3-fluoropyridine (799 mg, 4.81 mmol). (49% performance) !H-NMR (400 MHz, CHLOROFORM-D) £7.46 (t, J = 8.5 Hz, 1H), 7.38 (dd, J= 7.1, 2.5 Hz, 1H), 7.32 (dd, J = 8.7, 3.2Hz, 1H), 7.22 (td, J= 5.5, 2.7 Hz, 1H), 7.04 (dd, J = 9.8, 8.5 Hz, 1H), 2.85 (s, 2H), 1.54 (s, 2H), 1.40 (d, J = 7.8 Hz, 9H), 1.14 (s, 6H) Step 2: tert-butyl 3-(3-(6-amino-5-f luoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoate The title compound was synthesized in a similar manner to Preparation Example 19 (Step 3, Step 4) by using 3-(3-(6-chloro-3-fluoropyridin-2-yl)-4-fluorophenyl)2,2 -tert-butyl dimethylpropanoate (756 mg, 1.98 mmol) obtained in stage 1. (2-stage yield of 38%)XH-NMR (400 MHz, CHLOROFORM-D) £ 7.57-7.41 (m, 2H), 176 ccz / nn / zznz / E / Y 7.39 (dd, J = 6.9, 1.8 Hz, 1H), 7.22-7.11 (m, 1H), 7.06 (t, J= 9.1 Hz, 1H), 6.70 (dd, J = 8.9, 3.0 Hz, 1H), 4.38 (d, J = 22.9 Hz, 1H), 2.86 (s, 2H), 1.42-1.34 (9H), 1.16-1.06 (6H) Preparation Example 116: Methyl 3-(4-(6-Aminopyridin-2-yl)-lHpyrazol-l-yl)-2,2-dimethylpropanoate By using methyl 3-hydroxy-2,2-dimethylpropanoate (1.08 g, 8.16 mmol) and 4-bromo-1H-pyrazole (1.00 g, 6.80 mmol), the method similar to Step 1 of Preparation Example 1, Step 2 of Preparation Example 58, and Preparation Example 19 (Step 3 and Step 4) was used sequentially to obtain the desired product. (0.3% 4-stage performance) ), 6.30 (d, J= 7.8 Hz, 1H), 4.52 (s, 2H), 4.27 (s, 2H), 3.70 (s, 3H), 1.21 (s, 6H) Preparation Example 117: 4-(( Ethyl 2-Aminopyrimidin-4-yl)oxy)cyclohexan-1-carboxylate or h2n^n Step 1: Ethyl 4-((2-Chloropyrimidin-4-yl)oxy)cyclohexan-1carboxylate 2,4-Dichloropyrimidine (0.300 g, 2.014 mmol) is 177 ccz / nn / zznz / E / Y was dissolved in DMF (10 ml), and then ethyl 4hydroxycyclohexan-l-carboxylate (0.357 ml, 2.215 mmol) and cesium carbonate (1.640 g, 5.03 mmol) were added. After stirring at 80°C for 3 hours, it was diluted with diethyl ether and washed with water. After drying the organic solvent with magnesium sulfate, it was purified by silica gel column to obtain the desired product. (29% yield)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.29-8.17(m, 1H), 6.64-6.46 (m, 1H), 5.46-4.97 (m, 1H), 4.18-4.00(m, 2H), 2.46-2.21 (m, 1H), 2.14 (dt, J = 9.0, 3.5Hz, 1H), 2.08-1.89 (m, 2H), 1.89-1.79 (m, 1H), 1.791.70 (1H), 1.70-1.51 (m, 2H), 1.51-1.32 (m, 1H), 1.29-1.12 ( m, 3H) Step 2: Ethyl 4-((2-Aminopyrimidin-4-yl)oxy)cyclohexan-1carboxylate The desired product was obtained in a similar manner to Preparation Example 2 by using ethyl 4-((2-chloropyrimidin-4yl)oxy)cyclohexane-1-carboxylate (0.165 g, 0.579 mmol) prepared in step 1. (yield 2-stage 98%) m / z (M+H)+calculated for C13H20N3O3: 266.32, found 266.1 Preparation Example 118: (.R)-2-chloro-6-(3-(2-ethoxy-4fluorophenoxy)piperidin-l-yl)pyrazine 178 ccz / nn / zznz / E / Y Stage 1: 1-(Benzyloxy)-2-ethoxy-4-fluorobenzene 2-(Benzyloxy)-5-fluoroenenol (1.00 g, 4.58 mmol), iodoethane (0.44 mL, 5.5 mmol) and cesium carbonate (2.24 g, 6.87 mmol) were added to 6.74 mL of acetone and stirred for 24 hours at room temperature. The reaction mixture was filtered and water was added, followed by extraction with ethyl acetate. After washing with water and brine, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The desired product was obtained by purification with a silica gel column. (82% performance) dd, J = 9.1, 5.5 Hz, 1H), 6.64 (dd, J = 10.1, 2.7 Hz, 1H), 6.51 (td, J = 8.3, 3.0 Hz, 1H), 5.09 (s, 2H), 4.08 (q , J = 7.0 Hz, 2H) , 1.47 (t, J = 7.1 Hz, 3H) Stage 2: 2-Ethoxy-4-fluorophenol 1-(Benzyloxy)-2-ethoxy-4-fluorobenzene (921 mg, 3.74 mmol) obtained in step 1 was dissolved in methanol, and Pd / C (19.9 mg, 0.187 mmol) was added, followed by stirring under conditions of hydrogen. After completion of the reaction, it was filtered through Celite to obtain the desired product. (92% performance) 179 ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D) δ 6.83 (dd, J = 8.7, 5.5 Hz, 1H), 6.68-6.48 (m, 2H), 5.45-5.31 (1H ), 4.09 (q, J = 7.0 Hz, 2H), 1.50-1.37 (3H) Step 3: (R)-2-chloro-6-(3-(2-ethoxy-4-fluorophenoxy)piperidin-l-yl)pyrazine The desired product was obtained in a similar manner to Preparation Example 1 (step 1, step 2, step 3) by using 2-ethoxy-4-fluorophenol (539 mg, 3.45 mmol) obtained in step 2. (yield of 3 37% stages) 6.70-6.47 (m, 2H), 4.28-4.14 (1H), 4.07-3.89 (3H), 3.72 (q, J = 6.4 Hz, 1H), 3.67-3.46 (m, 2H), 2.15-1.85 (m, 3H), 1.59 (qd, J = 8.5, 4.3 Hz, 1H), 1.41 (t, J = 7.1 Hz, 3H) Preparation Example 119: Methyl 2-(4-(4-Aminopyrimidin-2-yl)phenoxy)-2-methylpropanoate EITHER The desired product was obtained in a similar manner to Step 1 of Preparation Example 68, Preparation Example 53 (Step 1, Step 2), and Preparation Example 19 (Step 4) by using 4-bromophenol (1 g, 5.78 mmol). (4-stage performance of 6%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.31-8.00 (m, 3H), 180 ccz / nn / zznz / E / Y 6.96-6.60 (m, 2H), 6.33-6.07 (m, 1H), 5.26 (d, J = 44.4 Hz, 2H), 4.22-4.09 (m, 2H), 1.63-1.50 (m, 6H), 1.29-1.07 (m, 3H) Example 1: (R)-2-((6- (3-(2-ethoxyphenoxy) acid )piperidin-l-yl)pyrazin-2-yl)amino)thiazole-5-carboxylic acid (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (20 mg, 0.06 mmol) prepared in Preparation Example 1 and methyl 2-aminothiazol-5-carboxylate ( 0.011 g, 0.072 mmol) were dissolved in 1,4-dioxane, cesium carbonate (49 mg, 0.150 mmol), tris(dibenzylideneacetone)dipalladium(0) (4.39 mg, 0.005 mmol) and 4,5-bis(diphenylphosphine). -9,9dimethylxanthine (3.47 mg, 0.006 mmol) was added, and then stirred at reflux for 4 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with aqueous sodium hydrogen carbonate solution and brine, and then dried over magnesium sulfate, and the Organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (hexane: ethyl acetate = 2:1). (81% performance) The obtained ester compound (22 mg, 0.05 mmol) was dissolved in THE:water:methanol = 1:1:1, and hydroxide was added 181 ccz / nn / zznz / E / Y lithium (2 mg, 0.074 mmol), followed by stirring at 60°C for 12 hours. After cooling the reaction to room temperature, the pH was adjusted to 4.5, followed by extraction with an organic solvent. The organic layer was dried over magnesium sulfate, removed under reduced pressure, and then synthesized by purification with silica gel column chromatography. NMR (bs, 1H), 3.75-3.91 (m, 8H), 1.82-1.97 (m, 4H), 1.55 (m, 1H), 1.18 (m, 5H) Example 2: (K)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4,5-dimethylthiazol-2-amine similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Preparation Example 1 and 2-amino-4, 5dimethylthiazole (0.038 g, 0.30 mmol). (63% performance) -4.36 (m,2H) , 3.98-4.05 (m, 3H) , 3.49 (m, 1H) , 3.38 (m, 1H) , 2.21 (s,3H) , 2.19 (s, 3H) , 2.20 (m, 1H) , 1.78 (m, 1H) , 1.61-1.69 (m,2H), ccz / nn / zznz / E / Y 1.39 (t, 3H) Example 3: (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)thiazol-2-amine N N N N |l I I Ί h The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Example Preparation 1 and 2-aminothiazole (0.03 g, 0.30 mmol). (25% performance)XH-NMR (400 MHz, CHLOROFORM-D): δ 10.97 (s 1 HOUR) 7.64 (s, 1H) , 7.59 (s, 1H) , 7.45 (s, 1H) , 7.02 (m, 2H) , 6.86(m, 2H), 6.71 (s, 1H), 4.46 (m, 1H), 4.34 (m, 1H), 4.03 (m,3H), 3.34-3.45 (m, 2H) , 2.24 (m, 1H) , 2.02 (m, 1H) , 1.91 (m,1H) , 1.71 (m, 1H), 1.39 (t, 3H) Example 4: (R)-N- (6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4-phenylthiazol-2-amine σθ. X X Xk / y. / / N N N NV—Y I I H The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Example Preparation 1 and 2-amino-4183 benzothiazole (0.053 g, 0.30 mmol). (28% performance)XH-NMR (400 MHz, CHLOROFORM-D): δ 8.72 (brs,1H), 7.85 (d, 2H), 7.63 (s, 1H), 7.40 (t, 2H), 7.35 (s,1H), 7.29 (t, 1H), 7.02 (m, 2H), 6.87 (m, 3H), 4.44 (m,1H), 4.33 (m, 1H), 3.95-4.06 (m, 3H), 3.35-3.47 (m,2H), 2.23 (m, 1H), 2.02 (m, 1H), 1.89 (m, 1H), 1.70 (m, 1H), 1.39 (t, 3H) Example 5: (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)benzo[d]thiazol-2-amine ccz / nn / zznz / E / Y I I H The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Example Preparation 1 and 2-aminobenzothiazole (0.045 g, 0.30 mmol). (37% performance)XH-NMR (400 MHz CHLOROFORM-D): £9.20 (brs 1H), 7.73 (s, 1H), 7.64-7.71 (m, 2H), 7.42 (s, 1H), 7.38 (m,1H), 7.22 (m, 1H), 7.04 (d, 1H), 6.83-6.93 (m, 3H), 4.31-4.40 (m, 2H), 4.03 (m, 3H), 3.63 (m, 1H), 3.59 (m, 1 HOUR) , 2.21 (m, 1H), 2.09 (m, 1H), 1.97 (m, 1H), 1.74 (m, 1H), 1.39 (t, 3H) Example 6: (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-6-methoxybenzo[d]thiazol-2-amine 184 o— ccz / nn / zznz / E / Y similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Preparation Example 1 and 2-amino-(6methoxy )benzothiazole (0.054 g, 0.30 mmol). (28% performance) , 1H) , 6.82-7.06 (m, 4H) , 4.40 (m, 2H) , 3.99-4.06 (m, 3H) , 3.86 (s, 3H) , 3.60 (m, 1H) , 3.48 (m, 1H) , 2.20 (m, 1H), 2.07 (m, 1H), 1.96 (m, 1H), 1.73 (m, 1H), 1.39 (t, 3H) Example 7: (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)-6-(methanesulfonyl)benzo[d]thiazol-2-amine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.3 mmol) prepared in Example Preparation 1 and 2-amino-(6methylsulfoni1)benzothiazole (0.068 g, 0.30 mmol). (Performance 19%) 185 ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D): δ 9.70 (brs, 1H), 8.24 (s, 1H), 7.89 (m, 1H), 7.80 (s, 1H) , 7.76 (m,1H) , 7.53 (s, 1H), 7.03 (d, 1H), 6.96 (m, 2H), 6.83 (m,1H), 4.45 (m, 1H), 4.29 (m, 1H), 4.03 (m, 3H), 3.89 (m,1H), 3.72 (m, 1H), 3.59 (m, 1H), 3.11 (s, 3H), 2.19 (m,1H), 2.11 (m, 1H) , 2.01 (m, 1H) , 1.76 (m, 1H) , 1.39(t, 3H) Example 8: (R)-W-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-3-(1-(2-methoxyethoxy)-2-methylpropan-2-yl) isooxazole-5-amine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) prepared in Example Preparation 1 and 3-(1-(2methoxyethoxy)-2-methylpropan-2-yl)isooxazole-5-amine (0.1 g, 0.49 mmol). (57% yield)XH-NMR (500 MHz, CHLOROFORM-D): δ 7.73 (s, 1H), 7.69 (s, 1H), 7.59 (s, 1H), 7.03-6.90 (m, 2H), 6.89-6.75 (m, 2H), 5.99 (s, 1H), 4.36-4.25 (m, 1H), 4.08 ( dd, J = 12.8, 3.1 Hz, 1H), 4.03-3.88 (m, 2H), 3.88-3.76 (m, 1H), 3.593.52 (m, 3H), 3.52-3.46 (m, 4H), 3.46-3.38 (m, 1H), 3.33 186 ccz / nn / zznz / E / Y (d, J = 6.1 Hz, 3H), 2.17-2.07 (m, 1H), 1.99 (td, J = 6.6, 3.5 Hz, 1H), 1.90 (q, J = 4.3 Hz, 1H), 1.62 (q, J = 4.5 Hz, 1H), 1.36 (t, J = 7.0 Hz, 3H), 1.29 (d, J = 2.6 Hz, 6H) Example 9: (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4-phenyloxazole-2-amine similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.03 g, 0.09 mmol) prepared in Preparation Example 1 and 4-phenyloxazole-2amine ( 0.016 g, 0.099 mmol) prepared in Preparation Example 25. (4% yield) = 7.6 Hz, 1H), 7.66 (s, 1H), 7.41 (t, J =7.6 Hz, 1H), 7.34 (d, J = 7.3 Hz, 1H), 7.28 (m, 2H), 7.01-6.84(m, 3H), 6.84-6.74 (m, 1H), 4.29-4.18 (m, 1H), 4.06 (dd, J= 13.4, 3.4 Hz, 1H), 4.01 (q, J = 7.0 Hz, 2H), 3.75 (td , J = 8.9,4.3 Hz, 1H), 3.35 (dd, J = 13.1, 8.2 Hz, 1H), 3.30-3.16 (m, 1H), 2.20- 2.02 (m, 1H), 1.98-1.75 (m, 2H), 1.57-1.51 (m, 1H), 1.39 (t, J = 6.9 Hz, 3H) Example 10: (R)-N- (6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin2-yl)benzo[d]oxazol-2-amine 187 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 1 using (R)-2-cioro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.1 g, 0.30 mmol) prepared in Example 1. Preparation 1 and 2-aminobenzoxazole (0.05 g, 0.36 mmol). (19% performance)1H-NMR (500 MHz, CHLOROFORM-D) δ 8.77 (s, 1H), 7.87 (s, 1H), 7.55 (d, J = 7.3 Hz, 1H), 7.44-7.34 (m, 1H), 7.17(t, J = 7.6 Hz, 1H), 7.06 (d, J = 16.5 Hz, 1H), 6.97 (t, J = 7.9 Hz, 2H), 6.88 (q, J= 7.1 Hz, 2H), 4.32 (s, 1H) , 4.10-3.90(m, 3H), 3.78 (d, J = 14.1 Hz, 1H), 3.62 (q, J = 6.9 Hz, 1H), 3.43 (d, J = 9.8 Hz, 1H), 2.21-1.87 (m, 4H), 1.61 ( s, 1H), 1.37(t, J = 7.0 Hz, 3H) Example 11: (J?)-5-chloro-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)benzo[d]oxazol-2-amine similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.14 g, 0.42 mmol) prepared in Preparation Example 1 and 2-amino- (5 -chloro)benzothiazole (0.071 g, 0.42 mmol). (51% yield) 188 ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D): δ 8.73 (s, 1H), 7.89 (s, 1H), 7.52 (s, 1H), 7.16 (m, 1H) , 7.13 (m, 2H) , 6.99 (m, 2h), 6.86-6.91 (m, 2H), 4.34 (m, 1H), 3.93-4.03 (m, 3H), 3.75 (m, 1H), 3.67 (m, 1H), 3.49 (m, 1H), 2.11 (m, 1H) , 2.02 (m, 1H), 1.93 (m, 1H), 1.63 (m, 1H), 1.37 (t, 3H) Example 12: (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)acetic acid or (R)-2-Chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.777 g, 2.328 mmol) obtained in Preparation Example 1 and 2-(2-aminobenzo[d]oxazole -5-yl)methyl acetate (0.4 g, 1.940 mmol) obtained in Preparation Example 16, tris(dibenzylideneacetone)dipalladium (0) (0.178 g, 0.194 mmol), 4,5-bis(diphenyliosfino)-9,9-dimethylxanthine (0.135 g, 0.233 mmol) and cesium carbonate (1,580 g, 4.85 mmol) were added to 20 ml of 1,4-dioxane and stirred under reflux for 4 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with aqueous sodium hydrogen carbonate solution and brine, and dried over magnesium sulfate and the organic solvent. was removed under reduced pressure. The desired ester product was obtained by purification with a silica gel column (silica acetate). 189 ccz / nn / zznz / E / Y ethyl:hexane = 4:1). (36% performance)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.81-8.66 (m, 1H), 8.03 (d, J = 50.8 Hz, 1H), 7.95-7.77 (m, 1H), 7.54-7.38 (m, 1H), 7.26 (q, J= 7.8 Hz, 1H), 7.12-7.01 (m, 1H), 6.99-6.87 (m, 2H), 6.87-6.77 (m, 2H), 4.36-4.20 (m, 1H) , 4.06-3.99 (m, 1H), 3.99-3.89 (m, 2H), 3.75 (td, J = 9.6, 3.8 Hz, 1H), 3.69 (d, J = 9.6 Hz, 5H), 3.61-3.46 (m , 1H) , 3.46-3.30 (m, 1H) , 2.18-2.03 (m, 1H) , 2.01-1.74 (m, 2H) , 1.68-1.44 (m, 1H) , 1.44-1.28 (m, 3H) The obtained ester compound (0.330 g, 0.655 mmol) was dissolved in 5 ml of THF, 2 ml of MeOH, and 2 ml of water. After adding sodium hydroxide (0.786 g, 19.66 mmol), the mixture was stirred at room temperature for 15 hours. After confirming the completion of the reaction by TLC, the titration was adjusted to pH 4.5 using 1 N aqueous hydrogen chloride solution, diluted with ethyl acetate, and the water layer was removed. After drying the reaction product over magnesium sulfate, the organic solvent was removed under reduced pressure to obtain the title compound. (3% performance) , 7.11 (q, J= 7.3 Hz, 1H) , 6.96 (d, J = 7.3 Hz, 1H) , 6.86 (d, J = 3.7 Hz, 2H) , 6.84-6.71 (m, 2H) , 4.40 (s, 1H), 3.89-3.83 (m, 2H), 3.82-3.74 (m, 2H), 3.62 (dd, J = 16.9, 12.8 Hz, 1H), 3.55-3.50 (2H), 2.63 190 ccz / nn / zznz / E / Y (s, 1H), 2.00 (dd, J = 13.5, 3.4 Hz, 2H), 1.90 (d, J = 8.2 Hz, 1H), 1.64-1.48 (m, 1H) , 1.25 (t, J = 6.9 Hz, 3H) Example 13: acid (R) -2- (2-( (6- (3- (2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)-2- methylpropanoic acid The ester product was obtained in a similar manner to Example 12 by using (_R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.855 g, 2.56 mmol) obtained in the Preparation Example 1 and methyl 2-(2-aminobenzo[d]oxazol-5-yl)-2methylpropanoate (0.5 g, 2.134 mmol) obtained in Preparation Example 17. (66% yield) MHz, CHLOROFORM-D) δ 8.82 (q, J = 14.8 Hz, 1H), 8.62 (s, 1H), 7.86 (t, J = 15.1 Hz, 1H), 7.56-7.46(m, 1H), 7.34-7.20 (m, 1H), 7.21-7.03 (m, 1H), 7.03-6.83 (m,2H), 6.83-6.69 (m, 2H), 4.33-4.15 (m, 1H), 4.16-3.97 (m, 1H), 3.90 (td, J = 15.4, 8.1 Hz, 2H), 3.82-3.68 (m, 1H), 3.68-3.58(m, 3H), 3.58-3.45 (m, 1H), 3.45-3.29 (m, 1H), 2.16-2.02 (m,1H), 1.98-1.87 (m, 1H), 1.87-1.71 (m, 1H), 1.68-1.56 (m, 6H), 1.561.48 (m, 1H), 1.30 (t, J= 6.9 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the ester compound obtained in a similar manner to Example 12. (Yield of 56%) 191 ccz / nn / zznz / E / Y m / z (M+H)+ calculated for C28H32N5O5: 518, found 518 Example 14: (R) -3-(2-( (6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)-2 acid, 2-dimethylpropanoic acid similar to Example 1 by using (_R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (0.30 g, 0.90 mmol) prepared in Preparation Example 1 and 3-(2-aminobenzo Methyl [d]oxazol-5-yl)-2,2-dimethylpropanoate (0.22 g, 0.90 mmol) synthesized in Preparation Example 21. (2-step yield of 32%) D) δ 8.27 (s, 1H), 7.78 (s, 1H), 7.51 (s, 1H), 7.21 (d, J = 8.2 Hz, 1H), 6.96 (d, J = 8.2 Hz, 2H), 6.93- 6.81 (m, 2H), 6.77 (t, J = 7.5 Hz, 1H), 4.36-4.25 (m, 1H), 4.12 (d, J = 16.5 Hz, 1H), 4.04-3.90 (m, 2H), 3.84 (d, J = 13.3 Hz, 1H) , 3.59 (dd, J = 13.0, 7.5 Hz, 1H) , 3.43 (t, J = 9.6 Hz, 1H) , 2.99 (s, 2H) , 2.13 (t, J = 5.9 Hz, 1H), 2.06-1.95 (m, 1H), 1.95-1.83 (m, 1H), 1.68-1.54 (m, 1H), 1.35 (t, J = 6.9 Hz, 3H), 1.29 (s, 6H) ) Example 15: (R,E)-3-(2-( (6-(3-(2-ethoxyphenoxy)piperidin-1192 ccz / nn / zznz / E / Y il)pyrazin-2-yl)amino)benzo acid [d]oxazol-5-yl)acrylic OH The ester product was obtained in a similar manner to Example 12 by using (R) -2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.973 g, 2.91 mmol) obtained in the Preparation Example 1 and methyl (E)-3-(2-aminobenzo[d]oxazol-5-yl)acrylate (0.53 g, 2.429 mmol) obtained in Preparation Example 22. (Yield of 6%)XH- NMR (400 MHz, CHLOROFORM-D) δ 8.74 (s, 1H), 7.88 (s, 1H), 7.80-7.68 (m, 2H), 7.35 (dd, J = 10.5, 8.7 Hz, 2H), 7.23-7.18 (1H), 6.99-6.91 (m, 2H), 6.91-6.84 (m, 2H), 6.42 (dd, J = 16.7, 6.6 Hz, 1H), 4.41-4.24 (m, 1H), 4.06-3.87 (m , 3H), 3.85-3.79 (m, 3H), 3.79-3.70 (m, 1H), 3.69-3.54 (m, 1H), 3,543.35 (m, 1H), 2.21-2.07 (m, 1H), 2.02 -1.86 (2H), 1.70-1.58 (1H), 1.36 (t, J = 7.1 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the ester compound obtained in a similar manner to Example 12. (1% yield) m / z (M+H)+calculated for C27H28N5O5: 502, found 502 Example 16: (J?)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)propanoic acid 193 OH ccz / nn / zznz / E / Y The ester product was obtained in a similar manner to Example 12 by using (R) -2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (1 g, 3.00 mmol) obtained in the Preparation Example 1 and methyl 3-(2-aminophenzo[d]oxazol-5-yl)propanoate (0.550 g, 2.496 mmol) obtained in Preparation Example 23. (28% yield)XH-NMR (400 MHz , CHLOROFORM-D) δ 8.61 (d, J = 4 . 1 Hz, 1H), 7.81 (s, 1H), 7.43-7.32 (m, 1H), 7.27 (d, J= 8.2 Hz,1H), 7.04-6.90 (m, 3H), 6.84 (t, J = 7.1 Hz, 2H), 4.34-4.22 (m,1H), 4.20-4.09 (m, 1H), 4.09-3.87 (m, 3H), 3.88-3.70 (m, 1H), 3.653.49 (m, 3H), 3.50-3.32 (m, 1H), 3.14-2.97 (m , 2H), 2.71 (t, J = 7.8 Hz, 2H), 2.27-2.11 (m, 1H), 2.02-1.81 (m, 2H), 1.72-1.52 (m, 1H), 1.36 (t, J = 6.9 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the ester compound obtained in a similar manner to Example 12. (5% yield) m / z (M+H)+calculated for C27H30N5O5: 504, found 504 Example 17: (R)-2-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)benzo[d]oxazol-6-yl)-2-acid methylpropanoic acid 194 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.293 g, 0.878 mmol) obtained in Example 12. Preparation 1 and methyl 2-(2-aminobenzo[d]oxazol-6-yl)-2-methylpropanoate (0.187 g, 0.798 mmol) obtained in Preparation Example 18. (2-step yield of 7%)XH- NMR (400 MHz, CHLOROFORM-D) δ 8.55 (d, J = 11.9 Hz, 1H), 7.82 (d, J = 10.1 Hz, 1H), 7.55-7.44 (m, 1H), 7.44-7.36 (m, 1H) ), 7.31 (d, J = 7.3 Hz, 1H), 7.02-6.87 (2H), 6.86-6.74 (m, 2H), 4.29 (t, J = 3.4 Hz, 1H), 4.15-4.06 (m, 1H) , 4.06-3.83 (m, 3H) , 3.81-3.67 (m, 1H) , 3.66-3.50 (1H), 3.50-3.35 (m, 1H) , 2.15-2.04 (m, 1H), 2.03 (d, J = 2.7 Hz, 1H), 2.01-1.82 (m, 2H), 1.62 (d, J= 12.3 Hz, 6H), 1.37-1.28 (m, 3H) Example 18: (K)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)benzo[d]oxazol-6-yl)propanoic acid 195 cc7 / nni77n7ieiy The product was obtained in a similar manner to Example 12 by using (R) -2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.8 g, 2.398 mmol) obtained in the Preparation Example 1 and methyl 3-(2-aminobenzo[d]oxazol-6-yl)propanoate (0.44 g, 1.998 mmol) obtained in the Preparation Example 24. (11% yield) 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.74 (s, 1H), 7.85 (s, 1H), 7.43 (d, J= 8.2 Hz, 1H), 7.13 -7.01 (m, 1H), 6.97 (t, J = 7.1 Hz, 3H), 6.92-6.83 (m, 3H), 4.33 (d, J = 4.1 Hz, 1H), 4.03-3.90 (3H), 3.79 ( s, 1H), 3.66 (s, 3H), 3.60 (dd, J = 13.0, 7.5 Hz, 2H), 3.03 (t, J = 7.8 Hz, 2H), 2.71-2.60 (2H), 2.ΙΟΙ.05 (1H), 1.98 (d, J = 40.7 Hz, 2H), 1.75-1.63 (1H), 1.36 (t, J = 7.1 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the ester compound obtained in a similar manner to Example 12. (3% yield) m / z (M+H)+calculated for C27H30N5O5: 504, found 504 Example 19: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(1Hpyrazol-3-yl)pyrazin-2-amine Step 1: (R)-3-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino-lH-pyrazole-l-carboxylate tert-butyl ccz / nn / zznz / E / Y 196 The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (1.540 g, 4.61 mmol) prepared in Example of Preparation 1 and tert-butyl 3-amino-l-pyrazole-l-carboxylate (0.930 g, 5.08 mmol) prepared in Preparation Example 64. (Yield of 1%)XH-NMR (CHLOROFORM-D) δ 7. 91 (d, J = 2.7 Hz, 1H), 7.73-7.57 (m, 2H), 7.46-7.34 (1H), 7.07-6.95 (m, 2H), 6.95-6.80 (2H), 6.67-6.55 (1H) , 4.30 (td, J= 8.2, 3.9 Hz, 1H), 4.21 (dd, J= 13.0, 3.5 Hz, 1H), 4.09-3.95 (m, 2H), 3.93-3.78 (1H), 3.41 (dd, J = 13.0, 8.1 Hz, 1H), 3.36-3.23 (m, 1H), 2.20 (dd, J = 12.7, 5.0 Hz, 1H), 2.00 (dd, J = 9.3, 4.1 Hz, 1H), 1.95-1.81 ( 1H), 1.66 (s, 10H), 1.40 (t, J = 7.0 Hz, 3H) Step 2: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N(lH-pyrazol-3-yl)pyrazin-2-amine (R)-3-((6-( Tert-butyl 3-(2-Ethoxy phenoxy)piperidin-l-yl)pyrazin-2yl)amino-lH-pyrazole-l-carboxylate (0.0124 g, 0.026 mmol) obtained in step 1 was dissolved in DCM (0.2 ml ), then trif luoroacetic acid (0.026 ml) dissolved in DCM was added and stirred at room temperature for 1 hour 30 minutes. After removing the solvent under reduced pressure, it was dissolved in DCM and washed with water, and purified by silica gel column to obtain the title compound. (50% yield)XH-NMR (500MHz, MeOD) δ 7.49 (s, 1H), 7.45 (s, 1H), 197 ccz / nn / zznz / E / Y 7.40 (s, 1H), 7.02 (d, J = 7.6 Hz, 1H), 6.95 (d, J = 3.7 Hz, 2H), 6.87 (d, J = 11.9 Hz, 1H), 6.31 (s, 1H), 4.60 (s, 1H), 4.46-4.34 (1H), 4.13-3.90 (m, 2H), 3.75-3.66 (1H), 3.66-3.52 (m, 2H), 2.18-1.85 (3H), 1.75-1.56 ( 1H), 1.32 (t, J = 6.7 Hz, 3H) Example 20: (R)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)-lH-pyrazol-l-yl)acetic acid? o £ 1 j£^OHΗ Ί I i h Step 1: Ethyl (R)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)-pyrazin-2-yl)amino)-IH-pyrazol-l-yl)acetate ( R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(1Hpyrazol-3-yl)pyrazin-2-amine (0.200 g, 0.526 mmol) prepared in Example 19 and sodium hydride (0.025 g, 0.631 mmol) were dissolved in tetrahydrofuran (2.63 ml) and stirred for 30 minutes. Ethyl 2-bromoacetate (0.087 ml, 0.789 mmol) dissolved in tetrahydrofuran (2.63 ml) was added dropwise to the reaction solution, followed by stirring for 2 hours. Water was added dropwise to terminate the reaction, then dissolved in ethyl acetate and washed with brine. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column. (3% yield) 198 ccz / nn / zznz / E / Y iH-NMR (500MHz, CHLOROFORM-D) £7.69 (s, 1H), 7.59 (s, 1H), 7.32 (d, J = 1.8 Hz, 1H), 7.09-6.81 (m, 4H), 6.66 (s, 1H), 6.36 (d, J = 2.1 Hz, 1H), 4.83-4.70 (m, 2H), 4.37-4.18 (m, 4H), 4.05 (qd, J = 6.8 , 3.1 Hz, 2H), 3.99-3.83 (m, 1H), 3.35 (dd, J = 13.0, 8.4 Hz, 1H), 3.31-3.18 (m, 1H), 2.29-2.12 (m, 1H), 1.98 ( q, J = 4.5 Hz, 1H), 1.93-1.78 (m, 1H), 1.79-1.55 (m, 2H), 1.42 (t, J = 7.0 Hz, 3H), 1.31 (t, J = 7.2 Hz, 3H ), 1.28 (s, 1H) Step 2:(R)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)-IH-pyrazol-l-yl)acetic acid ( R)-2-(3-((6-(3-(2-Ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)-1H-pyrazol-1-yl)ethyl acetate (0.0073 g, 0.016 mmol) obtained in step 1 was dissolved in aqueous solution of 50% ethyl alcohol (0.156 ml), and lithium hydroxide (1.124 mg, 0.047 mmol) was added thereto, followed by stirring at 0°C for 1 hour. . After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The title product was obtained by purification with a silica gel column. (26% yield) m / z (M+H)+calculated for C22H27N6O4: 439, found 439 Example 21: (K)-3-(3-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)-lH-pyrazol-l-yl)-2,2 acid -dimethylpropanoic acid 199 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner as in Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.10 g, 0.30 mmol) prepared in the Preparation Example 1 and methyl 3-(3-amino-lHpyrazol-l-yl)-2,2-dimethylpropanoate (0.059 g, 0.30 mmol) obtained in Preparation Example 66. (45% yield)XH-NMR (400 MHz, CHLOROFORM-D): δ 9.32 (s, 1H), 7.45 (d, J = 7.3 Hz, 2H), 7.13 (d, J = 2.3 Hz, 1H), 7.06-6.77 (m, 5H), 6.47 (d, J = 2.3 Hz, 1H), 4.35-4.14 (m, 4H), 4.06-3.89 (m, 2H), 3.89-3.78 (m, 1H), 3.37-3.08 (m, 2H), 2.17 ( q, J = 4.3 Hz, 1H), 1.99-1.71 (m, 2H), 1.71-1.53 ​​(m, 1H), 1.36 (t, J= 6.9 Hz, 3H), 1.22-1.09 (m, 6H) Example 22: (R)-3-(3-(6-((4-(3-(2-ethoxyphenoxy)piperidinl-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)phenyl acid )-2,2dime tiIpropanoic (R)-2-chloro-4-(3-(2-ethoxyphenoxy)piperidin-l-yl)-5fluoropyrimidine (54 mg, 0.15 mmol) synthesized in Preparation Example 8 and 3-(3-(6-aminopyridin tert-butyl -2-yl)phenyl)-2,2dimethylpropanoate (50 mg, 0.15 mmol) synthesized in Preparation Example 113 were dissolved in 1,4-dioxane, and the dissolved oxygen was removed, and filled with nitrogen ccz / nn / zznz / E / Y 200 to block exposure to outside air. Tris(dibenzylideneacetone)dipalladium (0) (8.4 mg, 9.19 pmol) were added. 4,5-bis(diphenylphosphino)-9,9-dimethylxanthine (8.0 mg, 0.01 mmol), cesium carbonate (125 mg, 0.38 mmol), a reflux cooling device was connected and heated for 12 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, diluted with ethyl acetate, dried over magnesium sulfate, and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (hexane:ethyl acetate). (15% yield) The obtained ester compound (15 mg, 0.02 mmol) was dissolved in DCM, trifluoroacetic acid (36 μΐ, 0.47 mmol) was added, followed by stirring at room temperature for 2 hours. After completion of the reaction, the mixture was distilled under reduced pressure to remove excess trifluoroacetic acid, neutralized with 1 N sodium hydroxide, and extracted with ethyl acetate. The organic solvent was dried over magnesium sulfate and the organic solvent was removed under reduced pressure. The desired product was obtained by purification with a silica gel column (hexane:ethyl acetate). (37% performance) -7.57 (1H), 7.54 (t, J = 8.0 Hz, 1H), 7.45-7.23 (m, 5H), 7.23-7.11 (1H), 7.00ccz / nn / zznz / E / Y 6.88 (m, 1H), 6.86 (d, J = 4.1 Hz, 2H), 6.82-6.70 (m, 1H), 4.44 (d, J = 2.7 Hz, 1H), 4.14-3.94 (m, 2H), 3.94 -3.75 (m, 4H), 3.62 (d, J = 8.7 Hz, 1H), 2.90 (s, 2H), 2.14-1.84 (m, 4H), 1.60 (d, J = 7.3 Hz, 1H), 1.34- 1.20 (m, 3H), 1.19-1.11 (m, 6H) Example 23: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(1-methyllH-tetrazol-5-yl)pyrazin-2-amine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) prepared in Example Preparation 1 and 1-methyl-lH-tetrazol5-amine (0.049 g, 0.49 mmol). (44% performance)XH-NMR (500 MHz, CHLOROFORM-D): δ 8.18 (s 1 HOUR) 7.79 (s, 1H), 7.41 (s, 1H), 7.01-6.89 (m, 2H), 6.88-6.75 (m, 2H), 4.34-4.23 (m, 1H), 4.06-3.91 (m, 2H), 3.88 (s, 3H), 3.86 (s, 1H), 3.70-3.56 (2H), 3.42 (q, J = 4.5 Hz, 1H), 2.13-2.03 (m, 1H), 2.02-1.95 (m, 1H) , 1.90 (q, J = 4.1 Hz, 1H), 1.57 (q, J = 4.5 Hz, 1H), 1.34 (t, J = 7.0 Hz, 3H) Example 24: (R)-N-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-phenylpyrazin-2-amine 202 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.09 g, 0.27 mmol) prepared in Example Preparation 1 and aniline (0.025 g, 0.27 mmol). XH-NMR (400 MHz, Chloroform-D): δ 7.56 (S, 1h), 7.52 (S, 1h), 7.36 (D, J = 8 Hz, 2h), 7.03 (D, J = 8 Hz, 2h) ,6.947.03 (m, 3H) , 6.82-6.91 (m, 2H) , 6.20 (s, 1H) , 4.31 (m,1H), 4.19 (m, 1H) , 4.04 (m, 3H) , 3.89 (m, 1H) , 3.43 (m, 1H) ,3.29 (m, 1H) , 2.15 (m, 1H) , 1.96 (m, 1H) , 1.86 (m, 1H) , 1.64(m, 1H), 1.39 (t, 3H) Example 25: (R)-N- (4-((6- (3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)methanesulfonamide The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) prepared in Example Preparation 1 and N-(4aminophenyl)methanesulfonamide (0.092 g, 0.49 mmol). (69% performance) 2.6 Hz, 2H), ccz / nn / zznz / E / Y 203 7.03-6.93 (m, 2H), 6.89 (dd, J= 7.9, 1.2 Hz, 1H), 6.82 (td, J = 7.5, 1.4 Hz, 1H), 6.48 (s, 1H), 6.28 (s, 1H) , 4.35-4.24(m, 1H), 4.16 (dd, J = 13.1, 3.4 Hz, 1H), 4.07-3.95 (m, 2H) ,3.83 (td, J = 8.9, 4.1 Hz, 1H), 3.43 (dd, J = 13.4, 7.9 Hz ,1 HOUR), 3.37-3.24 (m, 1H), 2.96 (s, 3H), 2.23-2.09 (m, 1H), 1.98 (dd, J = 9.8, 3.7 Hz, 1H), 1.93-1.80 (m, 1H), 1.69- 1.61 (m, 1H),1.38 (t, J = 7.0 Hz, 3H) Example 26: (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)-N-(pyridin-4-ylmethyl) acetamide The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) prepared in Example Preparation 1 and 2-(4-aminophenyl)N-(pyridin-4-yl-methyl)acetamide (0.11 g, 0.49 mmol). (54% performance) = 8.6 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 7.07 (d, J= 5.5 Hz, 2H), 7.01-6.96 (1H), 6.95-6.91 (m, 1H), 6.90-6.85 (m, 1H), 6.80 (td, J = 7.6, 1.4 Hz, 1H), 6.43 (s, 1H), 5.96 (s, 1H), 4.40 (d, J = 6.1 Hz, 2H), 4.32-4.24 ( m, 1H), 4.17 (dd, J = 12.8, 3.1 Hz, 1H), 4.06-3.95 204 ccz / nn / zznz / E / Y (m, 2H) , 3.83 (td, J = 8.6, 4.1 Hz, 1H) , 3.60 (s, 2H) , 3.40 (dd, J = 12.8, 8.0 Hz, 1H) , 3.34-3.24 (m, 1H), 2.21-2.11 (m, 1H), 1.97 (dd, J = 9.7, 3.8 Hz, 1H), 1.87 (dd, J = 9.2, 3.7 Hz, 1H), 1.67-1.55 (m, 1H), 1.37 (t, J = 7.0 Hz, 3H) Example 27: (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.30 g, 0.90 mmol) prepared in Example of Preparation 1 and methyl 2-(4-aminofeni1)-2-methylpropanoate (0.19 g, 0.99 mmol) prepared in Preparation Example 14. (Yield 91%)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.55 (s, 1H), 7.48 (s, 1H), 7.29-7.32 (m, 2H), 7.23 (dd, J = 6.9, 1.8 Hz, 2H), 6.81-7.01 (m, 4H), 6.18 (s, 1H), 4.26-4.30 (m, 1H), 4.19 (dd, J = 12.8, 3.7 Hz, 1H), 3.99-4.05 (m, 2H), 3.84-3.88 (m, 1H), 3.64 (s, 3H) , 3.38 (dd, J = 12.8, 8.2 Hz, 1H) , 3.24-3.30 (m, 1H) , 2.14-2.18 (m, 1H), 1.97 (q, J= 4.6 Hz, 1H), 1.87 (dd, J = 9.4, 3.4 Hz, 1H), 1.60-1.64 (m, 1H), 1.56 (s, 6H), 1.38 (t, J = 6.9 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.40 g, 205 ccz / nn / zznz / E / Y 0.82 mmol) in a manner similar to Example 1. (23% yield) ), 6.85-6.99 (m, 4H), 6.34 (s,1H), 4.25- 4.29 (m, 1H), 4.16 (d, J = 12.8 Hz, 1H), 3.97-4.03(m, 2H), 3.79-3.82 (m, 1H), 3.39 (dd, J = 13.0, 8.0 Hz, 1H), 3.26 (t, J = 10.1 Hz, 1H), 2.12-2.15 (m, 1H), 1.93-1.97 (m,1H) , 1.81- 1.89 (m, 1H), 1.58 (s, 7H), 1.36 (t, J = 6.9 Hz, 3H) Example 28: acid (R)-2-(4-((6-(3-(2- ethoxyphenoxy)pyridin-1yl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyridine (0.30 g, 0.90 mmol) prepared in Example Preparation Example 4 and methyl 2-(4-aminophenyl)-2-methylpropanoate (0.19 g, 0.99 mmol) prepared in Preparation Example 14. (88% yield) 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.30 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 3.2 Hz, 1H), 7.20-7.22 (m, 2H), 7.04 (dd, J= 8.0, 1.6 Hz, 1H), 6.82-6.96 (m, 3H), 6.19 (s, 1H), 6.11 (q, J= 8.4 Hz, 2H) , 4.24-4.36 (m, 2H) , 3.96-4.06 (m, 3H) , 3.64(s, 3H), 3.47 (d, J= 7.3 Hz, OH), 3.03-3.19 (m, 2H), 2.19 (dd, J= 12.6, 4.3 Hz, 1H), 1.77-1.91 (m, 2H), 1.38-1.63 (m, 12H), 1.18- 206 ccz / nn / zznz / E / Y 1.24 (m, 1H), -0.01 (t, J= 3.2 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.40 g, 0.82 mmol) in a similar manner to Example 1. XH-NMR (400 MHz, CHLOROFORM-D) δ 7.22-7.30 (m,5H), 7.03 (d, J = 7.8 Hz, 1H), 6.89 (dq, J = 28.9, 7.5 Hz, 3H), 6.14 (d, J = 7.8 Hz, 1H), 6.08 (d, J = 7.8 Hz, 1H), 4.24-4.32 (m, 2H), 4.03 (q, J = 6.9 Hz, 2H), 3.95 (d, J = 12.8 Hz, 1H), 3.17 (dd, J = 11.9, 8.2 Hz, 1H), 3.07 (t , J = 10.5 Hz, 1H) , 2.19 (d, J = 8.2 Hz, 1H), 1.89 (q, J = 4.3 Hz, 1H), 1.78 (d, J =11.9 Hz, 1H), 1.57-1.65 (m, 7H), 1.39 (t, J = 6.9 Hz, 3H) Example 29: (K)-2-(3-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid similar as in Example 12 when using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (1.036 g, 3.10 mmol) obtained in Preparation Example 1 and 2-(3 -aminophenyl)-methyl 2methylpropanoate (0.5 g, 2.59 mmol) obtained in Preparation Example 15. (2-step yield of 4%)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.63 (s, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 7.22 (d, J = 7.8 Hz, 1H), 7.07 (t, J = 9.8 Hz, 2H), 7.00-6.89 (m, 2H), 6.89-6.76 (m, 2H), 6.42 (s, 207 ccz / nn / zznz / E / Y 1Η), 4.44-4.21 (m, 2H), 4.05-3.91 (m, 2H), 3.83 (q, J= 4.4 Hz, 1H), 3.42-3.26 (1H), 3.26-3.05 (m, 1H), 2.25 -2.06 (m, 1H), 1.93 (q, J = 4.6 Hz, 1H), 1.83-1.67 (1H), 1.67-1.59 (m, 1H), 1.591.48 (m, 6H), 1.35 (t, J = 6.9Hz, 3H) Example 30: (K)-3-(3'-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)-[1,1'-biphenyl]-4-acid il)-2,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.192 g, 0.575 mmol) obtained in Example Preparation 1 and tert-butyl 3-(3'-amino-[1,1'biphenyl]-4-yl)-2,2-dimethylpropanoate (0.17 g, 0.522 mmol) obtained in Preparation Example 94. (yield 2-stage 12%) (q, J= 7.6 Hz, 3H), 6.93 (q, J = 7.6 Hz, 2H), 6.88-6.83 (m, 1H), 6.83-6.73 (m, 1H), 6.53 (s, 1H), 4.37- 4.18 (m, 1H), 4.18-4.06 (m, 1H), 4.05-3.89 (m, 2H), 3.83 (q, J = 4.3 Hz, 1H), 3.53-3.36 (1H), 3.36-3.19 (m, 1H), 2.90 (s, 2H), 2.25-2.06 (1H), 1.99-1.74 (m, 2H), 1.70-1.48 (m, 1H), 1.34 (q, J= 7.3 Hz, 3H), 1.23 (s , 6H) ccz / nn / zznz / E / Y Example 31: (Λ)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(pyridin2-yl)pyrazin-2-amine η N N N [II I i h The title compound was obtained in a similar manner to Example 1 by using (.R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.20 g, 0.60 mmol) prepared in Example of Preparation 1 and 2-aminopyridine (0.06 g, 0.66 mmol). (94% yield)1H-NMR (500 MHz, CHLOROFORM-D): δ 8.24 (d, J 4.9Hz 1H), 7.89 (s, 1H), 7.66 (s, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.54-7.42 (m, 1H), 7.09 (s, 1H), 6.99 (d, J = 7.9 Hz, 1H), 6.95 (t, J= 7.0 Hz, 1H), 6.90-6.72 (m, 3H), 4.36-4.25 (m, 1H), 4.19 (dd, J = 13.2, 3.3 Hz, 1H) , 4.08-3.94 (m, 2H) , 3.89-3.81 (m, 1H) , 3.44 (dd, J = 13.4, 7.9 Hz, 1H) , 3.38-3.25 (m, 1H) , 2.17 (t, J = 5.8 Hz , 1H), 2.05-1.95 (1H), 1.93-1.79 (m, 1H), 1.67 (d, J = 6.1 Hz, 1H), 1.37 (t, J = 7.0 Hz, 3H) Example 32: (R)-6-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)nicotinic acid The desired product was obtained in a similar manner to Example 1 by using (Λ)-2-chloro-6-(3-(2-ethoxyphenoxy)ccz / nn / zznz / E / Y 209 piperidin-l-yl)pyrazine (0.30 g, 0.90 mmol) prepared in Preparation Example 1 and methyl 6-aminonicotinate (0.15 g, 0.99 mmol). (72% performance) ), 7.73 (s, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.36 (s, 1H), 7.04-6.92 (m, 2H), 6.90-6.68 (m, 2H), 4.32 (td, J = 7.9, 3.7 Hz , 1H), 4.12 (dd, J = 13.1, 3.4 Hz, 1H), 4.07-3.95 (m, 2H), 3.91 (s, 3H), 3.80 (td, J = 9.2, 4.5 Hz, 1H), 3.53 ( dd, J = 13.1, 7.6 Hz, 1H), 3.463.31 (m, 1H), 2.27-2.11 (m, 1H), 2.09-1.99 (m, 1H), 1.97-1.84 (m, 1H), 1.66 ( q, J = 4.5 Hz, 1H), 1.36 (t, J = 6.7 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.29 g, 0.65 mmol) in a similar manner to Example 1. (21% yield)XH-NMR (500 MHz, DMSO-D6) : δ 12.99-12.26 (1H), 10.00 (s, 1H), 8.71 (s, 1H), 8.12 (s, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.76 (s, 1H), 7.61 (d, J = 8.6 Hz, 1H), 7.00 (d, J = 7.9 Hz, 1H), 6.89 (d, J = 6.7 Hz, 1H), 6.84 (d, J = 7.3 Hz, 1H), 6.76 (t , J= 7.0 Hz, 1H), 4.40-4.24 (1H), 4.03 (d, J= 11.6 Hz, 1H), 3.96-3.80 (m, 2H), 3.68 (d, J = 13.4 Hz, 1H), 3.57 -3.39 (m, 2H), 2.12-1.94 (1H), 1.86 (s, 1H), 1.72 (d, J = 9.2 Hz, 1H), 1.54 (s, 1H), 1.18 (t, J = 7.0 Hz, 3H) Example 33: (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)isonicotinic acid 210 ccz / nn / zznz / E / Y The desired product was obtained in a similar manner to Example 1 by using (β)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.20 g, 0.60 mmol) prepared in Example of Preparation 1 and methyl 2-aminoisonicotinate (0.10 g, 0.66 mmol). (71% performance)1H-NMR (500 MHz, CHLOROFORM-D): δ 8.46 (s, 1H), 8.36 (d, J = 4.9 Hz, 1H), 7.80 (s, 1H), 7.68 (s, 1H) ), 7.40 (d, J = 5.5 Hz, 1H), 7.22 (s, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.92-6.88 (1H), 6.86-6.82 (m, 1H), 6.80-6.67 (m, 1H), 4.38-4.28 (1H), 4.11 (dd, J = 13.1, 3.4 Hz, 1H), 4.05-3.96 (m, 2H), 3.92 (dt, J = 13.4, 3.8 Hz, 1H), 3.88 (s, 3H), 3.60 (dd, J= 13.1, 7.6 Hz, 1H), 3.51-3.35 (m, 1H), 2.13 (s, 1H), 2.04 (td, J = 6.6, 3.3 Hz, 1H), 1.93 (q, J = 4.1 Hz, 1H), 1.66 (q, J = 4.5 Hz, 1H), 1.36 (t, J = 7.0 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.18 g, 0.40 mmol) in a similar manner to Example 1. (57% yield)XH-NMR (500 MHz, DMSO-D6) : δ 9.76 (s, 1H), 8.31 (d, J = 5.5 Hz, 2H), 8.04 (s, 1H), 7.66 (s, 1H), 7.24 (d, J= 5.5 Hz, 1H), 6.96 (d , J = 7.3 Hz, 1H) , 6.87 (s, 1H) , 6.81 (t, J = 7.6 Hz, 1H) , 6.72 (t, J = 7.6 Hz, 1H) , 4.29 (s, 1H) , 3.93 (d , J = 211 ccz / nn / zznz / E / Y 13.4 Hz, 1H), 3.89-3.76 (m, 2H), 3.70 (d, J = 15.9 Hz, 1H), 3.64-3.51 (m, 2H), 1.97 (s, 1H), 1.84 (s, 1H), 1.73 (d, J = 7.9 Hz, 1H), 1.53 (d, J = 4.3 Hz, 1H), 1.18 (q, J = 7.3 Hz, 3H) Example 34: acid (R)-2-((6-( 3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)nicotinic The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.20 g, 0.60 mmol) prepared in Example of Preparation 1 and methyl 2-aminonicotinate (0.10 g, 0.66 mmol). (85% performance) = 7.6, 2.1 Hz, 1H), 7.79 (s, 1H), 7.06 (q, J= 3.1 Hz, 1H), 6.99-6.91 (m, 2H), 6.88 (q, J = 3.3 Hz, 1H), 6.83 (q, J = 4.3 Hz, 1H), 4.31-4.22 (m, 2H), 4.04 (qd, J = 6.9, 2.3 Hz, 2H), 3.98 (t, J = 4.6 Hz, 1H), 3.95 (s, 3H), 3.36 (dd, J = 14.1, 9.2 Hz, 1H), 3.33-3.23 (m, 1H), 2.22-2.13 (m, 1H), 1.95 (q, J= 4.5 Hz, 1H), 1.86 (d , J= 10.4 Hz, 1H) , 1.66-1.55 (m, 1H) , 1.41 (t, J= 7.0 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.21 g, 0.47 mmol) in a manner similar to Example 1. (Yield of 74%) 212 ccz / nn / zznz / E / Y iH-NMR (500 MHz, DMSO-D6): δ 10.63 (s, 1H), 8.91 (s, 1H), 8.48 (q, J = 2.2 Hz, 1H), 8.37 -8.20 (1H), 7.90 (s, 1H), 7.11-6.97 (m, 2H), 6.87 (dt, J = 12.2, 4.9 Hz, 3H), 4.43-4.20 (m, 1H), 4.04 (d, J = 12.8 Hz, 1H), 3.95-3.79 (m, 2H), 3.763.62 (m, 1H), 3.59-3.42 (m, 2H), 2.08-1.94 (m, 1H), 1.83 (t, J = 3.4 Hz, 1H), 1.75 (q, J = 4.1 Hz, 1H), 1.51 (q, J = 4.3 Hz, 1H), 1.20 (t, J = 7.0 Hz, 3H) Example 35: (Λ)-2-(2-((6- (3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)-2-methylpropanoic acid similar to Example 1 by using (5)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (1.12 g, 3.35 mmol) prepared in Preparation Example 1 and 2-(2-aminopyridin Methyl -4yl)-2-methylpropanoate (650 mg, 3.35 mmol) prepared in Preparation Example 60. (2-step yield of 1%)1H-NMR (CHLOROFORM-D) δ 8.31 (s, 1H), 7.96 (d, J = 4.6 Hz, 1H), 7.69 (s, 2H), 6.97-6.73 (5H), 4.36 (q, J = 4.1 Hz, 1H), 4.06-3.92 (m, 3H), 3.89-3.75 (1H), 3.46 (t, J = 10.2 Hz, 1H), 3.38-3.22 (m, 1H), 2.12 (d, J = 5.5 Hz, 1H), 2.05 (d, J = 15.3 Hz, 1H), 1.96 (s, 1H), 1.80-1.54 (7H), 1.33 (t, J = 7.0 Hz, 3H) 213 ccz / nn / zznz / E / Y Example 36: (.R)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-3-yl)acetic acid The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.14 g, 0.42 mmol) prepared in Example of Preparation 1 and methyl 2-(6-aminopyridin-3-yl)acetate (0.08 g, 0.46 mmol) prepared in Preparation Example 12. (62% yield)XH-NMR (400 MHz, CHLOROFORM-D) : £8.14(s, 1H), 7.87(s, 1H) , 7.66(s, 1H) , 7.62(d, J= 8 Hz, 1H) , 7.46(d, J = 8 Hz, 1H) , 7.08(s , 1H) , 6.99(m, 2H) , 6.88(m, 2H) , 4.32(m, 1H) , 4.29(m, 1H), 4.02(m, 2H), 3.87(m, 1H), 3.83(s, 1H), 3.56(s, 2H), 3.48(m, 1H) , 3.34(m, 1H) , 2.17(m, 1H) , 2.02 (m, 1H) , 1.91 (m, 1H), 1.66(m, 1H), 1.38(t, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.11 g, 0.24 mmol) in a similar manner to Example 1. (19% yield) 1H-NMR (400 MHz, DMSO-D6) : £9.54(s, 1H), 8.10(s, 1H), 8.06(s, 1H) , 7.67(s, 1H) , 7.60(d, J= 8 Hz, 1H) , 7.41(d, J= 6 Hz) , 1H) , 7.04(d, <7=8 Hz, 1H) , 6.95 (m, 2H) , 6.84(m, 1H), 4.33(m, 1H), 4.10 (m, 1 HOUR) , 3.95(m, 2H) , 3.72 (m, 1H), 3.51(s, 214 ccz / nn / zznz / E / Y 2Η), 3.45(m, 2H), 2.04(m, 1H), 1.87(m, 1H), 1.75(m, 1H), 1.57(m, 1H) , 1.25(t, 3H) Example 37: (R,E)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-3-yl)acrylic acid The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.50 g, 1.50 mmol) prepared in Example of Preparation 1 and (E)-3-(6-aminopyridin-3-yl)methyl acrylate (0.29 g, 1.65 mmol) prepared in Preparation Example 13. (70% yield) CHLOROFORM-D): δ 8.35 (s, 1H), 7.957.81 (1H), 7.71 (s, 1H), 7.64 (d, J = 2.4 Hz, 2H), 7.62 (d,J = 15.9 Hz, 1H), 7.23 (s, 1H), 7.01-6.92 (m, 2H), 6.91-6.79(m, 2H), 6.34 (d, J = 16.5 Hz, 1H), 4.33 (d, J = 4.3 Hz, 1H), 4.194.13 (m, 1H), 4.05-3.96 (m, 2H), 3.82 (d, J = 7.9 Hz, 4H),3.50 (dd, J = 12.8, 7.9 Hz, 1H), 3.36 (d, J = 9.8 Hz, 1H), 2.21-2.13 (1H), 2.06-1.97 (1H), 1.97-1.87 (1H), 1.66 (s, 1H), 1.37 (t, J = 7.0 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.15 g, 0.32 mmol) in a manner similar to Example 1. (Yield of 82%) 215 ccz / nn / zznz / E / Y iH-NMR (500 MHz, DMSO-D6): δ 10.71 (s, 1H), 8.49 (s, 1H), 8.16 (s, 1H), 8.04 (d, J = 6.7 Hz, 1H), 7.88 (s, 1H), 7.56-7.47 (m, 2H), 6.97 (d, J = 6.1 Hz, 1H), 6.86-6.81 (1H), 6.80-6.70 (m, 2H), 6.47 (d, J = 15.9 Hz, 1H), 4.45 (s, 1H), 3.92-3.72 (m, 5H), 3.61 (s, 1H), 1.96 (d, J = 7.9 Hz, 1H), 1.84 (d , J = 29.3 Hz, 2H) , 1.55 (s, 1H) , 1.13 (t, J= 7.0 Hz, 3H) Example 38: (R)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-3-yl)propanoic acid (R,E)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-3-yl)acrylic acid (0.3 g, 0.63 mmol) obtained in Example 37 and Pd / C (67 mg) were dissolved in 20 ml of methanol, and a reduction reaction was carried out using a hydrogen balloon. After stirring at room temperature for 2 hours, it was filtered and the organic solvent was removed under reduced pressure to obtain the desired product. (63% performance) ), 7.37-7.32 (m, 1H), 7.12 (s, 1H), 7.01-6.92 (m, 2H), 6.90-6.79 (m, 2H), 4.354.27 (m, 1H), 4.19 (d, J = 12.8 Hz, 1H), 4.05-3.97 (m, 2H), 3.82 (d, J = 11.6 Hz, 1H), 3.67 (s, 3H), 3.42 (dd, J = 12.8, 7.9 Hz, 1H), 3.32 (d, J = 12.8 Hz, 1H), 2.87 (t, J = 7.6 Hz, 216 ccz / nn / zznz / E / Y 2Η), 2.60 (t, J = 7.6 Hz, 2H), 2.18 (s, 1H), 2.03-1.95 (1H), 1.88 (d, J = 9.8 Hz, 1H), 1.69 (s, 1H), 1.37 ( t, J = 7.0 Hz, 3H) The title compound was obtained through a hydrolysis reaction of the obtained ester compound (0.15 g, 0.32 mmol) in a similar manner to Example 1. (57% yield)XH-NMR (500 MHz, DMSO-D6) : δ 9.44 (s, 1H), 8.05 (d, J = 1.8 Hz, 1H), 8.02 (s, 1H), 7.62 (s, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.35 (dd, J = 8.6, 2.4 Hz, 1H), 7.00 (dd, J = 7.9, 1.8 Hz, 1H), 6.91 (dd, J= 7.9, 1.2 Hz, 1H), 6.87 (td, J= 7.6, 1.8 Hz, 1H), 6.78 (td, J = 7.6, 1.6 Hz, 1H), 4.35-4.24 (m, 1H), 4.06 (d, J = 12.8 Hz, 1H), 3.97-3.85 (m, 2H), 3.75-3.64 (m, 1H), 3.47-3.31 (m, 2H), 2.70 (t, J = 7.6 Hz, 2H), 2.47 (t, J = 1.5 Hz, 2H), 2.02 (s, 1H), 1.83 (s, 1H), 1.70 (d, J = 9.2 Hz, 1H), 1.60-1.48 (m, 1H), 1.20 (t, J = 7.0 Hz, 3H) Example 39: (K)-3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)-2,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (165 mg, 0.495 mmol) prepared in Example 22. Preparation 1 and tert-butyl 3-(2-aminopyridin-4217 ccz / nn / zznz / E / Y il)-2,2-dimethylpropanoate (124 mg, 0.495 mmol) prepared in Preparation 63. (41% 2-stage performance) !H-NMR (400 MHz, CHLOROFORM-D) £9.06 (s, 1H), 8,017.82 (m, 2H), 7.60 (s, 1H), 7.55-7.45 (1H ), 7.02-6.80 (m, 3H), 6.80-6.65 (m, 2H), 4.40-4.21 (m, 1H), 4.19-4.05 (m, 1H), 4.053.94 (m, 2H), 3.81-3.69 (m, 1H), 3.46 (dd, J = 13.3, 7.8Hz, 1H), 3.40-3.22 (m, 1H), 2.81-2.61 (2H), 2.15-2.03 (m, 1H), 1.97 (dd, J = 9.8, 3.4 Hz, 1H), 1.91-1.75 (m, 1H) , 1.72-1.49 (m, 1H), 1.34 (t, J= 7.1 Hz, 3H), 1.22 (d, J = 3.2 Hz, 6H) Example 40: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(5-phenylpyridin-2-yl)pyrazin-2-amine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.1 g, 0.30 mmol) prepared in Example Preparation 1 and 2-amino-(5phenyl)pyridine (0.05 g, 0.30 mmol). (71% performance)1H-NMR (500 MHz, CHLOROFORM-D) £ 8.48 (d, 5=2.4 Hz, 1H), 7.87 (s, 1H), 7.78-7.70 (2H), 7.67 (s, 1H) , 7.61-7.52 (m, 2H) , 7.51-7.42 (2H) , 7.35 (t, J = 7.3 Hz, 1H) , 7.32 (s, 1H) , 7.06-6.98 (1H), 6.93 (td, J = 7.6, 1.2 Hz, 1H), 6.88 (dd, J = 218 ccz / nn / zznz / E / Y 7.9, 1.8 Hz, 1H), 6.82 (td, J = 7.5, 1.6 Hz, 1H), 4.41-4.29 (m, 1H), 4.22 (dd, J = 12.8, 3.7 Hz, 1H), 4.10-3.94 (m , 2H), 3.86 (td, J = 8.9, 4.1 Hz, 1H), 3.46 (dd, J = 12.8, 7.9 Hz, 1H), 3.39-3.31 (m, 1H), 2.27-2.12 (m, 1H), 2.08-1.98 (m, 1H), 1.961.85 (m, 1H), 1.83-1.51 (m, 3H), 1.38 (t, J = 7.0 Hz, 3H), 1.29 (d, J = 39.7 Hz, 1H) , 0.87 (dd, J = 26.3, 19.6 Hz, OH) Example 41: (R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(4phenylpyridin-2-yl)pyrazin-2-amine The title compound was obtained in a similar manner to Example 1 by using (.R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.1 g, 0.30 mmol) prepared in Example of Preparation 1 and 2-amino-(4phenyl)pyridine (0.06 g, 0.36 mmol) prepared in Preparation Example 11. (45% yield)XH-NMR (500 MHz, CHLOROFORM-D) δ 8.35 (d, J = 5.5 Hz, 1H), 7.92 (d, J = 31.8 Hz, 1H), 7.86-7.82 (m, 3H), 7.65 (d, J = 37.3 Hz, 1H), 7.50 (s, 1H), 7.35 (dt , J = 19.0, 7.2 Hz, 3H), 7.29-7.26 (m, 1H), 6.92 (t, J = 7.6 Hz, 2H), 6.84 (d, J = 7.9 Hz, 1H), 6.78 (t, J = 7.6 Hz, 1H), 5.53 (s, 1H), 4.41-4.26(m, 1H), 4.11 (q, J = 7.1 Hz, 1H), 4.06-3.88 (m, 3H), 3.85-3.70(m, 1H), 3.61 (q, J = 6.7 Hz, 1H), 3.54-3.39 (m, 1H), 2.18-2.06(m, 2H), 2.05-1.98 (m, 2H), 1.97-1.85 (m, 1H), 1.63 (qd, J = 8.8, 219 ccz / nn / zznz / E / Y 4.3 Hz, 1H), 1.44-1.30 (m, 3H), 1.29-1.14 (m, 2H) Example 42: (R)-2-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2 acid -methylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.237 g, 0.709 mmol) prepared in Example Preparation 1 and methyl 2-(3-(2aminopyridin-4-i1)pheni1)-2-methylpropanoate (0.230 g, 0.851 mmol) prepared in Preparation Example 27. (56% yield) CHLOROFORM-D) δ 8.27 (s, 1H),8.168.05 (1H), 7.81 (s, 1H), 7.66 (s, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.40 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 5.5 Hz, 1H) ,6.936.84 (m, 2H) , 6.81 (d, J = 7.0 Hz, 1H) , 6.77-6.65 (m, 1H) , 4.29 (d, J = 3.7 Hz, 1H), 4.10 (d, J = 3.1 Hz, 1H), 3.94 (t, J = 7.0 Hz, 2H), 3.90-3.79 (1H), 3.58 (dd, J =13.1, 7.6 Hz, 1H), 3.42 (s, 1H), 2.08 (m, 1H), 1.94-1.84(m, 2H), 1.71 (d, J = 8.2 Hz, 6H), 1.67-1.55 (1H), 1.33 (t, J= 7.0 Hz, 3H) Example 43: (R)-2-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl) acid phenyl)-2-methylpropanoic acid 220 ccz / nn / zznz / E / Y in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2 ethoxyphenoxy)piperidin-l-yl)pyrazine (0.329 g, 0.986 mmol) prepared in Preparation Example 1 and methyl 2 Methyl -(4-(2aminopyridin-4-yl)phenyl)-2-methylpropanoate (0.32 g, 1.184 mmol) prepared in Preparation Example 26. (1% yield) Y-NMR (400 MHz, CHLOROFORM-D) δ 9.51 (s, 1H), 8.45 (d, J = 8.7 Hz, 1H), 8.13-7.99 (m, 1H), 7.78 (d, J = 10.1 Hz, 1H) ), 7.71-7.62 (m, 1H), 7.59 (d, J = 8.7 Hz, 2H), 7.49 (t, J = 9.1 Hz, 2H), 7.13-7.01 (m, 1H), 6.93-6.66 (m, 4H), 4.36-4.23 (m, 1H), 4.16-4.02 (m, 1H), 3.99-3.87 (m, 2H), 3.87-3.77 (m, 1H), 3.57 (dd, J = 13.0, 7.5 Hz, 1H), 3.47-3.36 (m, 1H), 2,161.79 (m, 3H), 1.61 (s, 7H), 1.35-1.25 (m, 3H) Example 44: (R)-3-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2 acid ,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2221 ccz / nn / zznz / E / Y ethoxyphenoxy)piperidin-l-yl)pyrazine (210 mg, 0.629 mmol) prepared in Preparation Example 1 and methyl 3-(3-(2aminopyridin-4-yl)phenyl)-2,2-dimethylpropanoate (179 mg, 0.629 mmol) prepared in Preparation Example 58. 5 (4% ​​2-stage performance) ), 7.52 (s, 1H), 7.37 (d, J = 7.9 Hz, 1H) , 7.33 (t, J = 7.5 Hz, 1H), 7.20 (d, J= 7.3 Hz, 1H) , 6.93 (s, 1H) ), 6.80 (dd, J= 14.6, 7.9 Hz, 2H), 6.74 (d, J = 7.9 Hz, 1H), 6.63 (t, J = 7.6 Hz, 1H), 6.51 (d, J = 4.9 Hz, 1H), 4.37-4.29 (m, 1H), 4.00 (dd, J = 13.1, 2.7 Hz, 1H), 3.933.87 (m, 2H), 3.86-3.79 (m, 1H), 3.65 (dd, J = 12.4, 7.8Hz, 1H), 3.56-3.47 (m, 1H), 2.94 (dd, J = 29.1, 13.0 Hz, 2H), 2.16- 2.11 (m, 1H), 2.07-1.90 (m, 2H), 1.73-1.62 (m, 1H), 1.36-1.29 (m, 9H) Example 45: (R)-3-(4-(2-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2 acid ,2-dimethylpropanoic acid EITHER The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (175 mg, 0.524 mmo1) prepared in the Preparation Example and tert-butyl 3-(4-(2222 ccz / nn / zznz / E / Y aminopyridin-4-yl)phenyl)-2,2-dimethylpropanoate (171 mg, 0.524 mmol ) prepared in Preparation Example 71. (20% 2-step yield) !H-NMR (400 MHz, CHLOROFORM-D) δ 9.13 (s, 1H), 8.438.28 (1H), 8.08 (d, J = 5.5 Hz, 1H), 7.70 (s, 1H), 7.59 (s, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 7.02 (d, J = 5.5 Hz, 1H), 6.96-6.64 (m, 4H), 4.34-4.18 (m, 1H), 4.01 (d, J = 12.8 Hz, 1H), 3.93 (q, J = 7.0 Hz, 2H), 3.79 (d, J = 12.8 Hz, 1H), 3.50 (dd, J = 12.8, 7.8 Hz, 1H), 3.43-3.25 (1H), 2.90 (s, 2H), 2.09-1.99 (m, 1H), 1.98- 1.87 (m, 1H), 1.87-1.73 (m, 1H), 1.66-1.45 (m, 1H), 1.29 (q, J = 6.9 Hz, 9H) Example 46: (.R)-3-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)propanoic acid Step 1: Methyl (R)-3-(3-(2-((6-(3-(2-Ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)propanoate The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.189 g, 0.568 mmol) prepared in Example of Preparation 1 and methyl 3-(3-(2-aminopyridin-4-yl)phenyl)propanoate (0.160 g, 0.624 mmol) prepared in Preparation Example 56. (64% yield) D) >'8.32 (d, J= 5.2 Hz, 1H) , 8.03 223 ccz / nn / zznz / E / Y (s, 1H) , 7.92 (s, 1H) , 7.75-7.63 (1H), 7.56-7.45 (m, 2H) , 7.37 (t, J = 7.5 Hz, 1H) , 7.28-7.24 (1H), 7.22 (s, 1H) , 7.17-7.02 (m, 1H) , 7.01-6.89 (m, 2H) , 6.89-6.83 (m, 1H) , 6.79 (td, J = 7.6, 1.5 Hz, 1H), 4.40-4.25 (m, 1H), 4.22-4.09 (m, 1H), 4.043.95 (m, 2H), 3.93 (dt, J = 13.1, 4.8 Hz, 1H), 3.70 (s , 3H), 3.58 (dd, J = 13.1, 7.9 Hz, 1H), 3.51-3.37 (m, 1H), 3.03 (t, J = 7.9 Hz, 2H), 2.69 (t, J = 7.8 Hz, 2H) , 2.24-2.11 (m, 1H) , 2.05-1.97 (m, 1H) , 1.97-1.84 (m, 1H) , 1.76-1.66 (m, 1H) , 1.37 (t, J = 6.9 Hz, 3H) Step 2: (R)-3-(3-(2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl acid Methyl propanoic (R)-3-(3-(2-((6-(3-(2-Ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)propanoate (0.090 g, 0.163 mmol) obtained in step 1 was dissolved in methanol (0.813 mi) and THE (0.813 mi), and then 7 N aqueous sodium hydroxide solution (0.232 mi, 1.626 mmol) was added thereto and stirred at room temperature for 4 hours. After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The title product was obtained by purification with a silica gel column. (29% yield) m / z (M+H)+calculated for C31H34N5O4: 540, found 540 Example 47: (R)-3-(3-(5-((6-(3-(2-ethoxyphenoxy)piperidin l-yl)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-acid 2,2-dimethyl224 ccz / nn / zznz / E / Y propanoic The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (20.3 mg, 0.0610 mmol) prepared in Example Preparation 1 and methyl 3-(3-(5aminopyridin-3-yl)phenyl)-2,2-dimethylpropanoate (17.3 mg, 0.0610 mmol) prepared in Preparation Example 83. (2-step yield of 29%)XH -NMR (400 MHz, CHLOROFORM-D) δ 8.50 (s, 1H), 8.24 (d, J = 17.4 Hz, 2H), 7.81 (s, 1H), 7.47 (s, 1H), 7.43 (s, 1H) , 7.32 (t, J = 7.5 Hz, 2H) , 7.24 (s, 1H), 7.14 (d, J = 7.3 Hz, 1H) , 6.90 (d, J = 7.8 Hz, 1H) , 6.84 (t, J = 7.8 Hz, 1H), 6.77 (d, J = 6.9 Hz, 1H), 6.74-6.61 (1H), 4.40 (s, 1H), 4.04-3.70 (m, 4H), 3.59 (d, J = 12.8 Hz, 1H), 3.48 (d, J = 6.9 Hz, 1H), 3.06-2.80 (m, 2H), 2.15-1.81 (m, 3H), 1.56 (d, J = 4.6 Hz, 1H), 1.32-1.30 (3H) ), 1.29 (d, J = 3.7 Hz, 6H) Example 48: (R)-3-(3-(5-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid ,2-dimethylpropanoic acid 225 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner as in Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (51.9 mg, 0.155 mmol) prepared in the Preparation Example 1 and methyl 3-(3-(5aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (44.2 mg, 0.155 mmol) prepared in Preparation Example 102. (2-step yield of 60% )XH-NMR (400 MHz, CHLOROFORM-D) £ 8.54 (d, J = 2.7 Hz, 1H), 7.87-7.70 (m, 3H), 7.41 (s, 1H), 7.40-7.31 (m, 2H), 7.20 (d, J= 7.3 Hz, 1H), 7.14 (s, 1H), 6.98-6.84 (m, 3H), 6.84-6.74 (m, 1H), 6.70 (s, 1H), 4.37-4.19 (1H) , 4.11-3.94 (m, 2H) , 3.943.84 (m, 1H) , 3.62-3.53 (m, 1H) , 3.49 (dd, J = 12.6, 7.5 Hz, 1H) , 3.31-3.15 (m, 1H) , 2.99 (dd, J = 19.7, 13.3 Hz, 2H) ,2.05 (d, J = 4.6 Hz, 1H) , 2.00-1.90 (m, 1H) , 1.90-1.77 (m,1H), 1.64-1.48 (m, 1H), 1.35 (t, J = 7.1 Hz, 3H), 1.30 (d, J = 4.6 Hz, 6H) Example 49: (K)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-2-methylpropanoic acid a The title compound was obtained in a similar manner as in Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (137 mg, 0.409 mmol) prepared in Example of Preparation 1 and methyl 2-(6-aminopyridin-3226 ccz / nn / zznz / E / Y il)-2-methylpropanoate (79.5 mg, 0.409 mmol) prepared in Preparation Example 19. (yield of 2 steps of 30%) !H-NMR (400 MHz, CHLOROFORM-D) δ 10.36 (s, 1H), 8.21 (s, 1H), 8.07 (d, J = 9.1 Hz, 1H), 7.71 (s, 1H), 7.67 -7.51 (2H), 7.06-6.70 (m, 4H), 4.42-4.25 (m, 1H), 4.19 (dd, J = 13.0, 3.4 Hz, 1H), 4.09-3.89 (m, 2H), 3.81 (td, J = 8.8, 4.1 Hz, 1H), 3.42 (dd, J = 12.8, 8.2 Hz, 1H), 3.36-3.21 (m, 1H ), 2.17 (t, J = 6.2 Hz, 1H), 2.01 (dd, J = 9.6, 3.7 Hz, 1H), 1.95-1.78 (m, 1H), 1.77-1.46 (m, 7H), 1.44-1.19 ( m, 3H) Example 50: (K)-2-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-2-methylpropanoic acid The title compound was obtained in the same manner as in Example 1 by using (.R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (56.1 mg, 0.168 mmol) prepared in Preparation Example 1 and ethyl 2-(6-aminopyridin-2yl)-2-methylpropanoate (35.0 mg, 0.168 mmol) prepared in Preparation Example 61. (2-step yield of 39%) MHz, CHLOROFORM-D) δ 8.05 (s, 1H), 7.65 (s, 1H), 7.62-7.49 (m, 2H), 7.45 (d, J = 8.7 Hz, 1H), 7.06-6.73 (m, 5H) , 4.41-4.22 (m, 1H) , 4.11 (dd, J = 13.0, 3.4 Hz, 1H) , 227 ccz / nn / zznz / E / Y 4.06-3.87 (m, 2H), 3.77 (td, J= 8.9, 4.1 Hz, 1H), 3.51 (dd, J = 13.3, 7.8 Hz, 1H), 3.44-3.26 (m, 1H), 2.24-2.10 ( m, 1H), 2.04-1.94 (m, 1H), 1.94-1.79 (m, 1H), 1.65 (d, J = 2.7 Hz, 6H), 1.63-1.44 (m, 1H), 1.40-1.30 (m, 3H) Example 51: (R)-3-(6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-2,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (151 mg, 0.451 mmol) prepared in Example 22. Preparation 1 and tert-butyl 3-(6-aminopyridin-2yl)-2,2-dimethylpropanoate (113 mg, 0.451 mmol) prepared in Preparation Example 62. (2-step yield of 27%)XH-NMR ( CHLOROFORM-D) δ 9.67 (s, 1H), 7.91 (d, J= 8.2 Hz, 1H), 7.61 (s, 1H), 7.56 (s, 1H), 7.42 (t, J= 7.9 Hz, 1H), 7.04-6.90 (m, 2H), 6.87 (d, J = 7.6 Hz, 1H), 6.80 (t, J = 7.6 Hz, 1H), 6.69 (d, J = 7.3 Hz, 1H), 4.28 (td, J = 8.1, 4.0 Hz, 1H), 4.23-4.14 (m, 1H), 4.05-3.90 (m, 2H), 3.81 (q, J= 4.4 Hz, 1H), 3.37 (dd, J= 13.0, 8.1 Hz, 1H), 3.26 (t , J= 9.9 Hz, 1H), 2.99 (t, J = 14.5 Hz, 2H), 2.18-2.11 (m, 1H), 1.97 (dd, J = 9.2, 4.0 Hz, 1H), 1.92-1.78 (m, 1H), 1.72-1.54 (m, 1H), 1.36 (t, J = 6.9 Hz, 3H), 1.26 (d, J = 4.0 Hz, 6H) 228 ccz / nn / zznz / E / Y Example 52: 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)pyrrolidine-3-carboxylic acid similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.093 g, 0.280 mmol) prepared in Preparation Example 1 and 1-(6-aminopyridin Methyl -2yl)pyrrolidine-3-carboxylate (0.065 g, 0.294 mmol) prepared in Preparation Example 38. (22% yield) (s, 1H), 7.33 (t, J= 7.9 Hz, 1H), 7.09-6.92 (m, 2H), 6.92-6.81(m, 2H), 6.42 (d, J= 6.4 Hz, 1H), 5.94 (d, J= 8.2 Hz, 1H), 4.404.25 (1H), 4.16 (d, J = 12.8 Hz, 1H), 4.10-3.97 ( 2H), 3.92(t, J = 9.0 Hz, 1H), 3.88-3.77 (m, 2H), 3.68-3.55 (m,1H), 3.52-3.42 (m, 2H), 3.42-3.29 (m, 1H), 3.23 (t, J = 7.0Hz, 1H), 2.40 (dt, J = 20.0, 7.6 Hz, 1H), 2.30 (td, J= 12.2, 7.0 Hz, 1H), 2.23-2.13 (m, 1H), 2.05-1.95 (m,1H), 1.95- 1.81 (m, 1H), 1.76-1.50 (m, 1H), 1.39 (t, J =7.0 Hz, 3H) Example 53: 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-3-methylpyrrolidine-3carboxylic acid 229 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 1 by using (R)-2-cioro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.068 g, 0.202 mmol) prepared in Example of Preparation 1 and methyl 1-(6-aminopyridin-2yl)-3-methylpyrrolidine-3-carboxylate (0.050 g, 0.213 mmol) prepared in Preparation Example 49. (40% yield) ^-NMR (500MHz, CHLOROFORM-D) δ 11.21-9.78 (1H), 8.62 (d, J = 16.5 Hz, 1H), 7.75-7.62 (m, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.04-6.99 (m , 1H) , 6.99-6.93 (m, 1H) , 6.93-6.83 (2H) , 6.48-6.32 (m, 1H) , 6.02-5.86 (m, 1H) , 4.40-4.24 (m, 1H) , 4.17 (dd , J = 13.1, 3.1 Hz, 1H) , 4.12-3.91 (m, 3H) , 3.82 (td, J = 8.8, 4.1 Hz, 1H) , 3.66-3.53 (m, 2H) , 3.50 (s, 1H) , 3.48 (t, J = 6.7 Hz, 1H), 3.43-3.25 (m, 1H), 2.70-2.53 (m, 1H), 2.16 (dd, J = 12.4, 5.6 Hz, 1H), 2.03-1.80 (m, 3H), 1.75-1.57 (m, 1H), 1.47 (s, 3H), 1.39 (t, J = 6.9 Hz, 3H) Example 54: 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3-carboxylic acid Stage 1: 1-(6-( (6-( (R)-3-(2-Ethoxyphenoxy)piperidin-1ccz / nn / zznz / E / Y 230 ethyl il)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3-carboxylate The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.224 g, 0.670 mmol) prepared in Example of Preparation 1 and ethyl 1-(6-aminopyridin-2-yl)piperidine-3carboxylate (0.192 g, 0.770 mmol) prepared in Preparation 65. (38% yield)XH-NMR (CHLOROFORM-D) δ 8.14 ( d, J = 23.8 Hz, 1H), 7.73-7.57 (1H), 7.42-7.32 (1H), 7.03 (d, J= 7.9 Hz, 1H), 6.97 (t, J = 7.6 Hz, 1H), 6.94- 6.77 (m, 3H), 6.70 (d, J = 7.9 Hz, 1H), 6.27 (d, J = 8.2 Hz, 1H), 4.32 (d, J = 10.4 Hz, 2H), 4.264.09 (m, 4H) ), 4.09-3.93 (m, 2H), 3.88 (d, J = 12.8 Hz, 1H), 3.42 (dd, J = 13.0, 8.1 Hz, 1H), 3.36-3.23 (m, 1H), 3.23-3.08 ( m, 1H), 3.00 (t, J = 11.9 Hz, 1H), 2.68-2.50 (1H), 2.19 (d, J = 7.3 Hz, 1H), 2.09 (d, J = 13.1 Hz, 1H), 1.99 ( d, J = 9.8 Hz, 1H), 1.94-1.84 (m, 1H), 1.84-1.70 (m, 2H), 1.70-1.48 (m, 2H), 1.40 (t, J = 6.9 Hz, 3H), 1.34 -1.12 (m, 3H) Stage 2: 1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3carboxylic acid Ethyl 1-(6-((6-((R)-3-(2-Ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-3-carboxylate (0.140 g, 0.256 mmol) obtained in stage 1 was dissolved in ethanol (1,280 ml) and THF (1,280 ml), and then added to the 231 ccz / nn / zznz / E / Y same 6N aqueous sodium hydroxide solution (0.427 ml, 2.56 mmol) and stirred at room temperature for 6 hours. After removing the solvent under reduced pressure, it was dissolved in ethyl acetate and washed with water. The title product was obtained by purification with a silica gel column. (52% yield) m / z (M+H)+calculated for C28H35N6O4: 519, found 519 Example 55: (R)-1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-3 acid -carboxylic ethyl piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-3carboxylate The desired product was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazine (0.370 g, 1.108 mmol) prepared in Example of Preparation 1 and ethyl (R)-1-(6-aminopyridin-2-yl)piperidine-3-carboxylate (0.290 g, 1.163 mmol) prepared in Preparation Example 31. (33% yield)XH-NMR (500 MHz, CHLOROFORM-D) δ 8.13 (s, 1H), 7.65 (s, 1H), 7.37 (t, J= 7.9 Hz, 1H), 7.08-6.84 (m, 4H), 6.78-6.64 (m, 2H), 6.28 (d, J = 8.2 Hz, 1H), 4.42-4.27 (m, 2H), 4.27-4.09 232 ccz / nn / zznz / E / Y (m, 4H), 4.04 (t, J = 6.0 Hz, 2H), 3.91 (s, 1H), 3.43 (dd, J = 13.0, 8.1 Hz, 1H), 3.31 (s, 1H), 3.24-3.09 (m, 1H), 3.01 (s, 1H), 2.60 (s, 1H), 2.19 (s, 1H), 2.10 (d, J = 27.2 Hz, 1H), 2.05-1.95 (1H), 1.95-1.85 (1H), 1.81 (d, J = 13.4 Hz, 2H), 1.66 (s, 2H), 1.46-1.38 (3H), 1.30 (t, J = 7.2 Hz, 3H ) Step 2: (R)-1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin acid -3carboxylic The title compound was obtained in a similar manner to Step 2 of Example 54 by using (R)-1-(6-((6((R)-3-(2-ethoxyphenoxy)piperidin-1-yl)pyrazin Ethyl -2-yl)amino)pyridin-2-yl)piperidin-3-carboxylate (0.200 g, 0.366 mmol) obtained in step 1. (30% yield) m / z (M+H)+ calculated for C28H35N6O4: 519, found 519 Example 56: (R)-1-(6-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidine-4-carboxylic acid similar to Example 1 by using (R)-2-chloro-6-(3-(2 ethoxyphenoxy)piperidin-l-yl)pyrazine (0.306 g, 0.917 mmol) prepared in Preparation Example 1 and 1-(6- Ethyl aminopyridin-2yl)piperidine-4-carboxylate (0.240 g, 0.963 mmol) 233 ccz / nn / zznz / E / Y prepared in Preparation Example 29. (38% yield)XH-NMR (500MHz, CHLOROFORM-D) δ 8.66 (s, 1H), Ί.ΙΟΊ 62 (1H), 7.39 (t, J = 7.9 Hz, 1H), 7.05-6.87 (m, 4H), 6.73 (s, 1H), 6.25 (q, J = 4.1 Hz, 2H), 4.43-4.28 (m , 1H), 4.24 (dd, J = 12.8, 4.3 Hz, 2H) , 4.15 (q, J = / .2 Hz, 2H) , 3.82 (d, J = 18.3 Hz, 1H) , 3.54 (dd, J = 12.8, 7.6 Hz, 1H), 3.46-3.30 (m, 1H), 3.04 (t, J= 11.4 Hz, 2H), 2.60 (d, J= 10.7 Hz, 1H), 2.16 (d, J = 12.2 Hz, 3H), 2.02 (s, 1H), 1.96-1.79 (m, 3H), 1.65 (s, 1H), 1.40 (t, J = 7.0 Hz, 3H) Example 57: (R) -2-(1- (6- ( (6- (3- (2-eth.oxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin- acid 4-yl)acetic The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.237 g, 0.710 mmol) obtained in Example Preparation 1 and ethyl 2-(1-(6-aminopyridin2-yl)piperidin-4-yl)acetate (0.17 g, 0.646 mmol) obtained in Preparation Example 36. (2-step yield of 11%)1H- NMR (400 MHz, CHLOROFORM-D) δ 8.25 (d, J= 15.6 Hz, 1H), 7.63-7.54 (m, 1H), 7.33 (t, J = 8.2 Hz, 1H), 7.05-6.90 (m, 2H), 6.90-6.78 (m, 2H), 6.58 (d, J = 7.8 Hz, 1H), 6.24-6.16 (m, 1H), 5.28 (s, 1H), 4.39-4.25 (m, 1H), 4.24-4.10 (m, 3H), 4.07ccz / nn / zznz / E / Y 3.91 (m, 2H), 3.88-3.75 (m, 1H), 3.53-3.36 (1H), 3.36-3.24 (m, 1H), 2.86 (t, J = 11.7 Hz, 2H), 2.37-2.20 (m, 2H) m, 5H) Example 58: (K)-2-(l-(6-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-4-acid il)-2-methylpropanoic acid The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.093 g, 0.278 mmol) obtained in Example 12. Preparation 1 and methyl 2-(1-(6-aminopyridin2-yl)piperidin-4-yl)-2-methylpropanoate (0.07 g, 0.252 mmol) obtained in Preparation Example 34. (2-step yield of 49% )XH-NMR (400 MHz, CHLOROFORM-D) δ 8.20 (s, 1H) 7.59 (s, 1H), 7.38 (s, 1H), 7.32 (g, J = 8.1 Hz, 1H), 7.04-6.90 (m, 2H), 6.90-6.79 (2H), 6.64 (d, J = 7.8 Hz, 1H), 6.20 (d, J = 8.2 Hz, 1H), 4.29 (q, J = 4.1 Hz, 3H), 4.22-4.13 ( m, 1H), 4.06-3.91 (m, 2H), 3.82 (q, J= 4.4 Hz, 1H), 3.42 (dd, J = 13.0, 8.0 Hz, 1H), 3.36-3.23 (1H), 2.86-2.69 (m, 2H), 2.23-2.10 (m, 1H), 1.96 (dd, J = 9.6, 3.7 Hz, 1H), 1.91-1.77 (m, 2H) , 1.72 (d, J = 11.9 Hz, 2H), 1.67-1.52 (m, 1H), 1.52-1.40 (m, 1 HOUR) , 1.40235 ccz / nn / zznz / E / Y 1.29 (m, 3H), 1.24 (q, J = 7.3 Hz, 1H), 1.15 (d, J = 16.9 Hz, 6H) Example 59: 2-(((S)-1-(6-((6-((R)-3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)piperidin-3-yl)acetic acid The desired title compound was obtained in a similar manner to Example 19 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (0.047 g, 0.139 mmol) prepared in Example Preparation Example 1 and (5)-2-((1-(6aminopyridin-2-yl)piperidin-3-yl)oxy)tert-butyl acetate (0.045 g, 0.146 mmol) prepared in Preparation Example 45. ( Yield 11.4%) (t, J= 7.3 Hz, 2H), 6.34 (s, 1H), 6.25-6.15 (1H), 4.78-4.44 (1H), 4.31 (s, 2H), 4.19-4.06 (2H), 4.06-3.93 ( 2H), 3.77 (s, 1H), 3.64 (s, 1H), 3.59-3.44 (m, 2H), 3.44-3.28 (1H), 3.15 (s, 1H), 3.00 (s, 1H), 2.13 (s, 1H), 2.08 (d, J = 13.1 Hz, 1H), 2.021.93 (1H), 1.93-1.80 (2H), 1.60 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H) Example 60: (R)-2-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid -methylpropanoic acid 236 ccz / nn / zznz / E / Y The desired title compound was obtained in a similar manner to Example 1 by using (R)-2-cioro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (74.1 mg, 0.222 mmol) prepared in Example of Preparation 1 and methyl 2-(3-(6aminopyridin-2-yl)phenyl)-2-methylpropanoate (60.0 mg, 0.222 mmol) prepared in Preparation Example 52. (2-step yield of 66%)XH- NMR (400 MHz, CHLOROFORM-D) δ 8.84 (s, 1H), 8.23 ​​(s, 1H), 7.68 (d, J = 9.1 Hz, 2H), 7.59 (t, J = 8.0 Hz, 1H), 7.51- 7.36 (m, 2H), 7.33 (s, 1H), 7.28 (s, 1H), 7.05-6.92 (m, 3H), 6.88 (dq, J = 9.7, 1.9 Hz, 2H), 4.33 (td, J= 7.8, 3.8 Hz, 1H), 4.14 (dd, J = 12.8, 3.2 Hz, 1H), 4.08-3.90 (2H), 3.82 (q, J= 4.4 Hz, 1H), 3.52 (dd, J = 12.8, 7.8 Hz, 1H), 3.46-3.28 (m, 1H), 2.00 (d, J= 9.6 Hz, 2H), 1.95-1.80 (m, 1H), 1.74-1.53 ​​(m, 7H), 1.38 (t, J = 7.1Hz, 3H) Example 61: (R)-2-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid -methylpropanoic acid similar to Example 1 when using (R)-2-chloro-6-(3-(2 237 ethoxyphenoxy)piperidin-l-yl)pyrazine (61.7 mg, 0.185 mmol) prepared in Preparation Example 1 and methyl 2-(4-(6-aminopyridin-2-yl)phenyl)-2-methylpropanoate (50.0 mg , 0.185 mmol) prepared in Preparation Example 54. (2-step yield of 16%) (m, 3H), 7.68 (s, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.47 (d, J= 8.2 Hz, 2H), 7.16 (d, J= 7.3 Hz, 1H), 7.086 .74 (m, 4H), 4.43-4.26 (m, 1H), 4.20 (dd, J = 13.3, 3.2Hz, 1H), 4.11-3.93 (m, 2H), 3.85 (q, J = 4.4 Hz, 1H), 3.49 (dd,J = 13.0, 8.0 Hz, 1H), 3.43-3.26 (m, 1H), 2.28-2.09 (m, 1H), 2.09- 1.97 (m, 1H) , 1.96-1.80 (m, 1H) , 1.78-1.65 (m, 1H) , 1.63(s, 6H), 1.38 (t, J= 6.9 Hz, 3H) Example 62: (R)-2-(4-(6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)phenyl)-2methylpropanoic acid The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (0.272 g, 0.814 mmol) obtained in Preparation Example 3 and methyl 2-(4-(6aminopyridin-2-yl)phenyl)-2-methylpropanoate (0.2 g, 0.740 mmol) obtained in Preparation Example 54. 238 ccz / nn / zznz / E / Y (43% 2-stage performance) , 2H) , 7.65-7.49 (m, 3H) , 7.46 (dd, J = 8.7, 2.3 Hz, 2H), 7.29 (ddd, J = 19.4, 7.8, 2.5 Hz, 2H), 7.07- 6.94 (m, 1H), 6.82-6.64 (m, 1H), 5.18 (d, J = 2.7 Hz, 1H), 4.12-4.02 (m, 2H), 3.90-3.79 (m, 2H), 3.79-3.69 (m, 2H), 3.66- 3.48 (1H), 2.20-2.00 (m, 2H), 1.96 (d, J = 4.6 Hz, 1H), 1.ΙΟΙ. 60 (1H), 1.57 (d, J = 2.3 Hz, 6H), 1.22-1.19 (m, 3H) Example 63: (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid ,2-dimethylpropanoic acid similar to Example 22 when using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (81.0 mg, 0.242 mmol) prepared in Preparation Example 1 and 3-(3-( Tert-butyl 6-aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (79.0 mg, 0.242 mmol) prepared in Preparation Example 113. (2-step yield of 77%) 1H-NMR (400 MHz , CHLOROFORM-D) £ 9.57 (s, 1H) ,8.22 (s, 1H) , 7.68 (d, J = 7.8 Hz, 1H) , 7.65 (s, 1H) , 7.60 (t,J = 7.8 Hz, 1H), 7.33 (t, J = 7.5 Hz, 2H), 7.15 (d, J = 7.8Hz, 1H), 7.08-6.82 (4H), 6.78 (s, 1H), 6.58 (d, J = 8.2 Hz,1H), 239 ccz / nn / zznz / E / Y 4.42- 4.23 (m, 1H), 4.17-4.04 (m, 1H), 4.04-3.88 (m, 2H), 3.80 (dt, J = 13.3, 4.9 Hz, 1H), 3.56 (dd, J = 13.0, 7.5 Hz, 1H), 3.44-3.28 (m, 1H), 3.01 (s, 2H), 2.21-2.08 (m, 1H), 2.08-1.94 (m, 1H), 1.94-1.80 (m, 1H), 1.72- 1.50 (m, 1H), 1.38 (t, J = 7.1 Hz, 3H), 1.25 (s, 6H) Example 64: (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin acid -2-yl)phenyl)-2,2dime tiIpropanoic similar to Example 22 when using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (205 mg, 0.613 mmol) prepared in Preparation Example 3 and tert-butyl 3-(3-(6aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (200 mg, 0.613 mmol) prepared in Preparation Example 113. (2-step yield of 39%) -NMR (CHLOROFORM-D) δ 9.54 (s, 1H), 8.24 (s,1H), 7.77 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 4.6 Hz, 2H), 7.62 (t, J = 7.9 Hz, 1H), 7.36 (d, J = 7.6 Hz, 2H), 7.18 ( d, J = 7.6 Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 6.83 (dd, J = 7.6,5.2 Hz, 1H), 6.61 (s, 1H), 6.55 (d, J = 7.9 Hz, 1H), 5.305.14 (1H), 4.05-3.80 (4H), 3.80-3.68 (1H), 3.68-3.54 (1H ), 3.12-2.90 (2H), 2.28-2.12 (1H), 2.12-1.93 (2H),1.78240 ccz / nn / zznz / E / Y 1.63 (1Η), 1.33-1.29 (3H), 1.29-1.27 (3H), 1.27-1.24 (3H) Example 65: (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyridin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid ,2-dimethylpropanoic acid similar to Example 22 when using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyridine (204 mg, 0.613 mmol) prepared in Preparation Example 4 and 3-(3-( Tert-butyl 6aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (200 mg, 0.613 mmol) prepared in Preparation Example 113. (2-step yield of 12%)XH-NMR (400 MHz, METHANOL -D4) 5 7.80 (d, J = 8.7 Hz, 2H), 7.63-7.47 (m, 2H), 7.44 (t, J= 8.0 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 7.8 Hz, 2H), 7.04-6.70 (m, 5H), 6.28 (d, J = 8.2 Hz, 1H), 4.41-4.22 (m, 1H), 4.12 ( d, J = 11.4 Hz, 1H), 4.04-3.87 (m, 2H), 3.76 (d, J = 12.8 Hz, 1H), 3.47-3.32 (m, 2H), 2.96 (s, 2H), 2.15-2.03 (m, 1H), 1.94 (td, J = 6.6, 3.2 Hz, 1H), 1.88-1.72 (m, 1H), 1.71-1.53 ​​(m, 1H), 1.31 (t, J = 6.9 Hz, 3H), 1.21 (s, 6H) Example 66: (R)-3-(3-(6-((2-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)-2 acid ,2-dimethyl241 ccz / nn / zznz / E / Y propanoic similar to Example 22 when using (R)-4-chloro-2-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrimidine (205 mg, 0.613 mmol) prepared in Preparation Example 5 and 3-(3-( Tert-butyl 6aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (200 mg, 0.613 mmol) prepared in Preparation Example 113. (2-step yield of 49%)XH-NMR (CHLOROFORM-D) ¿8.28 (s, 1H), 7.98 (d, J = 5.8 Hz, 1H), 7.76 (s, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.45 (t, J = 7.3 Hz, 2H) , 7.33 (t, J = 7.6 Hz, 1H), 7.20 (d, J = 7.6 Hz, 1H) , 7.12 (d, J= 7.3 Hz, 1H) , 7.04 (d, J= 7.9 Hz, 1H) , 6.966 .86 (m, 2H), 6.83 (d, J= 7.6 Hz, 1H), 6.46 (s, 1H), 4.51 (d, J = 12.8 Hz, 1H), 4.39-4.24 (m, 1H), 4.19 ( q, J = 4.5 Hz, 1H), 4.08-3.86 (m, 2H), 3.48 (d, J= 21.4 Hz, 1H), 3.37 (d, J = 12.8 Hz, 1H), 2.96 (s, 2H), 2.20 (dd, J = 15.4, 4.1 Hz, 1H), 1.94 (dt, J = 9.2, 3.8 Hz, 1H), 1.88 (dd, J = 9.9, 3.5 Hz, 1H), 1.70-1.56 (m, 1H) , 1.37 (t, J= 6.9 Hz, 3H) , 1.24 (s, 6H) Example 67: (R)-3-(3-(6-((4-(3-(2-et.oxyphenoxy)piperidinl-yl)pyrimidin-2-yl)amino)pyridin-2-yl)phenyl acid) -2,2-dimethylpropanoic acid 242 ccz / nn / zznz / E / Y similar to Example 22 when using (R)-2-chloro-4-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrimidine (205 mg, 0.613 mmol) prepared in Preparation Example 6 and 3-(3-( Tert-butyl 6aminopyridin-2-yl)pheny1)-2,2-dimethylpropanoate (200 mg, 0.613 mmol) prepared in Preparation Example 113. (2-step yield of 46%) 1H-NMR (400 MHz, METHANOL -D4) δ 8.23 ​​(d, J = 6.4 Hz, 1H), 7.84 (s, 1H), 7.76 (t, J = 7.1 Hz, 2H), 7.48 (t, J = 7.3 Hz, 2H), 7.38 (t, J = 7.5 Hz, 1H), 7.28 (d, J = 7.8 Hz,1H), 7.00 (d, J = 7.3 Hz, 1H), 6.96-6.76 (m, 3H), 6.45 (d, J = 5.9 Hz, 1H), 4.55 (s, 1H), 4.28-4.01 (m, 2H), 4.01-3.73 (m,3H), 3.59 (d, J = 9.1 Hz, 1H), 2.95 (s, 2H), 2.15-1.98 (m,3H), 1.76-1.58 (m, 1H), 1.30 (t, J= 6.9 Hz, 3H), 1.21 (s, 6H) Example 68: acid (R)-3-(3-(6-((4-(3- ((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrimidin-2-yl)amino)pyridin-2-yl)phenyl)2,2-dimethylpropanoic similar to Example 22 when using (R)-2-chloro-4-(3-((3243 ccz / nn / zznz / E / Y ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrimidine (205 mg, 0.613 mmol) prepared in Preparation Example 7 and tert-butyl 3-(3-(6aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (200 mg, 0.613 mmol) prepared in Preparation Example 113. (29% 2-stage performance) , 1H) , 7.60 (s,1H) , 7.49 (d, J = 20.1 Hz, 1H), 7.36-7.27 (m, 2H), 7.21 (d, J = 7.3 Hz, 1H) , 6.98 (d, J = 7.3 Hz, 1H) , 6.69 (s, 1H) , 6.05 (s,1H) , 5.28 (t, J = 2.7 Hz, 1H), 4.09-3.82 (m, 4H), 3.70 (s, 2H),3.02 (d, J = 13.3 Hz, 2H), 2.16-1.94 (m, 3H), 1.69 (s, 1H), 1.30 (t, J= 7.1 Hz, 3H), 1.26 (d, J= 1.4 Hz, 6H) Example 69: (H)-3-(3-(3-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)-IH-pyrazol-l-yl)phenyl acid )-2,2-dimethylpropanoic acid similar to Example 22 when using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (0.10 g, 0.30 mmol) prepared in Preparation Example 1 and 3-(3-( Methyl 3-amino-lHpyrazol-l-yl)phenyl)-2,2-dimethylpropanoate (0.094 g, 0.30 mmol) obtained in Preparation Example 67. (40% yield) 244 ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D): δ 8.53 (s, 1H), 7.61 (s, 2H), 7.57 (s, 1H), 7.50 (s, 1H) , 7.35-7.27 (m, 2H) , 7.06 (t, J= 2.5 Hz, 1H), 7.00-6.88 (m, 2H), 6.88-6.72 (m, 2H), 6.51 (d, J = 2.3 Hz, 1H ), 4.25 (t, J = 3.9 Hz, 1H) , 4.21-4.14 (m, 1H) , 3.98 (qd, J = 6.9, 1.5 Hz, 2H) , 3.79 (q, J = 4.4 Hz, 1H) , 3.42 -3.17 (m, 2H), 2.99 (s, 2H), 2.20-2.08 (m, 1H), 1.99-1.77 (m, 2H), 1.64-1.54 (m, 1H), 1.35 (t, J = 7.1 Hz , 3H) , 1.26(s, 6H) Example 70: (R)-3-(3-(6-((2-(3-(2-ethoxyphenoxy)piperidinl-yl)-5-(trifluoromethyl)pyrimidin-4-yl)amino)pyridin-2- acid yl)phenyl)-2,2-dimethylpropanoic acid similar to Example 22 when using (R)-4-chloro-2-(3-(2ethoxyphenoxy)piperidin-l-yl)-5-(trifluoromethyl)pyrimidine (7 9 mg, 0.20 mmol) from Preparation Example 9 and 3 -(3-(6aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate tert-butyl (64 mg, 0.20 mmol) synthesized in Preparation Example 113. (2-step yield of 65%)1H-NMR (400 MHz, METHANOL-D4) δ 8.25 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.75 (s, 1H), 7.68 (s, OH), 7.44 (d, J = .1 Hz, 1H), 7.38-7.28 (1H), 7.24 (d, J = 7.8 Hz, 1H), .06-6.43 (m, 5H), 4.46 (s, 1H), 4.07 (q, J = 7.2 Hz, 245 ccz / nn / zznz / E / Y 2Η), 3.98-3.56 (m, 4H), 2.94 (s, 2H), 2.13-1.88 (m, 4H), 1.59 (d, J = 3.7 Hz, 1H), 1.21 (t, J = 7.1 Hz, 3H ), 1.18 (s, 6H) Example 71: (R)-3-(3-(6-( (4-(3-(2-ethoxyphenoxy)piperidinl-yl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)pyridin-2- acid yl)phenyl)-2,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-4-(3-(2ethoxyphenoxy)piperidin-l-yl)-5-(trifluoromethyl)pyrimidine (135 mg, 0.38 mmol ) synthesized in Preparation Example 10 and tert-butyl 3-(3-(6-aminopyridin-2-yl)phenyl)-2,2-dimethylpropanoate (110 mg, 0.238 mmol) synthesized in Preparation Example 113. (2-stage performance of 18%) 2.7 Hz, 1H), 7.91 (q, J = 1.4 Hz, 1H), 7.33-7.19 (m, 3H), 7.19-7.06 (m, 4H), 7.01 (t, J = 7.5 Hz, 1H), 3.99 ( q, J = 7.0 Hz, 2H), 3.72 (s, 2H), 2.82 (s, 2H), 1.18-1.01 (m, 9H) Example 72: (R)-3-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2 acid ,2-dimethylpropanoic acid 246 ccz / nn / zznz / E / Y in a manner similar to Example 22 by using (R)-2-cioro-6-(3-(2 ethoxyphenoxy)piperidin-l-yl)pyrazine (146 mg, 0.438 mmol) prepared in Preparation Example 1 and 3- Tert-butyl (4-(6aminopyridin-2-yl)pheny1)-2,2-dimethylpropanoate (143 mg, 0.438 mmol) prepared in Preparation Example 77. (2-step yield of 71%)XH-NMR ( 400 MHz, CHLOROFORM-D) δ 8.16 (s, 1H),8.02 (s, 1H), 7.85 (d, J = 8.2 Hz, 2H), 7.67 (s, 1H), 7.55 (q,J = 8.1 Hz, 1H), 7.48 (d, J= 8.2 Hz, 1H), 7.40-7.29 (m, 2H), 7.247.15 (m, 1H), 7.08-6.76 (m, 4H), 4.32 (td, J = 7.9, 4.0Hz, 1H), 4.18 (dd, J = 13.5, 3.4 Hz, 1H), 4.07-3.91 (m, 2H) ,3.83 (td, J = 9.0, 4.1 Hz, 1H), 3.48 (dd, J = 13.0, 8.0 Hz ,1 HOUR) , 3.42-3.25 (m, 1H), 2.94 (s, 2H), 2.27-2.11 (m, 1H), 2.04-1.95 (m, 1H), 1.95-1.79 (m, 1H), 1.76-1.53 ​​(m, 1H) ), 1.37 (t, J = 7.1 Hz, 3H), 1.24 (s, 6H) Example 73: (K)-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine 247 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (70 mg, 0.21 mmol) synthesized in Example 22. Preparation 1 and ethyl (4-(6aminopyridin-2-ii)phenyl)glycinate (57 mg, 0.21 mmol) synthesized in Preparation Example 100. (2-step yield of 25%)XH-NMR (400 MHz, METHANOL -D4) £8.20 (s, 1H), 7.90-7.75 (2H), 7.49 (s, 1H), 7.47 (d, J= 8.5 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 7.21 (d, J = 7.8 Hz, 1H) , 6.98 (d, J = 7.8 Hz,2H) , 6.88 (d, J = 4.1 Hz, 3H), 6.81 (dt, J = 8.7, 3.9 Hz, 1H), 6.65 (d, J = 8.7 Hz, 2H), 4.40 (t, J = 3.4 Hz, 1H), 4.14-3.81 (m, 4H), 3.71 (d, J = 6.9 Hz, 1H), 3.68 (s, 2H), 3.67-3.55 (m,2H), 2.22-1.90 (m, 3H), 1.70-1.50 (m, 1H), 1.34-1.22 (m, 3H) Example 74: (R) - (4- (6- ( (6-(3-((3-ethoxypyridin-2-yl)oxy) piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2- il)phenyl)glycine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (58 mg, 0.17 mmol) synthesized in Preparation Example 3 and ethyl (4-(6aminopyridin-2-yl)phenyl)glycinate (47 mg, 0.17 mmol) 248 ccz / nn / zznz / E / Y synthesized in Preparation Example 100. (2-step yield of 21%)XH-NMR (400 MHz, METHANOL-D4) £8.19 (s, 1H), 7.82 (d, J = 8.7 Hz, 2H), 7.58 (q, J = 2.3 Hz, 1H), 7.51 (s, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.18 (q, J = 7.9 Hz, 2H) , 7.02 (dd, J = 7.8, 1.4 Hz, 1H), 6.72 (dd, J = 7.8, 5.0 Hz, 1H), 6.65 (d, J = 8.7 Hz, 2H), 5.18 (q, J= 2.9 Hz, 1H), 4.07 (dd, J= 13.7, 5.5 Hz, 1H), 3.93-3.76 (m, 5H), 3.73 (d, J = 7.3 Hz, 2H), 3.69-3.51 (m, 1H), 2.19-1.95 (m, 4H), 1.63 (dd, J = 9.5, 6.5 Hz, 1H) , 1.21 (t, J = 7.1 Hz, 3H) Example 75: (R)-(4-(6-((2-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)glycine The title compound was obtained in a similar manner to Example 1 by using (R)-4-chloro-2-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrimidine (58 mg, 0.17 mmol) synthesized in Example Preparation 5 and ethyl (4-(6aminopyridin-2-yl)phenyl)glycinate (47 mg, 0.17 mmol) synthesized in Preparation Example 100. (2-step yield of 18%)XH-NMR (400 MHz, METHANOL -D4) δ 7.98-7.85 (m, 2H), 7.81 (d, J = 9.1 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.39 (d, J = 8.2 249 ccz / nn / zznz / E / Y Hz, 1H), 7.31 (d, J = 7.3 Hz, 1H), 6.95 (d, J = 6.9 Hz, 1H), 6.92-6.80 (m, 3H), 6.80-6.68 (m, 2H), 6.66 (d , J = 8.7 Hz, 2H), 4.41 (q, J = 3.2 Hz, 1H), 4.06-3.98 (1H), 3.97-3.84 (4H), 3.83 (s, 2H), 3.79 (d, J = 13.7 Hz, 2H), 2.121. 84 (m, 4H), 1.67-1.51 (m, 1H), 1.26 (t, J = 6.9 Hz, 3H) Example 76: (R) - (4-(6-( (4-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-4-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrimidine (58 mg, 0.17 mmol) synthesized in Example Preparation 6 and ethyl (4-(6aminopyridin-2-yl)phenyl)glycinate (47 mg, 0.17 mmol) synthesized in Preparation Example 100. (2-step yield of 11%)XH-NMR (400 MHz, METHANOL -D4) δ 7.89 (d, J = 6.4 Hz, 1H), 7.65 (d, J = 8.2 Hz, 3H), 7.31 (d, J = 8.2 Hz, 1H), 7.18 (s, 1H), 6.96 (d , J= 8.2 Hz, 1H), 6.92-6.73 (m, 3H), 6.74-6.56 (2H), 6.39 (s, 1H), 4.51 (s, 1H), 4.30-3.98 (m, 1H), 3.97- 3.81 (m, 2H), 3.79 (s, 1H), 3.67 (d, J = 7.8 Hz, 2H), 3.50 (dd, J = 11.4, 6.9 Hz, 1H), 2.00 (s, 3H), 1.59 (q , J = 7.5 Hz, 1H) , > you N C N N 250 1.29-1.18 (m, 3H) Example 77: (K)-2-((4-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)amino acid )-2methylpropanoic acid N N N N IH title compound was obtained in a similar manner to Example 1 by using (.R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) synthesized in Example of Preparation 1 and ethyl 2-((4-(6aminopyridin-2-yl)phenyl)amino)-2-methylpropanoate (146 mg, 0.49 mmol) synthesized in Preparation Example 98. (2-step yield of 74% )XH-NMR (400 MHz, METHANOL-D4) δ 8.29 (s, 1H), 7.80 (d J= 8.2 Hz, 2H), 7.52-7.39 (2H), 7.24-7.12 (m, 2H), 6.97 (d, J = 8.2 Hz, 1H), 6.87 (d, J = 4.1 Hz, 2H), 6.84- 6.72 (m, 1H), 6.59 (d, J = 8.2 Hz, 2H), 4.38 (t, J = 3.2 Hz, 1H), 4.14 (q, J = 7.0 Hz, 2H), 4.02-3.79 (m, 3H), 3.68 (q, J = 6.7 Hz, 1H), 3.62 (s, 2H), 2.05 (d, J = 12.3 Hz, 2H), 1.88 (d, J = 10.5 Hz, 1H), 1.60 (s, 1H), 1.52 (d, J= 4.1 Hz, 7H), 1.34-1.23 (m, 3H), 1.19-1.15 (m, 3H) Example 78: (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenyl acid )-2,225 dime tiIpropanoic 251 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (73 mg, 0.22 mmol) synthesized in Example 22. Preparation 1 and tert-butyl 3-(3-(6aminopyridin-2-yl)-4-fluorophenyl)-2,2-dimethylpropanoate (69 mg, 0.20 mmol) synthesized in Example Preparation 89. (2-stage yield of 81%) = 8.0 Hz, 1H), 7.53 (s, 1H), 7.38-7.24 (m, 2H), 7.24-7.15 (m, 1H), 7.06 (dd, J = 11.2, 8.5 Hz, 1H), 6.98 (d, J= 7.3 Hz, 1H), 6.93-6.86 (m, 2H), 6.86-6.74 (m, 1H), 4.48-4.33 (m, 1H), 4.00-3.78 (m, 3H), 3.72 (q, J = 6.6 Hz, 1H), 3.64 (t, J= 5.5 Hz, 2H), 2.91 (s, 2H), 2.14-1.99 (m, 2H), 1.89 (d, J = 8.2 Hz, 1H), 1.61 (d, J = 5.9 Hz, 1H), 1.26 (t, J= 7.1 Hz, 4H), 1.18 (s, 6H) Example 79: (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)-4fluorophenyl)-2,2-dimethylpropanoic acid The title compound was obtained in a manner 252 ccz / nn / zznz / E / Y similar to Example 22 when using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (73 mg, 0.22 mmol) synthesized in Preparation Example 3 and tert-butyl 3-(3-(6aminopyridin-2-yl)-4-fluorophenyl)-2,2-dimethylpropanoate (69 mg, 0.20 mmol) synthesized in Preparation Example 89 (2-stage performance of 98%)XH-NMR (400 MHz, METHANOL-D4) 7.41-7.31 (m, 1H), 7.26 (s, 1H) , 7.19 (d, J= 8.2 Hz, 1H) , 7.13 (dd, J = 11.2, 8.5 Hz,1H) , 7.01 (dd, J = 7.8, 1.4 Hz, 1H), 6.78-6.62 (1H), 5.15 (s, 1H), 4.19-4.09 (m, 1H), 3.97-3.85 (m, 1H), 3.85-3.72 ( m, 2H), 3.69 (d, J = 12.8 Hz, 1H), 3.57 (d, J = 9.6 Hz, 1H), 2.93 (s,2H), 2.15-1.99 (m, 3H), 1.62 (d, J = 6.4 Hz, 1H), 1.25-1.15 (m,9H) Example 80: (R)-2-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy)-2 acid -methylpropanoic acid similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-1-yl)pyrazine (111 mg, 0.333 mmol) prepared in Preparation Example 1 and 2-(3-( Ethyl 6aminopyridin-2-yl)phenoxy)-2-methylpropanoate (100 mg, 0.333 mmol) prepared in Preparation Example 88. (2-step yield of 61%) 253 ccz / nn / zznz / E / Y iH-NMR (400 MHz, CHLOROFORM-D) δ 9.42 (s, 1H), 7.99 (t, J = 2.1 Hz, 1H), 7.62 (t, J = 8.5 Hz, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.44-7.28 (m, 2H), 7.09-6.93 (m, 3H), 6.89 (qd, J = 7.5, 1.6 Hz, 2H), 6.79 (s , 1H), 6.61 (d, J = 7.8 Hz, 1H), 4.424.24 (m, 1H), 4.07 (dd, J = 13.3, 3.7 Hz, 1H), 4.04-3.88 (m, 2H), 3.87-3.70 (m, 1H), 3.58 (dd, J = 13.0, 7.5 Hz, 1H), 3.483.30 (m, 1H), 2.25-2.08 (1H), 2.08-1.95 (m, 1H) , 1.95-1.81 (m, 1H), 1.72-1.48 (m, 7H), 1.37 (t, J = 7.1 Hz, 3H) Example 81: (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)phenoxy)2-methylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (111 mg, 0.333 mmol) prepared in Preparation Example 3 and ethyl 2-(3-(6aminopyridin-2-yl)phenoxy)-2-methylpropanoate (100 mg, 0.333 mmol) prepared in Preparation Example 88. (2-step yield of 76%) (s, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.437.29 (m, 2H), 7.03 (dd, J = 7.8, 2.3 Hz, 1H), 6.94 (dd, J = 254 ccz / nn / zznz / E / Y 7.8, 1.4 Hz, 1H), 6.81 (dd, J = Ί.8, 5.0 Hz, 1H), 6.64 (s, 1H), 6.57 (d, J = 7.8 Hz, 1H), 5.23 (q, J = 3.5 Hz, 1H), 3.91 (d, J = 5.0 Hz, 2H), 3.90-3.79 (m, 2H), 3.72 (q, J = 3.7 Hz, 1H), 3.59 (t, J = 3.9 Hz, 1H), 2.16 (t, J = 4.3 Hz, 1H), 2.10-1.94 (m, 2H), 1.73-1.55 (m, / H), 1.2 / (t, J = 6.9 Hz, 3H) Example 82: (R)-2-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy)-acid 2-methylpropanoic acid similar to Example 1 by using (R)-2-chloro-6-(3-(2 ethoxyphenoxy)piperidin-l-yl)pyrazine (111 mg, 0.333 mmol) prepared in Preparation Example 1 and 2-(4- Ethyl (6aminopyridin-2-yl)phenoxy)-2-methylpropanoate (100 mg, 0.333 mmol) prepared in Preparation Example 97. (2-step yield of 69%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.07 (s, 1H),7.74 (d, J = 8.7 Hz, 2H), 7.67 (d, J = 6.4 Hz, 2H), 7.62-7.48(1H), 7.13 (d, J= 7.3 Hz, 1H), 7.09-7.01 (2H), 7.01-6.96 (1H),6.93 (td, J = 7.7, 1.4 Hz, 1H), 6.89-6.74 (m, 2H), 4.42 -4.24 (m, 1H), 4.14 (dd, J = 12.8, 3.2 Hz, 1H), 4.07-3.89 (m, 2H), 3.89-3.69 (m, 1H), 3.52 (dd, J = 12.8, 7.8 Hz) , 1H) ,3.443.27 (m, 1H) , 2.26-2.09 (m, 1H) , 2.09-1.96 (m, 1H) ,1.961.81 (m, 1H) , 1.64 (t, J = 16.0 Hz, 7H ), 1.36 (t, J = 6.9 Hz, ccz / nn / zznz / E / Y 3Η) Example 83: (B)-2-(4-(6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin acid -2-yl)phenoxy)-2methylpropanoic title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1- yl)pyrazine (111 mg, 0.333 mmol) prepared in Preparation Example 3 and ethyl 2-(4-(6aminopyridin-2-yl)phenoxy)-2-methylpropanoate (100 mg, 0.333 mmol) prepared in Example Preparation 97. (2-stage yield of 71%)XH-NMR (400 MHz CHLOROFORM-D) δ 8.05 (s, 1H) 7.75 (d, J = 9.1 Hz, 2H), 7.71 (s, 1H), 7.66-7.46 (m, 3H), 7.12 (d, J = 7.3 Hz, 1H), 7.05 (d, J = 8.7 Hz, 2H) ), 6.95 (dd, J = 7.8, 1.4 Hz, 1H), 6.70 (dd, J = 7.8, 5.0 Hz, 1H), 5.26 (t, J = 3.2 Hz, 1H), 3.99 (dd, J = 13.5, 3.0 Hz, 1H), 3.94-3.81 (m, 3H), 3.75 (d, J = 13.7 Hz, 1H), 3.65-3.46 (m, 1H), 2.27-2.11 (m, 1H), 2.11-1.89 (2H) ), 1.79-1.67 (m, 1H), 1.65 (d, J = 1.8 Hz, 6H), 1.38-1.19 (m, 3H) Example 84: (B)-2-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenoxy acid )-2methylpropanoic acid Ν Ν Ν I Η The title ccz / nn / zznz / E / Y compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (115 mg , 0.35 mmol) synthesized in Preparation Example 1 and methyl 2-(3-(6aminopyridin-2-yl)-4-fluorophenoxy)-2-methylpropanoate (100 mg, 0.31 mmol) synthesized in Preparation Example 92. (2-stage performance of 45%)1H-NMR (400 MHz METHANOL-D4) £8.30 (s, 1H), 7.67-7.47 (m, 3H), 7.35 (d, J = 8.2 Hz, 1H), 7.31 (dd, J = 7.5, 2.1 Hz, 1H), 7.08 (dd , J = 11.0, 9.1 Hz, 1H), 7.02-6.92 (m, 2H), 6.87 (d, J = 4.1 Hz, 2H), 6.81 (q, J = 4.0 Hz, 1H), 4.42 (s, 1H) , 4.01-3.82 (m, 3H), 3.76 (q, J = 6.7 Hz, 1H), 3.72-3.56 (m, 2H), 2.14-2.00 (2H), 1.91 (d, J = 8.7 Hz, 1H), 1.70-1.58 (m, 1H), 1.56 (s, 6H), 1.26 (t, J = 7.1 Hz, 3H) Example 85: (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)-4fluorophenoxy)-2-methylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R) -2-chloro-6-(3- ((3257 ccz / nn / zznz / E / Y ethoxypyridin-2-yl)oxy)piperidin- 1-yl)pyrazine (116 mg, 0.35 mmol) synthesized in Preparation Example 3 and ethyl 2-(3-(6aminopyridin-2-yl)-4-fluorophenoxy)-2-methylpropanoate (100 mg, 0.31 mmol) synthesized in Preparation Example 92. (2-step yield of 42%) = 8.2, 2.7 Hz, 2H), 7.17-6.99 (m, 2H), 6.95 (dt, J = 9.0, 3.5 Hz, 1H), 6.72 (dd, J= 7.8, 5.0 Hz, 1H), 5.19 (q, J = 2.9 Hz, 1H), 4.17-3.98 (m, 2H), 3.93-3.70 (m, 4H), 3.67-3.51 (m, 1H), 2.17-2.00 (m, 2H), 1.96 (s, 1H) , 1.64 (t, J = 3.0 Hz, 1H), 1.56 (s, 6H), 1.21 (t, J= 7.1 Hz, 3H) Example 86: (R)-3-(4-(6-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)pyridin-2-yl)-l.H-pyrazole acid -1-il) -2,2dime tiIpropanoic The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.050 q, 0.15 mmol) prepared in Example Preparation 1 and methyl 3-(4-(6aminopyridin-2-yl)-IH-pyrazol-l-yl)-2,2-dimethylpropanoate (0.041 g, 0.15 mmol) obtained in Preparation Example 116. (Yield of 14%)XH-NMR (400 MHz, METHANOL-D4): δ 8.18 (s, 1H), 8.11 (s, 258 ccz / nn / zznz / E / Y 1Η), 7.95 (s, 1H), 7.63-7.50 (m, 2H), 7.21-7.07 (m, 2H), 6.996.86 (m, 1H), 6.86-6.70 (m, 3H), 4.41 (d, J = 9.1 Hz, 1H), 4.35 (s, 2H), 3.94-3.68 (m, 5H), 3.64-3.54 (m, 1H), 2.12-2.00 (m, 2H), 1.98-1.88 (m, 1H) , 1.68-1.53 ​​(m, 1H), 1.28-1.18 (m, 9H) Example 87: (R)-3-((6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl) pyrazin- 2-yl)amino)pyridin-2-yl)oxy)benzoic acid The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.098 g, 0.293 mmol) obtained in Example Preparation 1 and methyl 3-((6-aminopyridin-2yl)oxy)benzoate (0.065 g, 0.266 mmol) obtained in Preparation Example 107. (2-step yield of 50%)XH-NMR (400 MHz, METHANOL -D4) 5 7.84 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 2.1 Hz, 1H), 7.65 (s, 1H), 7.54 (t, J =8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.36-7.28(m, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.02-6.93 (m, 1H), 6.93-6.84(m, 2H), 6.80 (dg, J = 8.6, 2.6 Hz, 1H), 6.45 (d, J = 7.8 Hz, 1H), 4.40 (td, J= 6.6, 3.5 Hz, 1H), 3.98-3.76 (m, 3H ), 3.71 (q, J= 6.7 Hz, 1H), 3.66-3.52 (m, 2H), 2.14-1.97 (m, 2H), 1.94-1.80 (m, 1H), 1.67-1.50 (m, 1H), 1.23 (t, J= 6.9 Hz, 3H) Example 88: (R)-3-((6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)oxy)benzoic acid 259 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (0.098 g, 0.293 mmol) obtained in Preparation Example 3 and methyl 3-((6aminopyridin-2-yl)oxy)benzoate (0.065 g, 0.266 mmol) obtained in Preparation Example 107. (2-step yield of 21%)XH -NMR (400 MHz, METHANOL-D4) δ 7.84 (dd, J = 7.8, 1.4 Hz, 1H), 7.71 (t, J = 2.1 Hz, 1H), 7.61 (s, 1H), 7.59-7.45 (m, 3H), 7.42 (s, 1H), 7.36-7.27 (m, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.02 (dd, J= 8.0, 1.6 Hz, 1H), 6.73 (dd, J = 7.8, 5.0 Hz, 1H), 6.45 (d, J = 7.8 Hz, 1H), 5.17 (q, J = 2.7 Hz, 1H), 4.15-4.01 (1H), 3.87-3.62 (4H), 3.61-3.47 (m, 1H), 2.12-1.91 (m, 3H), 1.65-1.53 ​​(m, 1H), 1.15 (t, J = 7.1 Hz, 3H) Example 89: (R)-4-((6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.15 g, 0.45 mmol) 260 cc7 / nni77n7ieiY obtained in Preparation Example 1 and methyl 4-((6-aminopyridin-2yl)oxy)benzoate (0.1 g, 0.409 mmol) obtained in Preparation Example 104. (2-step yield of 70% ) !H-NMR (400 MHz, CHLOROFORM-D) δ 8.32-8.20 (m, 2H), 7.98 (s, 1H), 7.80 (d, J = 8.2 Hz, 1H), 7.59 (q, J = 7.6 Hz, 1H), 7.27 (t, J= 2.3 Hz, 1H), 7.04-6.78 (m, 5H) ), 6.62 (d, J= 8.2 Hz, 1H) , 6.60-6.47 (m, 1H) , 4.37-4.22 (m, 1H) , 4.05 (dd, J = 13.3, 3.2 Hz, 1H) , 4.01-3.83 ( m, 2H), 3.72 (td, J = 9.3, 4.1 Hz, 1H), 3.54 (dd, J = 13.3, 7.8 Hz, 1H), 3.42-3.33 (m, 1H), 2.19-2.05 (m, 1H) , 2.01-1.81 (m, 2H), 1.57 (qd, J = 8.8, 4.6 Hz, 1H), 1.37-1.28 (m, 3H) Example 90: (R)-4-((6-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2 acid -yl)oxy)benzoic acid The title compound was obtained in a similar manner to Example 12 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (0.151 g, 0.450 mmol) obtained in Preparation Example 3 and methyl 4-((6aminopyridin-2-yl)oxy)benzoate (0.1 g, 0.409 mmol) obtained in Preparation Example 104. (2-step yield of 71%)XH -NMR (40 0 MHz, CHLOROFORM-D) <¿8.19 (t, J = 8.9 Hz, 2H), 7.92 (d, J = 17.8 Hz, 1H), 7.75-7.66 (m, 2H), 7.58 (t, J = 261 ccz / nn / zznz / E / Y 7.8 Hz, 1H), 7.44-7.26 (m, 1H), 7.24-7.16 (m, 2H), 6.97-6.89 (m, 1H), 6.83-6.68 (m, 2H), 6.55 (t, J = 8.5 Hz) , 1H) , 5.20 (s, 1H) , 3.96-3.82 (m, 3H) , 3.82-3.72 (m, 1H) , 3.72-3.52 (m, 2H) , 2.10 (q, J = 4.1 Hz, 1H), 2.01 (q, J = 5.3 Hz, 2H), 1.65 (s, 1H), 1.26-1.20 (3H) Example 91: (R)-2-(3-((6-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl acid )-2-methylpropanoic acid similar to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (117 mg, 0.349 mmol) prepared in Preparation Example 1 and 2-(3-( Methyl (6aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate (100 mg, 0.349 mmol) prepared in Preparation Example 109. (2-step yield of 47%) D4) δ 7.72 (d, J = 4.1 Hz, 1H), 7.62-7.50 (1H), 7.47 (s, 1H), 7.44-7.31 (1H), 7.25 (d, J= 8.7 Hz, 1H), 7.22-7.16 (1H), 7.14 (t, J = 2.1 Hz, 1H), 7.076.96 (m, 2H), 6.96-6.87 (2H), 6.87-6.75 (m, 1H), 6.41 (d, J = 7.8 Hz, 1H), 4.41 (td, J = 6.7, 3.4 Hz, 1H), 4.02-3.80 (m, 3H), 3.71 (q, J = 6.6 Hz, 1H), 3.63 (t, J = 5.3 Hz, 2H), 2.18-1.99 (m, 2H), 1.91 ( qd, J = 7.9, 3.9 Hz, 1H), 1.71-1.56 (m, 1H), 262 ccz / nn / zznz / E / Y 1.54 (s, 6H), 1.27 (t, J = 6.9 Hz, 3H) Example 92: (R)-2-(3-((6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-acid 2-yl)oxy)phenyl)-2-methylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (117 mg, 0.349 mmol) prepared in Preparation Example 3 and methyl 2-(3-((6aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate (100 mg, 0.349 mmol) prepared in Preparation Example 109. (yield 2-stage 56%) 7.48 (s, 1H), 7.437.31 (m, 1H), 7.31-7.22 (m, 1H), 7.22-7.10 (m, 2H), 7.06 (dd, J = 7.8, 1.4 Hz, 1H), 7.03- 6.92 (m, 1H), 6.77 (dd, J = 7.8, 5.0 Hz, 1H), 6.40 (d, J = 7.3 Hz, 1H), 5.20 (q, J = 2.9 Hz, 1H), 4.04 (dd, J = 13.7, 5.9 Hz, 1H), 3.96-3.69 (m, 4H), 3.69-3.53 (m, 1H), 2.22-1.89 (3H), 1.77-1.58 (m, 1H), 1.55 (s, 6H), 1.20 (t, J = 7.1 Hz, 3H) Example 93: (R)-2-(4-((6-((6-(3-(2-ethoxyphenoxy)piperidin1-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl acid )-2-methylpropanoic acid 263 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 1 using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (117 mg, 0.349 mmol) prepared in Example 1. Preparation 1 and methyl 2-(4-((6aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate (100 mg, 0.349 mmol) prepared in Preparation Example 106. (2-step yield of 58%) 1H-NMR (400 MHz, METHANOL-D4) δ 7.66 (d, J = 8.7 Hz, 1H), 7.52 (t, J= 8.0 Hz, 1H), 7.49-7.41 (m, 3H), 7.29 (d, J = 7.8 Hz, 1H), 7.07 (dt, J = 9.5, 2.5 Hz, 2H), 6.99 (d, J =7.8 Hz, 1H), 6.94-6.87 (m, 2H), 6.87-6.74 (m, 1H), 6.40 (d, J =7.8 Hz, 1H), 4.51-4.33 (m, 1H), 4.05-3.81 (m, 3H), 3.73 (q, J =6.6 Hz, 1H), 3.68-3.54 (2H), 2.22-1.98 (m, 2H), 1.97-1.82 (m, 1H), 1.73-1.53 ​​(7H), 1.27 (t, J= 7.1 Hz, 3H) Example 94: (R)-2-(4-((6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin- acid 2-yl)oxy)phenyl)-2-methylpropanoic acid The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-((3264 ccz / nn / zznz / E / Y ethoxypyridin-2-yl)oxy)piperidin- 1-yl)pyrazine (117 mg, 0.349 mmol) prepared in Preparation Example 3 and methyl 2-(4-((6aminopyridin-2-yl)oxy)phenyl)-2-methylpropanoate (100 mg, 0.349 mmol) prepared in Preparation Example 106. (2-step yield of 71%)XH-NMR (400 MHz, METHANOL-D4) δ 7.68-7.55 (m, 2H), 7.55-7.35 (m, 4H), 7.21 (d, J = 7.8 Hz, 1H), 7.13-6.98 (m, 3H), 6.76 (dd, J = 7.8, 5.0 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 5.295.12 (m, 1H), 4.04 (dd, J = 13.7, 5.9 Hz, 1H), 3.96-3.67 (m, 4H), 3.67-3.50 (m, 1H), 2.20-1.89 (m, 3H), 1.73-1.59 (m, 1H), 1.57 (d, J = 7.8 Hz, 6H), 1.20 (t, J = 6.9 Hz, 3H) Example 95: (R)-2-(3-((6-( (6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl acid )acetic The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (90.0 mg, 0.271 mmol) prepared in Example Preparation 1 and 2-(3-((6aminopyridin-2yl)oxy)phenyl)methyl acetate (70.0 mg, 0.271 mmol) prepared in Preparation Example 108. (2-step yield of 27%)XH-NMR (400 MHz, CHLOROFORM-D) δ 8.04 (s, 1H), 7.667.46 (m, 2H), 7.37 (t, J = 7.8 Hz, 1H), 7.30 (d, J = 16.0 Hz, 265 ccz / nn / zznz / E / Y 1Η), 7.23 (s, 1H), 7.08-6.90 (m, 4H), 6.90-6.76 (m, 2H), 6.696.45 (m, 2H), 4.30 (t, J = 3.4 Hz, 1H), 4.06 -3.84 (m, 3H), 3.74 (s, 2H), 3.65 (s, 2H), 3.42 (d, J = 11.0 Hz, 1H), 2.08 (d, J = 6.4 Hz, 1H), 2.04-1.81 ( m, 2H), 1.58 (qd, J = 8.5, 4.2 Hz, 1H) , 1.33 (t, J = 7.1 Hz, 3H) Example 96: (R)-2-(3-((6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-acid 2-yl)oxy)phenyl)acetic acid similar to Example 1 when using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (91.0 mg, 0.271 mmol) prepared in Preparation Example 3 and methyl 2-(3-((6aminopyridin-2yl)oxy)phenyl)acetate (70.0 mg, 0.271 mmol) prepared in Preparation Example 108. (2-step yield of 13%)XH-NMR (400 MHz, METHANOL-D4) δ 7.69 (s, 1H), 7.61 (dd, J = 5.0, 1.4 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.40-7.28 (1H ), 7.23-6.94 (m, 5H), 6.77 (dd, J = 7.8, 5.0 Hz, 1H) , 6.41 (d, J= 7.8 Hz, 1H) , 5.28-5.11 (m, 1H) , 4.04 (dd, J = 13.7, 5.9 Hz, 1H), 3.93-3.68 (m, 4H), 3.64 (s, 2H), 3.63-3.50 (m, 1H), 2.14-1.91 (m, 3H), 1.73-1.54 (m, 1H), 1.20 (t, J= 7.1 Hz, 3H) 266 ccz / nn / zznz / E / Y Example 97: (R)-2-(4-((6-((6-(3-(2-ethoxyphenoxy)piperidin l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy acid phenyl)acetic The title compound was obtained in a similar manner to Example 1 by using (R)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (90.0 mg, 0.271 mmol) prepared in Example Preparation 1 and methyl 2-(4-((6aminopyridin-2-yl)oxy)phenyl)acetate (70.0 mg, 0.271 mmol) prepared in Preparation Example 105. (2-step yield of 17%)XH-NMR (400 MHz, CHLOROFORM-D) δ 7.57 (s, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.49-7.42 (m, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.10 (dt, J = 9.3, 2.3 Hz, 2H), 7.08-6.98 (m, 1H), 6.94 (td, J = 8.5, 1.5 Hz, 2H), 6.90-6.81 (m, 2H), 6.78 (d, J = 7.8 Hz, 1H), 6.50 (d, J = 7.8 Hz, 1H), 4.30 (td, J = 7.5, 3.7 Hz, 1H), 4.07-3.88 (m, 3H), 3.76 (d, J = 7.3 Hz, 2H), 3.69 (dd, J = 8.5, 4.8 Hz, 1H), 3.59-3.45 (m, 1H), 3.44 -3.26 (m, 1H), 2.21-2.05 (m, 1H), 2.03-1.92 (m, 1H), 1.91-1.77 (m, 1H), 1.58 (tt, J = 13.0, 4.4 Hz, 1H), 1.34 (t, J = 6.9 Hz, 3H) Example 98: (R)-2-(4-((6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-acid 2-yl)oxy)phenyl)acetic acid 267 ccz / nn / zznz / E / Y The title compound was obtained in a similar manner to Example 1 using (R)-2-chloro-6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (91.0 mg, 0.271 mmol) prepared in Preparation Example 3 and methyl 2-(4-((6aminopyridin-2-yl)oxy)phenyl)acetate (70.0 mg, 0.271 mmol) prepared in Preparation Example 105. (yield of 2 25%)XH-NMR (400 MHz, CHLOROFORM-D) , 1.7 Hz, 1H) , 7.44-7.33 (m, 3H) , 7.09 (dd, J = 8.9, 2.1 Hz, 2H) , 6.94 (dd, J = 7.8, 1.8 Hz, 1H) , 6.90 (s, 1H) , 6.78 (ddd, J = 7.7, 4.9, 1.0 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 6.51 (dd, J = 7.8, 2.3 Hz, 1H), 5.25-5.09 (m, 1H ), 3.96-3.86 (m, 2H), 3.863.75 (m, 4H), 3.75-3.61 (m, 1H), 3.59-3.36 (1H), 2.23-2.06 (m, 1H), 2.06-1.87 (m , 2H) , 1.75-1.55 (m, 1H) , 1.27 (t, J= 7.1 Hz, 3H) Example 99: (R)-4-(((6-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)methyl)benzoic acid The title compound was obtained in a manner 268 ccz / nn / zznz / E / Y similar to Example 12 when using (5)-2-chloro-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazine (0.095 g, 0.285 mmol) obtained in Example of Preparation 1 and methyl 4-(((6-aminopyridin2-yl)oxy)methyl)benzoate (0.067 g, 0.259 mmol) obtained in Preparation Example 110. (2-step yield of 21%)XH-NMR ( 400 MHz, METHANOL-D4) £ 8.03 (s, 1H), 7.99 (d, J = 8.2 Hz, 2H), 7.54 (dd, J = 17.8, 8.2 Hz, 2H), 7.47 (s, 1H), 7.43 ( t, J = 8.0 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 6.97 (d, J = 7.3 Hz, 1H), 6.90-6.83 (m, 2H), 6.83-6.76 (m, 1H) ), 6.40-6.31 (m, 1H), 5.43 (s, 2H), 4.48-4.29 (m, 1H), 3.96-3.75 (m, 3H), 3.75-3.66 (m, 1H), 3.60 (dd, J = 19.4, 4.8 Hz, 2H), 2.11-1.99 (m, 2H), 1.94-1.82 (m, 1H), 1.66-1.52 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H) Example 100: (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)-5-fluoropyridin-2-yl)phenyl acid )-2,2dime tiIpropanoic The title compound was obtained in a similar manner to Example 22 by using (R)-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazin-2-amine (44 mg, 0.14 mmol) synthesized in Example 22. Preparation 2 and tert-butyl 3-(3-(6-chloro-5fluoropyridin-2-yl)phenyl)-2,2-dimethylpropanoate 269 ​​ccz / nn / zznz / E / Y (51 mg, 0.14 mmol) synthesized in Step 1 of Preparation Example 85. (2-step yield of 12%)XH-NMR (400 MHz, METHANOL-D4) £8.91 (s, 1H) , 7.83 (s, 1H) , 7.79 (d, J = 8.2 Hz, 1H) , 7.68 (s, 1H) , 7.56 (dd, J = 10.5, 8.7 Hz, 1H), 7.43 (dd, J= 8.5, 3.0 Hz, 1H), 7.35 (t,J= 7.8 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.97 (q, J = 3.2Hz, 1H), 6.91-6.74 (m, 3H), 4.49 (d, J= 2.5 Hz, 1H), 4.15-4.01(m, 1H), 3.96 (d, J = 8.2 Hz, 1H), 3.85 (tdd, J = 16.8, 6.9, 2.7 Hz, 2H), 3.75 (d, J = 14.2 Hz, 1H), 3.61-3.47 (m, 1H) ), 2.95 (s, 2H) , 2.13-1.90 (m, 3H) , 1.60 (d, J = 5.9 Hz, 1H) , 1.23 (t,J = 6.9Hz, 3H), 1.20-1.09 (6H) Example 101: (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)-5-acid fluoropyridin-2yl)phenyl)-2,2-dimethylpropanoic acid The title compound was obtained in a similar manner to Example 22 by using (R)-2-chloro-6-(3-((3ethoxypyridin-2-yl)oxy)piperidin-1-yl)pyrazine (45 mg, 0.13 mmol) synthesized in Preparation Example 3 and tert-butyl 3-(3-(6amino-5-fluoropyridin-2-yl)phenyl)-2,2-dimethylpropanoate (46 mg, 0.13 mmol) synthesized in Preparation Example 85 (2-stage performance of 24%)XH-NMR (400 MHz, METHANOL-D4) £8.99 (s, 1H), 7.86 (s, 270 ccz / nn / zznz / E / Y 1Η), 7.79 (d, J = 7.8 Hz, 1H), 7.71-7.58 (m, 2H), 7.48 (dd, J= 10.5, 8.2 Hz, 1H), 7.41-7.34 (m, 1H), 7.31 (d , J = 7.8 Hz, 1H), 7.19 (d, J= 7.3 Hz, 1H) , 6.96 (dd, J = 7.8, 1.8 Hz, 1H) , 6.78 (dd, J = 7.8, 5.0 Hz, 1H), 5.16 (q, J = 2.6 Hz, 1H), 4.20 (dd, J = 14.0, 5.3 Hz, 1H), 3.94-3.82 (m, 1H), 3.81-3.70 (m, 2H), 3.70-3.63 (m, 1H) ), 3.63-3.47 (m, 1H), 2.94 (dd, J = 15.6, 13.3 Hz, 2H), 2.16-1.89 (m, 4H), 1.70-1.53 ​​(m, 1H), 1.19 (d, J = 5.9 Hz, 6H), 1.15 (d, J = 6.9 Hz, 3H) Example 102: (R)-3-(3-(6-((6-(3-(2-ethoxyphenoxy)piperidinl-yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl)phenyl acid )-2,2dime tiIpropanoic The title compound was obtained in a similar manner to Example 22 by using (R)-6-(3-(2ethoxyphenoxy)piperidin-l-yl)pyrazin-2-amine (43 mg, 0.14 mmol) synthesized in Example 22. Preparation 2 and tert-butyl 3-(3-(6-chloro-3fluoropyridin-2-yl)phenyl)-2,2-dimethylpropanoate (50 mg, 0.14 mmol) synthesized in Step 1 of Preparation...

Claims

CLAIMS 1. A compound of the following Formula (1), or a pharmaceutically acceptable salt or isomer: [Formula (1)] characterized in that A and D are each independently CH or N; B and E are each independently CH, C-halogen, C-haloalkyl or N; R1 is alkyl, cycloalkyl or haloalkyl; R2 is hydrogen, halogen or alkyl; R3 is -GJ; wherein G is aryl, arylene, aryl-alkylene, heteroaryl or heteroarylene; J is hydrogen, amino, aminocarbonyl, alkoxyalkyl, cycloalkyl, cycloalkyl-oxy, heterocycloalkyl, aryl, aryl-oxy, aryl-alkoxy, heteroaryl, heteroaryl-amino, carboxyalkyl, carboxyalkenyl, carboxyalkyl-aryl, carboxyalkoxy-aryl, carboxyalkyl-heterocycloalkyl, carboxyalkeni 1 -heterocycloalkyl, carboxyalkoxy-heterocycloalkyl, carboxyalkyl-amino-aryl, carboxyalkyl-aryl-oxy or carboxyalkyl-heteroaryl;ccz / nn / zznz / E / Y 350 wherein the alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with one or more substituents selected from halo, -COOH, alkyl, alkoxy, haloalkyl, alkylsulfoniium and heteroaryl; and the heterocycloalkyl, heteroaryl and heteroarylene include one or more heteroatoms selected from N, O and S.; 2. The compound, or a pharmaceutically acceptable salt or isomer thereof according to claim 1, characterized in that A and D are each independently CH or N; B and E are each independently CH, C-halogen, C-C1-C7 haloalkyl or N; R1 is C1-C7 alkyl, C3-C7 cycloalkyl or C1-C7 haloalkyl; R2 is hydrogen, halogen or C1-C7 alkyl; R3 is -GJ; wherein G is Ce-Cio aryl, Cg-Cio arylene, Ce-Cio arylene-C1-C7 alkylene, 5- to 12-membered heteroaryl or 5- to 12-membered heteroarylene;J is hydrogen, amino, aminocarbonyl, CiC7 alkoxy, C1-C7 alkyl, C3-C10 cycloalkyl, C3Cio-oxy cycloalkyl, 5- to 12-membered heterocycloalkyl, Ce-Cio aryl, Ce-Cio-oxy aryl, Cs-Cio-C1-C7 aryl alkoxy, 5- to 12-membered heteroaryl, 5- to 12-membered heteroaryl-amino, ccz / nn / zznz / E / Y 351, C1-C7 carboxyalkyl, C2-C7 carboxyalkenyl, Ci-C7 carboxyalkyl, Ce-Cio aryl, Ci-C7 carboxyalkoxy, Ci-C7 carboxyalkyl, 5- to 12-membered heterocycloalkyl, carboxyalkenyl of 5-to-12-membered C2-C7-heterocycloalkyl, 5-to-12-membered Ci-Cv-heterocycloalkyl carboxy-alkoxy, 5-to-12-membered Ci-C7-amino-aryl carboxy-alkyl, 5-to-12-membered Ci-C7-aryl Ci-C7-oxy-carboxy-alkyl or 5-to-12-membered Ci-C7-heteroaryl carboxy-alkyl;wherein the alkyl, alkoxy, cycloalkyl, aryl, heterocycloalkyl, heteroaryl or heteroarylene is optionally substituted with 1 to 4 substituents selected from halo, -COOH, C1-C7 alkyl, C1-C7 alkoxy, C1-C7 halo-alkyl, C1-C7 alkylsulfonyl and 5- to 12-membered C1-C7 heteroaryl-alkyl; and the heterocycloalkyl, heteroaryl and heteroarylene includes 1 to 5 heteroatoms selected from N, O and S.

3. The compound, or a pharmaceutically acceptable salt or isomer thereof according to claim 1, characterized in that the compound is selected from the following group: (R)-2-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)amino)thiazol-5-carboxylic acid; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)-4,5-dimethylthiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2-yl)-4-phenylthiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)benzo[dj thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-6-methoxybenzo[d]thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-6-(methanesulfonyl)benzo[d]thiazol-2-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-3-(1-(2-methoxyethoxy)-2-methylpropan-2-yl)isooxazole-5-amine; (R)-N-(6-(3-(2-ethoxyphenoxy)piperidin-l-yl)pyrazin-2yl)-4-phenyloxazole-2-amine;(R)-N- (6-(3-(2-ethoxyfenoxy)piperidin-1-yl)pyrazin-2yl)benzo[d]oxazol-2-amine; (R)-5-chloro-N-(6-(3-(2-ethoxyfenoxy)piperidin-1-yl) pyrazin-2-yl) benzo [d]oxazol-2-amine; (R)-2-(2-( (6- (3- (2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl) amino)benzo[d]oxazol-5-yl)acetic acid; ácido (R)-2-(2-( (6 - (3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)benzo[d]oxazol-5-yl)-2-metilpropanoico; ácido (R)-3-(2-((6-(3-(2-etoxifenoxi)piperidin-1il)pirazin-2-yl)amino)benzo[d]oxazol-5-yl)-2,2-dimetilpropanoico; ácido (R,E)-3-(2-((6-(3-(2-etoxifenoxi)piperidin-1> tu NCNNCCN 353 O u il)pirazin-2-il)amino)benzo[d]oxazol-5-il)acrílico; (R)-3-(2-( (6- (3- (2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)benzo[d]oxazol-5-yl)propanoic acid; (R)-2-(2-( (6- (3- (2-etoxifenoxi)piperidin-l- il) pyrazin-2-ii)amino)benzo LdJoxazol-6-yl)-2-methylpropanoic acid; (R)-3-(2-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)benzo[d]oxazol-6-yl)propanoic acid;(R)-6-(3-(2-ethoxyphenoxy)piperidin-l-yl)-N-(1Hpyrazol-3-yl)pyrazin-2-amine; (R)-2-(3-( (6- (3-(2-ethoxyphenoxy)piperidin-l- yl) pyrazin-2-yl)amino)-1H-pyrazol-1-yl)acetic acid; (R)-3-(3-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl) pyrazin-2-yl)amino)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-((4-(3-(2-ethoxyphenoxy)piperidin-l-yl) -5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)phenyl)-2,2dimethylpropanoic acid; (R)-6-(3-(2-ethoxyphenoxy)piperidin-1-yl)-N-(1-methyl H -tetrazol-5-yl)pyrazin-2-amine; (R)-N-6-(3-(2-ethoxyphenoxy)piperidin-1-yl)-N-phenylpyrazin-2-amine; (R)-N-(4-((6 - (3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)phenyl)metañosulfonamide; (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrazin-2-yl)amino)fenil)-N-(pyridin-4-ylmetil)acetamida; ácido (R)-2-(4-((6-(3-(2-ethoxyphenoxy)piperidin-l-yl)> s NCNNCCN 354 au pyrazin-2-yl)amino)fenil)-2-metilpropanoico; ácido (R)-2-(4-((6-(3-(2-ethoxyfenoxi)pyridin-lyl)pyrazin-2-yl)amino)fenil)-2-metilpropanoico;(R)-2-(3-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)phenyl)-2-methylpropanoic acid; (R)-3-(3'-((6-(3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)-[1,1'-biphenyl]-4-yl)-2,2-dimethylpropanoic acid; (R)-6-(3-(2-etoxifenoxi)piperidin-l-yl)-N-(pyridin-2yl)pyrazin-2-amine; (R)-6-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)nicotinic acid; (R)-2-((6 - (3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)isonicotinic acid; (R)-2-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)nicotinic acid; (R)-2-(2-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-4-yl)-2-methylpropanoic acid; (R)-2-(6-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-3-yl)acetic acid; (R,E)-3-(6-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-3-yl)acrylic acid; (R)-3-(6-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-3-yl)propanoic acid;(R)-3-(2-( (6- (3-(2-etoxifenoxi)piperidin-1355 il)pyrazin-2-yl)amino)pyridin-4-yl)-2,2-dimethylpropanoic acid; (R)-6-(3-(2-etoxifenoxi)piperidin-l-yl)-N-(5-phenylpyridin-2-yl)pyrazin-2-amine; (R)-6-(3-(2-etoxifenoxi)piperidin-l-yl)-N-(4-phenylpyridin-2-yl)pyrazin-2-amine; (R)-2-(3-(2-( (6-(3- (2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2-methylpropanoic acid; (R)-2 -(3-(2-( (6-(3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2-methylpropanoic acid; (R)-3-(3-(2-( (6- (3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(4-(2-( (6- (3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-((6-(3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-4-yl)phenyl)propanoic acid; (R)-3-(3-(5-( (6- (3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-2,2-dimethylpropanoic acid;(R)-3-(3-(5-((6-(3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-2-(6-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-3-yl)phenyl)-2-methylpropanoic acid; > tu NCNNCCN 356 O u (R)-2-(6-( (6- (3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-2-methylpropanoic acid; (R)-3-(6-((6-(3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-2,2-dimethylpropanoic acid; 1-(6-((6-((R)-3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)pyrrolidin-3-carboxylic acid; 1-(6 - ( (6-( (R)-3-(2-etoxifenoxi)piperidin-l- il)pyrazin-2-yl)amino)pyridin-2-yl)-3-methylpyrrolidin-3carboxylic acid; 1-(6 - ( (6-( (R)-3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)piperidin-3-carboxylic acid; (R)-1-(6-((6-((R)-3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)piperidin-3-carboxylic acid;(R)-1-(6-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)piperidin-4-yl)carboxylic acid; (R)-2-(1-(6-((6-(3-(2-etoxifenoxi)piperidin-1il)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-4-yl)acetic acid; (R)-2-(1-(6-( (6- (3- (2-etoxifenoxi)piperidin-1il)pyrazin-2-yl)amino)pyridin-2-yl)piperidin-4-yl)-2-methylpropanoic acid; ácido 2-(((S)-1-(6-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)piridin-2-yl)piperidin-3-yl)acetic acid; ácido (R)-2-(3-(6-( (6-(3- (2-etoxifenoxi)piperidin-1il)pirazin-2-yl)amino)piridin-2-yl)fenil)-2-metilpropanoico; > tu NCNNCCN 357 O u ácido (R)-2-(4-(6-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pirazin-2-yl)amino)piridin-2-yl)fenil)-2-metilpropanoico; ácido (R)-2-(4-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2-methylpropanoic acid; (R)-3-(3-(6-((6-(3-(2-ethoxyfenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid;(R)-3-(3-(6-((6-(3-((3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (6- (3- (2-ethoxyfenoxi)piperidin-lyl )pyridin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (2-(3- (2-ethoxyfenoxi)piperidin-lyl )pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (6- (3- (2-ethoxyfenoxi)piperidin-lyl )pyrimidin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (4- (3- ((3-ethoxipyridin-2-yl)oxy)piperidin-1-yl)pyrimidin-2-yl)amino)pyridin-2-yl)phenyl)-2,2dimethylpropanoic acid; acid (R)-3-(3-( (6- (3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)-IH-pyrazol-l-yl)phenyl)-2,2-dimethyl> tu NCNNCCN 358 O u propanoic acid; (R)-3-(3-(6-( (2 - (3- (2-etoxifenoxi)piperidin-l- il) -5-(trifluorometil)pirimidin-4-yl)amino)piridin-2-yl)phenyl) - 2,2-dimetilpropanoic acid;(R)-3-(3-(6-( (4 - (3- (2-etoxifenoxi)piperidin-l- il) -5-(trifluoromethyl)pyrimidin-2-yl)amino)pyridin-2-yl)phenyl) - 2,2-dimethylpropanoic acid; (R)-3-(4-(6-( (6- (3- (2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-(4-(6-((6-(3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-(4-(6-( (6- (3 - ( (3-ethoxypyridin-2-yl)oxi)piperidinl-yl )pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-(4-(6-((2-(3-(2-ethoxyfenoxy)piperidin-l-yl)pyrimidin-4-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-(4-(6-((4-(3-(2-ethoxyfenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenyl)glycine; (R)-2-((4- (6 - ( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)phenyl)amino)-2-methyl- propanoic acid; (R)-3-(3-(6-((6-(3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenyl)-2,2-dimethylpropanoic acid;(R)-3-(3-(6-((6-(3-((3-etoxipiridin-2-yl)oxi)ccz / nn / zznz / E / Y 359 piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorophenyl)2,2-dimethylpropanoic acid; (R)-2-(3-(6-((6-(3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)fenoxi)-2-methylpropanoic acid; (R)-2-(3-(6-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)fenoxi)-2-methylpropanoic acid; (R)-2-(4-(6-( (6- (3-(2-ethoxypyridin-2-yl)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)fenoxi)-2-methylpropanoic acid; (R)-2-(4-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)fenoxi)-2methylpropanoic acid; (R)-2-(3-(6-( (6- (3-(2-ethoxyfenoxi)piperidin-lyl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorofenoxi)-2-methylpropanoic acid; (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)-4-fluorofenoxi) -2-methylpropanoic acid;(R)-3-(4-(6-((6-(3-(2-ethoxyfenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)-1H-pyrazol-1-yl)-2,2-dimethylpropanoic acid; (R)-3-((6-((6-(3-(2-ethoxyfenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid; (R)-3-( (6-( (6- (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid; > s NCNNCCN 360 au ácido (R)-4-( (6-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl)amino)pyridin-2-yl)oxy)benzoic acid; (R)-4-((6-((6-(3-((3-ethoxipyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)benzoic acid; (R)-2-(3-( (6-( (6- (3-(2-ethoxyfenoxi)piperidin-1yl)pyrazine-2-yl)amino)pyridin-2-yl)oxy)phenyl)-2-methylpropanoic acid; (R)-2-(3-( (6-( (6-(3-( (3-ethoxypyridin-2yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)-2-methylpropanoic acid; (R)-2-(4-((6-((6-(3-(2-ethoxyfenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)-2-methylpropanoic acid;(R)-2-(4-( (6-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)-2methylpropanoic acid; (R)-2-(3-((6-((6-(3-(2-ethoxyfenoxi)piperidin-l- il)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)acetic acid; (R)-2-(3-( (6-( (6- (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)acetic acid; (R)-2-(4-( (6-( (6-(3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyridin-2-yl)oxy)phenyl)acetic acid; acid (R)-2-(4-( (6-( (6- (3- ( (3-etoxipyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)oxi)phenyl)> tu NCNNCCN 361 au acetico; (R)-4 -(( (6 - ((6- (3- (2-ethoxyfenoxi)piperidin-l-yl) pyrazine-2-yl)amino)pyridin-2-yl)oxy)methyl)benzoic acid; (R)-3-(3-(6-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-ii)amino)-5-fluoropiridin-2-ii)phenyl)-2,2dimethylpropanoic acid;(R)-3-(3-(6-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin-2-yl)phenyl)- 2,2-dimethylpropanoic acid; (R)-3-(3-(6-( (6- (3-(2-ethoxyfenoxi)piperidin-lyl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl) phenyl)-2,2-dimethylpropanoic acid; (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin-2-yl) phenyl)-2-methylpropanoic acid; (R)-2-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl)phenoxy)-2-methylpropanoic acid; (R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-3-fluoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoic acid; ácido (R)-3-(3-(6-( (6- (3-(2-etoxifenoxi)piperidin-1> s NCNNCCN 362 O u il)pirazin-2-yl)amino)-5-fluoropiridin-2-yl)-4-fluorofenil)- 2,2- dimetilpropanoico;(R)-3-(3-(6-((6-(3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-5-fluoropyridin-2-yl)-4fluorophenyl)-2,2-dimethylpropanoic acid; (R)-2-(4-(6-( (6-(3- (2-ethoxyfenoxi)piperidin-l- il)pyrazin-2-yl)amino)-3-(trifluoromethyl)pyridin-2-yl)phenyl)-2methylpropanoic acid; (R)-3-(3-(6-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pyrazin-2-yl) amino)-4-(triflucrómetil)piridin-2-il)fenil)- 2,2 -dimetilpropanoico acid; (R)-3-(3-(6-((6-(3-(2-etoxifenoxi)piperidin-lyl )pyrazin-2-yl)amino)-3-metilpiridin-2-yl)fenil)-2,2-dimetilpropanoico acid; (R)-3-(3-(6-((6-(3-(2-etoxifenoxi)piperidin-1il)pyrazin-2-yl)amino)pyrazin-2-yl)fenil)-2,2-dimetilpropanoico acid; (R)-N-(6-(3-(2-etoxifenoxi)piperidin-lyl )pyrazin-2-yl)pirimidin-2-amine; (R)-2-( (6-(3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidina-5-carboxylic acid; (R)-2-(2-( (6 - (3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)pirimidin-4-yl)-2-methylpropanoic acid;(R)-2-(2-((4-(3-((3-etoxipiridin-2-yl)oxi)piperidin-l-yl)pirimidin-2-yl)pirimidin-4-yl)-2-metil> tu NCNNCCN 363 O u propanoico acid; (2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pyrazin2-yl)amino)pirimidin-4-yl)-L-proline; 1-(2 - ( (6-( (R)-3-(2-etoxifenoxi)piperidin-1il)pyrazin-2-yl)amino)pirimidin-4-yl)pyrrolidin-3-carboxylic acid; 1-(2 - ( (6-( (R)-3-(2-ethoxyfenoxy)piperidin-lyl) pyrazin-2-yl)amino)pyrimidin-4-i1)-3-methylpyrrolidin-3carboxylic acid; 1-(2 - ( (6-( (R)-3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-i1)piperidin-3-carboxí1ic acid; (R)-1-(2-((6-((R)-3-(2-ethoxyfenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)piperidin-3-carboxylic acid; acid 1-(2 - ( (6-( (R)-3-(2-ethoxyfenoxi)piperidin-lyl) pyrazin-2-yl)amino)pyrimidin-4-yl)-3-methylpiperidin-3carboxylic acid; (R)-1-(2-((6-(3-(2-etoxifenoxi)piperidin-lyl) pyrazin-2-yl) amino)pyrimidin-4-yl)piperidin-4-carboxylic acid;ácido 5-(2-( (6-((R)-3-(2-etoxifenoxi)piperidin-lyl) pyrazin-2-yl)amino)pirimidin-4-yl)bicyclo[2.2.1]heptane-2carboxílico; ácido (R)-2 - (1- (2 - ( (6- (3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pirimidin-4-yl)piperidin-4-yl)acetico; ácido (R)-2-(1-(2-( (6- (3- (2-etoxifenoxi)piperidin-lyl) pyrazin-2-yl)amino)pirimidin-4-yl)piperidin-4-yl)-2 metilpropanoico; ccz / nn / zznz / E / Y 364 ácido (R)-2-(4-(2-( (6- (3-(2-etoxifenoxi)piperidin-l- il) pirazin-2-il)amino)pirimidin-4-il)piperazin-1-il)acético; ácido 2-((5)-1-(2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-il)pirazin-2-il)amino)pirimidin-4-i1)piperidin-3il)acético; (E)-3-((5)-1-(2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-i1)piperidin-3yl)acrylic acid; 3-((5)-1-(2-( (6-( (R)-3-(2-etoxifenoxi) piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-i1)piperidin-3yl)propanoic acid; 2-(((5)-1-(2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-i1)piperidin-3yl)oxi)acetic acid;2-(((R)— 1 —(2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)pirimidin-4-i1)piperidin-3yl)oxi)acetic acid; 2-(((R)-1-(2-((6— ((R)-3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)pirimidin-4-i1)piperidin-3yl)oxi)-2-methylpropanoic acid; (R)-4-(2-((6-(3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)pirimidin-4-i1)oxi)cyclohexane-1-carboxylic acid; ácido (lRz4r)-4-((2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pirazin-2-yl)amino)pirimidin-4-il1)oxi)ciclohexan-1-carboxylic acid; > tu NCNNCCN 365 O u ácido (IR,4r)-4-((2-((6-((R)-3-((3-etoxipiridin-2il)oxi)piperidin-l-yl)pirazin-2-yl)amino)pirimidin-4-il)oxi)ciclohexan-1-carboxylic acid; (lS,4s)-4-((2-((6-((R)-3-(2-etoxifenoxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-yl)oxi)cyclohexane-1-carboxylic acid; (lS,4s)-4-((2-((6-((R)-3-((3-etoxipiridin-2yl)oxi)piperidin-1-yl)pyrazin-2-yl)amino)pirimidin-4-yl)oxi)cyclohexane-1-carboxylic acid;(R)-6-(2-((6-(3-(2-etoxifenoxi)piperidin-l- il)pyrazin-2-yl)amino)pirimidin-4-yl)picolinic acid; (R)-2-(3-(2-( (6- (3-(2-etoxifenoxi)piperidin-l- il)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)acetic acid; (R)-2-(3-(2-((6-(3-(2-etoxifenoxi)piperidin-l- il)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)-2-methylpropanoic acid; (R)-2-(3-(2-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2-methylpropanoic acid; (R)-2-(4-(2-( (6- (3-(2-ethoxyfenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2-methylpropanoic acid; (R)-2-(4- (2- ( (6- (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)-2methylpropanoic acid; ácido (R)-3-(3-(2-( (6-(3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pirimidin-4-yl)fenil)propanoico; > s NCNNCCN 366 O u ácido (R)-3-(3-(2-( (6- (3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pirimidin-4-yl)fenil)-2,2-dimetilpropanoico;(R)-3-(3-(2-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-ii)pyrazin-2-ii)amino)pirimidin-4-ii)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (6- (3-(2-ethoxyfenoxi)piperidin-lyl )piridin-2-yl)amino)pirimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (2 - (3-(2-ethoxyfenoxi)piperidin-lyl )pirimidin-4-i1)amino)pirimidin-4-i1)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (4 - (3-(2-etoxifenoxi)piperidin-lyl )pirimidin-2-yl)amino)pirimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-2-(4-(2-((6-(3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)acetic acid; (R)-2-(4-(2-( (6- (3- ( (3-etoxipiridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)acetic acid; (R)-3-(4-(2-((6-(3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(4-(2-( (6- (3- ( (3-etoxipyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid;> tu NCNNCCN 367 au ácido (5)-3-(4-(2-( (2 - (3-(2-etoxifenoxi)piperidin-lil ) pirimidin-4 - i 1) amino) pirimidin-4-i 1) fenyl) -1,2. -dimetilpropanoico; (5)-3-(4-(2-((4-(3-(2-etoxifenoxi)piperidin-l-yl)pirimidin-2-ii)amino)pirimidin-4-ii)fenyl)-2,2-dimetiipropanoico; (5)-3-(4-(2-( (4- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pirimidin-2-yl)amino)pirimidin-4-yl) phenyl)-2,2-dimethylpropanoic acid; (5)-2-(3-(2-( (6- (3-(2-ethoxyfenoxi)piperidin-l- il) pyrazin-2-yl)amino)pirimidin-4-yl)phenoxy)-2-methylpropanoic acid; (5)-2-(3-(2-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-4-yl)phenoxy)-2-methylpropanoic acid; (5)-2-(4-(2-( (6-(3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-i1)fenoxi)-2-methypropanoic acid; (R)-2-( (4- (2 - ((6- (3- (2-ethoxyfenoxi)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-4-i1)phenyl)amino)-2-methylpropanoic acid;ácido (5)-2-(4-( (2-( (6-(3-(2-etoxifenoxi)piperidin-l- il) pirazin-2-il)amino)pirimidin-4-il)oxi)fenil)acético; (R)-2-(4-( (2-( (6- (3- ( (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-4-yl)phenyl)acetic acid; (5)-3-(3-(2-((6-(3-(2-ethoxyfenoxi)piperidin-lyl )pyrazin-2-yl)amino)-5-fluoropyrimidin-4-yl)phenyl)-2,2N CNN 368 dimethylpropanoic acid; (R)-3-(3-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (6- (3- ( (3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)-6-(trifluoromethyl)pyrimidin-4-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(2-( (6- (3-(2-( 2,2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)-6-(trifluoromethyl)pyrimidin-4-yl)phenyl) 2,2-dimethylpropanoic acid; (R)-2-(3-(4-((6-(3-(2-ethoxyphenoxy)piperidin-1yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenyl)-2-methylpropanoic acid;(R)-2-(4-(4-( (6- (3-(2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2-methylpropanoic acid; (R)-3-(3-(4-( (6- (3- (2-etoxifenoxi)piperidin-1yl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(3-(4-( (6- (3- ( (3-etoxipyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2,2dimethylpropanoic acid; (R)-3-(4-(4 - ( (6- (3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2,2-dimethylpropanoic acid; (R)-3-(4-(4-( (6- (3- ( (3-etoxipyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2,2369 dimethylpropanoic acid; (R)-2-(3-(4-((6-(3-(2-etoxifenoxi)piperidin-lyl)pyrazin-2-yl)amino)pirimidin-2-yl)phenyl)-2-methylpropanoic acid; (R)-2-(3-(4-((6-(3-((3-((3-ethoxypyridin-2-yl)oxi)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2-yl)fenoxi)-2-methylpropanoic acid; (R)-2-(3-(2-((6-(3-(2-ethoxypyridin-lyl)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-4-yl)fenoxi)-2-methylpropanoic acid;(R)-2-(4-(6-((6—(3—(2-ethoxy-4-fluorophenoxy)piperidin-l-yl)pyrazin-2-yl)amino)pyridin-2-yl)phenoxy)-2-methylpropanoic acid; (R)-2-(4-(4-((6-(3-(2-ethoxyphenoxy)piperidin-lyl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenoxy)-2-methylpropanoic acid; and (R)-2-(4-(4-((6-(3-((3-ethoxypyridin-2-yl)oxy)piperidin-l-yl)pyrazin-2-yl)amino)pyrimidin-2-yl)phenoxy)-2methylpropanoic acid.; 4. A pharmaceutical composition for the treatment of diseases associated with diacylglycerol acyltransferase 2 (DGAT2), characterized in that it comprises the compound of Formula (1), or a pharmaceutically acceptable salt or isomer thereof as defined in any of claims 1 to 3 as an active ingredient, together with a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claim 4, characterized in that the disease associated with DGAT2 is selected from the group consisting of fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), diabetes, obesity, hyperlipidemia, atherosclerosis, and hypercholesteroleemia.